Publications
2024
Comparative analysis of transcriptomic and proteomic expression between two non-small cell lung cancer subtypes
ASO Visual Abstract: Efficacy and Safety of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter, Phase 3 Study.
Zager, J. S., Orloff, M., Ferrucci, P. F., Choi, J., Eschelman, D. J., Glazer, E. S., . . . Ottensmeier, C. H. (2024). ASO Visual Abstract: Efficacy and Safety of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter, Phase 3 Study.. Annals of surgical oncology, 31(8), 5220-5221. doi:10.1245/s10434-024-15421-7
Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study.
Zager, J. S., Orloff, M., Ferrucci, P. F., Choi, J., Eschelman, D. J., Glazer, E. S., . . . Ottensmeier, C. H. (2024). Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study.. Annals of surgical oncology. doi:10.1245/s10434-024-15293-x
The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy.
Martin, M. V., Aguilar-Rosas, S., Franke, K., Pieterse, M., Langelaar, J. V., Schreurs, R., . . . Kloosterman, W. P. (2024). The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy.. Cancer immunology research, 12(6), 759-778. doi:10.1158/2326-6066.cir-23-0158
Proteogenomics guided identification of functional neoantigens in non-small cell lung cancer
Intra-tumoral T cells in pediatric brain tumors display clonal expansion and effector properties.
Upadhye, A., Meza Landeros, K. E., Ramírez-Suástegui, C., Schmiedel, B. J., Woo, E., Chee, S. J., . . . Ganesan, A. -P. (2024). Intra-tumoral T cells in pediatric brain tumors display clonal expansion and effector properties.. Nature cancer, 5(5), 791-807. doi:10.1038/s43018-023-00706-9
Abstract LB310: Single-cell transcriptomics and TCR clonality reveal a role for immunotherapy in pediatric brain tumors
Ganesan, A. P., Upadhye, A., Landeros, K. M., Ramírez-Suástegui1, C., Schmiedel, B., Woo, E., . . . Vijayanand, P. (2024). Abstract LB310: Single-cell transcriptomics and TCR clonality reveal a role for immunotherapy in pediatric brain tumors. Cancer Research, 84(7_Supplement), LB310. doi:10.1158/1538-7445.am2024-lb310
204 REFINE-Lung is a multicentre phase III study to determine the optimal frequency of pembrolizumab in advanced non-small cell lung cancer (NSCLC) utilising a novel multi-arm design
Ghorani, E., Quartagno, M., Blackhall, F., O'Brien, M., Ottensmeier, C., Pizzo, E., . . . Seckl, M. J. (2024). 204 REFINE-Lung is a multicentre phase III study to determine the optimal frequency of pembrolizumab in advanced non-small cell lung cancer (NSCLC) utilising a novel multi-arm design. Lung Cancer, 190, 107765. doi:10.1016/j.lungcan.2024.107765
Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trial.
Larkin, J., Marais, R., Porta, N., Gonzalez de Castro, D., Parsons, L., Messiou, C., . . . Turajlic, S. (2024). Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trial.. Cell reports. Medicine, 5(3), 101435. doi:10.1016/j.xcrm.2024.101435
INHBA is Enriched in HPV-negative Oropharyngeal Squamous Cell Carcinoma and Promotes Cancer Progression.
Abou Kors, T., Hofmann, L., Betzler, A., Payer, K., Bens, M., Truong, J., . . . Laban, S. (2024). INHBA is Enriched in HPV-negative Oropharyngeal Squamous Cell Carcinoma and Promotes Cancer Progression.. Cancer research communications, 4(2), 571-587. doi:10.1158/2767-9764.crc-23-0258
Tumor-Infiltrating CD103+ Tissue-Resident Memory T Cells and CD103-CD8+ T Cells in HNSCC Are Linked to Outcome in Primary but not Metastatic Disease.
von Witzleben, A., Ellis, M., Thomas, G. J., Hoffmann, T. K., Jackson, R., Laban, S., & Ottensmeier, C. H. (2024). Tumor-Infiltrating CD103+ Tissue-Resident Memory T Cells and CD103-CD8+ T Cells in HNSCC Are Linked to Outcome in Primary but not Metastatic Disease.. Clinical cancer research : an official journal of the American Association for Cancer Research, 30(1), 224-234. doi:10.1158/1078-0432.ccr-23-0445
Correction: Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study.
Zager, J. S., Orloff, M., Ferrucci, P. F., Choi, J., Eschelman, D. J., Glazer, E. S., . . . Ottensmeier, C. H. (2024). Correction: Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study.. Annals of surgical oncology, 31(12), 8262-8263. doi:10.1245/s10434-024-15886-6
Multi-omics analysis of overexpressed tumor-associated proteins: gene expression, immunopeptide presentation, and antibody response in oropharyngeal squamous cell carcinoma, with a focus on cancer-testis antigens.
Abou Kors, T., Meier, M., Mühlenbruch, L., Betzler, A. C., Oliveri, F., Bens, M., . . . Laban, S. (2024). Multi-omics analysis of overexpressed tumor-associated proteins: gene expression, immunopeptide presentation, and antibody response in oropharyngeal squamous cell carcinoma, with a focus on cancer-testis antigens.. Frontiers in immunology, 15, 1408173. doi:10.3389/fimmu.2024.1408173
2023
Transcriptomes and metabolism define mouse and human MAIT cell populations.
Chandra, S., Ascui, G., Riffelmacher, T., Chawla, A., Ramírez-Suástegui, C., Castelan, V. C., . . . Kronenberg, M. (2023). Transcriptomes and metabolism define mouse and human MAIT cell populations.. Science immunology, 8(89), eabn8531. doi:10.1126/sciimmunol.abn8531
1500TiP REFINE-Lung is a multicentre phase III study to determine the optimal frequency of pembrolizumab in non-small cell lung cancer utilising a novel multi-arm design
Ghorani, E., Quartagno, M., Blackhall, F., Gilbert, D. C., O'Brien, M. E. R., Ottensmeier, C. H. H., . . . Seckl, M. J. (2023). 1500TiP REFINE-Lung is a multicentre phase III study to determine the optimal frequency of pembrolizumab in non-small cell lung cancer utilising a novel multi-arm design. Annals of Oncology, 34, S845. doi:10.1016/j.annonc.2023.09.2531
868P A DNA methylation classifier to predict recurrence from clear surgical margins
Abou Kors, T., Chteinberg, E., Ammerpohl, O., Siebert, R., Fehn, A., Benckendorff, J., . . . Laban, S. (2023). 868P A DNA methylation classifier to predict recurrence from clear surgical margins. Annals of Oncology, 34, S562. doi:10.1016/j.annonc.2023.09.2014
878P INHBA is overexpressed in HPV-negative oropharyngeal squamous cell carcinoma and contributes to an aggressive phenotype
Laban, S., Hofmann, L., Betzler, A. C., Payer, K., Bens, M., Truong, J., . . . Abou Kors, T. (2023). 878P INHBA is overexpressed in HPV-negative oropharyngeal squamous cell carcinoma and contributes to an aggressive phenotype. Annals of Oncology, 34, S565. doi:10.1016/j.annonc.2023.09.2024
Advancing Understanding of Non-Small Cell Lung Cancer with Multiplexed Antibody-Based Spatial Imaging Technologies.
Gray, S., & Ottensmeier, C. H. (2023). Advancing Understanding of Non-Small Cell Lung Cancer with Multiplexed Antibody-Based Spatial Imaging Technologies.. Cancers, 15(19), 4797. doi:10.3390/cancers15194797
Efficacy, cellular and molecular determinants of PD-1 checkpoint inhibition in relapsed mesothelioma.
Fennell, D. A., Ewings, S., Hill, K., Poile, C., Baitei, E., Zhou, Z., . . . Griffiths, G. O. (2023). Efficacy, cellular and molecular determinants of PD-1 checkpoint inhibition in relapsed mesothelioma.. Journal of Clinical Oncology, 41(16_suppl), 8506. doi:10.1200/jco.2023.41.16_suppl.8506
Modi-1, anti-citrullinated neoepitope vaccine, alone and combined with checkpoint inhibitors in patients with head and neck, breast, renal, and ovarian cancers: ModiFy phase I/II basket clinical trial—Report after completion of monotherapy dose-finding.
Ottensmeier, C. H. H., Pinato, D. J. J., Armstrong, A. C., Symeonides, S. N., Patel, P. M., Danson, S., . . . Durrant, L. G. (2023). Modi-1, anti-citrullinated neoepitope vaccine, alone and combined with checkpoint inhibitors in patients with head and neck, breast, renal, and ovarian cancers: ModiFy phase I/II basket clinical trial—Report after completion of monotherapy dose-finding.. Journal of Clinical Oncology, 41(16_suppl), 2566. doi:10.1200/jco.2023.41.16_suppl.2566
REFINE-Lung: A multicentre phase III study to determine the optimal frequency of pembrolizumab in non-small cell lung cancer utilising a novel multi-arm design.
Seckl, M., Ghorani, E., Quartagno, M., Blackhall, F. H., Gilbert, D. C., O'Brien, M. E. R., . . . Parmar, M. K. B. (2023). REFINE-Lung: A multicentre phase III study to determine the optimal frequency of pembrolizumab in non-small cell lung cancer utilising a novel multi-arm design.. Journal of Clinical Oncology, 41(16_suppl), TPS9145. doi:10.1200/jco.2023.41.16_suppl.tps9145
Safety and immunogenicity of TG4050: A personalized cancer vaccine in head and neck carcinoma.
Ottensmeier, C. H. H., Delord, J. -P., Lalanne, A., Lantz, O., Jamet, C., TAVERNARO, A., . . . Le Tourneau, C. (2023). Safety and immunogenicity of TG4050: A personalized cancer vaccine in head and neck carcinoma.. Journal of Clinical Oncology, 41(16_suppl), 6082. doi:10.1200/jco.2023.41.16_suppl.6082
Immunotherapy-related adverse events in real-world patients with advanced non-small cell lung cancer on chemoimmunotherapy: a Spinnaker study sub-analysis
Anpalakhan, S., Huddar, P., Behrouzi, R., Signori, A., Cave, J., Comins, C., . . . Banna, G. L. L. (2023). Immunotherapy-related adverse events in real-world patients with advanced non-small cell lung cancer on chemoimmunotherapy: a Spinnaker study sub-analysis. FRONTIERS IN ONCOLOGY, 13. doi:10.3389/fonc.2023.1163768
Cytotoxic CD4+ T cells decrease under primary chemoradiotherapy of HNSCC
Döscher, J., Currall, E., Abou, T. K., Schuler, P., Laban, S., Hoffmann, T., & Ottensmeier, C. (2023). Cytotoxic CD4+ T cells decrease under primary chemoradiotherapy of HNSCC. In Laryngo-Rhino-Otologie. Georg Thieme Verlag. doi:10.1055/s-0043-1767248
Die Zahl zytotoxischer CD4+ T-Zellen nimmt unter primärer Radiochemotherapie von HNSCC ab
Döscher, J., Currall, E., Abou, T. K., Schuler, P., Laban, S., Hoffmann, T., & Ottensmeier, C. (2023). Die Zahl zytotoxischer CD4+ T-Zellen nimmt unter primärer Radiochemotherapie von HNSCC ab. In Laryngo-Rhino-Otologie. Georg Thieme Verlag. doi:10.1055/s-0043-1766640
REFINE-Lung implements a novel multi-arm randomisedtrial design to address possible immunotherapy overtreatment
Ghorani, E., Quartagno, M., Blackhall, F., Gilbert, D. C., O'Brien, M., Ottensmeier, C., . . . Seckl, M. J. (2023). REFINE-Lung implements a novel multi-arm randomisedtrial design to address possible immunotherapy overtreatment. LANCET ONCOLOGY, 24(5), E219-E227. Retrieved from https://www.webofscience.com/
PINCER (A Platform Study for solId orgaN CancERs): an agile pan-network platform study to deliver high-quality translational research
Jones, R. P., Mielgo, A., Schmid, M., Bury, D., Andrews, T., Burdak-Rothkamm, S., . . . Vimalachandran, D. (2023). PINCER (A Platform Study for solId orgaN CancERs): an agile pan-network platform study to deliver high-quality translational research. BRITISH JOURNAL OF SURGERY. doi:10.1093/bjs/znad097
Abstract CT256: Modi-1, anti-citrullinated neoepitope vaccine alone and combined with checkpoint inhibitors in patients with head and neck, breast, renal and ovarian carcinoma: protocol for the ModiFY phase I/II basket clinical Ttial
Durrant, L. G., Masters, F., Paston, S., Miller, R., Pinato, D. J., Herbertson, R., . . . Ottensmeier, C. (2023). Abstract CT256: Modi-1, anti-citrullinated neoepitope vaccine alone and combined with checkpoint inhibitors in patients with head and neck, breast, renal and ovarian carcinoma: protocol for the ModiFY phase I/II basket clinical Ttial. Cancer Research, 83(8_Supplement), CT256. doi:10.1158/1538-7445.am2023-ct256
Abstract LB205: Feasibility and immunogenicity of adjuvant TG4050, a patient tailored cancer vaccine in head and neck and ovarian cancer
Lalanne, A., Jamet, C., Ottensmeier, C. H., Delord, J. -P., Tourneau, C. L., Block, M. S., . . . Bendjama, K. (2023). Abstract LB205: Feasibility and immunogenicity of adjuvant TG4050, a patient tailored cancer vaccine in head and neck and ovarian cancer. Cancer Research, 83(8_Supplement), LB205. doi:10.1158/1538-7445.am2023-lb205
Immunotherapy-related adverse events (irAEs) in real world patients with advanced non-small cell lung cancer (aNSCLC) on chemoimmunotherapy: a Spinnaker study sub-analysis
Anpalakhan, S., Huddar, P., Behrouzi, R., Signori, A., Cave, J., Comins, C., . . . Banna, G. (2023). Immunotherapy-related adverse events (irAEs) in real world patients with advanced non-small cell lung cancer (aNSCLC) on chemoimmunotherapy: a Spinnaker study sub-analysis. Lung Cancer, 178, S33. doi:10.1016/s0169-5002(23)00503-2
JAML immunotherapy targets recently activated tumor CD8<SUP>+</SUP> T cells
Eschweiler, S., Wang, A., Ramirez-Suastegui, C., von Witzleben, A., Li, Y., Chee, S. J., . . . Vijayanand, P. (2023). JAML immunotherapy targets recently activated tumor CD8<SUP>+</SUP> T cells. CELL REPORTS, 42(2). doi:10.1016/j.celrep.2023.112040
SARS-CoV-2 in the abdomen or pelvis: SAFE SURGERY study
Vimalachandran, D., Jones, R. P., Dickson, E., Seehra, J., Acheson, A., Griffiths, E. A., . . . Taylor, G. S. (2023). SARS-CoV-2 in the abdomen or pelvis: SAFE SURGERY study. BRITISH JOURNAL OF SURGERY, 110(3), 306-309. doi:10.1093/bjs/znac297
Single-cell analysis reveals prognostic fibroblast subpopulations linked to molecular and immunological subtypes of lung cancer
Hanley, C. J., Waise, S., Ellis, M. J., Lopez, M. A., Pun, W. Y., Taylor, J., . . . Thomas, G. J. (2023). Single-cell analysis reveals prognostic fibroblast subpopulations linked to molecular and immunological subtypes of lung cancer. NATURE COMMUNICATIONS, 14(1). doi:10.1038/s41467-023-35832-6
The Effects of GCSF Primary Prophylaxis on Survival Outcomes and Toxicity in Patients with Advanced Non-Small Cell Lung Cancer on First-Line Chemoimmunotherapy: A Sub-Analysis of the Spinnaker Study
Anpalakhan, S., Huddar, P., Behrouzi, R., Signori, A., Cave, J., Comins, C., . . . Banna, G. L. (2023). The Effects of GCSF Primary Prophylaxis on Survival Outcomes and Toxicity in Patients with Advanced Non-Small Cell Lung Cancer on First-Line Chemoimmunotherapy: A Sub-Analysis of the Spinnaker Study. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 24(2). doi:10.3390/ijms24021746
Efficacy, cellular and molecular determinants of PD-1 checkpoint inhibition in relapsed mesothelioma
Fennell, D. A., Ewings, S., Hill, K., Poile, C., Baitei, E., Zhou, Z., . . . Griffiths, G. O. (2023). Efficacy, cellular and molecular determinants of PD-1 checkpoint inhibition in relapsed mesothelioma. In JOURNAL OF CLINICAL ONCOLOGY Vol. 41. Retrieved from https://www.webofscience.com/
Human CD79b<sup>+</sup> neutrophils in the blood are associated with early-stage melanoma.
Meyer, M. A., Dinh, H. Q., Alimadadi, A., Araujo, D. J., Chatterjee, N., Gutierrez, N. A., . . . Hedrick, C. C. (2023). Human CD79b<sup>+</sup> neutrophils in the blood are associated with early-stage melanoma.. Frontiers in immunology, 14, 1224045. doi:10.3389/fimmu.2023.1224045
Immunotherapy-related adverse events (irAEs) in real world patients with advanced non-small cell lung cancer (aNSCLC) on chemoimmunotherapy: a Spinnaker study sub-analysis
Anpalakhan, S., Huddar, P., Behrouzi, R., Signori, A., Cave, J., Comins, C., . . . Banna, G. (2023). Immunotherapy-related adverse events (irAEs) in real world patients with advanced non-small cell lung cancer (aNSCLC) on chemoimmunotherapy: a Spinnaker study sub-analysis. In LUNG CANCER Vol. 178 (pp. S33). Retrieved from https://www.webofscience.com/
Modi-1, anti-citrullinated neoepitope vaccine, alone and combined with checkpoint inhibitors in patients with head and neck, breast, renal, and ovarian cancers: ModiFy phase I/II basket clinical trial-Report after completion of monotherapy dose-finding
Ottensmeier, C. H. H., Pinato, D. J. J., Armstrong, A. C., Symeonides, S. N., Patel, P. M., Danson, S., . . . Durrant, L. G. (2023). Modi-1, anti-citrullinated neoepitope vaccine, alone and combined with checkpoint inhibitors in patients with head and neck, breast, renal, and ovarian cancers: ModiFy phase I/II basket clinical trial-Report after completion of monotherapy dose-finding. In JOURNAL OF CLINICAL ONCOLOGY Vol. 41. Retrieved from https://www.webofscience.com/
REFINE-Lung: A multicentre phase III study to determine the optimal frequency of pembrolizumab in non-small cell lung cancer utilising a novel multi-arm design.
Seckl, M., Ghorani, E., Quartagno, M., Blackhall, F. H., Gilbert, D. C., O'Brien, M. E. R., . . . Parmar, M. K. B. (2023). REFINE-Lung: A multicentre phase III study to determine the optimal frequency of pembrolizumab in non-small cell lung cancer utilising a novel multi-arm design.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 41. Retrieved from https://www.webofscience.com/
Safety and immunogenicity of TG4050: A personalized cancer vaccine in head and neck carcinoma
Ottensmeier, C. H. H., Delord, J. -P., Lalanne, A., Lantz, O., Jamet, C., Tavernaro, A., . . . Le Tourneau, C. (2023). Safety and immunogenicity of TG4050: A personalized cancer vaccine in head and neck carcinoma. In JOURNAL OF CLINICAL ONCOLOGY Vol. 41. Retrieved from https://www.webofscience.com/
2022
155P BNT113 + pembrolizumab as first-line treatment in patients with unresectable recurrent/metastatic HNSCC: Preliminary safety data from AHEAD-MERIT
Klinghammer, K., Saba, N. F., Castelluci, E., Colevas, A. D., Rutkowski, T., Greil, R., . . . Sahin, U. (2022). 155P BNT113 + pembrolizumab as first-line treatment in patients with unresectable recurrent/metastatic HNSCC: Preliminary safety data from AHEAD-MERIT. Immuno-Oncology and Technology, 16, 100267. doi:10.1016/j.iotech.2022.100267
Single-cell immune profiling reveals long-term changes in myeloid cells and identifies a novel subset of CD9<SUP>+</SUP> monocytes associated with COVID-19 hospitalization
Pandori, W. J., Padgett, L. E., Alimadadi, A., Gutierrez, N. A., Araujo, D. J., Huh, C. J., . . . Hedrick, C. C. (2022). Single-cell immune profiling reveals long-term changes in myeloid cells and identifies a novel subset of CD9<SUP>+</SUP> monocytes associated with COVID-19 hospitalization. JOURNAL OF LEUKOCYTE BIOLOGY, 112(5), 1053-1063. doi:10.1002/JLB.4COVA0122-076R
Differences in ERAP1 allotype function correlate with HPV epitope processing and level of tumour infiltration with CD8+ T cells in HPV-positive OPSCC
Reeves, E., Wood, O., Ottensmeier, C., King, E., Thomas, G., Elliott, T., & James, E. (2022). Differences in ERAP1 allotype function correlate with HPV epitope processing and level of tumour infiltration with CD8+ T cells in HPV-positive OPSCC. Molecular Immunology, 150, 21. doi:10.1016/j.molimm.2022.05.074
Transcriptional analysis highlights three distinct immune profiles of high-risk oral epithelial dysplasia
Gan, C. P., Lee, B. K. B., Lau, S. H., Kallarakkal, T. G., Zaini, Z. M., Lye, B. K. W., . . . Lim, K. P. (2022). Transcriptional analysis highlights three distinct immune profiles of high-risk oral epithelial dysplasia. FRONTIERS IN IMMUNOLOGY, 13. doi:10.3389/fimmu.2022.954567
A randomised, double-blind, placebo-controlled phase II study of setanaxib plus pembrolizumab for the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (rmSCCHN)
Rullan, A., Adkins, D. R., Bossi, P., Cohen, E. E. W., Daste, A., Harrington, K. J., . . . Rutkowski, T. (2022). A randomised, double-blind, placebo-controlled phase II study of setanaxib plus pembrolizumab for the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (rmSCCHN). In ANNALS OF ONCOLOGY Vol. 33 (pp. S863-S864). doi:10.1016/j.annonc.2022.07.827
Efficacy outcomes and prognostic factors from real-world patients with advanced non-small-cell lung cancer treated with first-line chemoimmunotherapy: The Spinnaker retrospective study
Banna, G. L., Cantale, O., Muthuramalingam, S., Cave, J., Comins, C., Cortellini, A., . . . Gomes, F. (2022). Efficacy outcomes and prognostic factors from real-world patients with advanced non-small-cell lung cancer treated with first-line chemoimmunotherapy: The Spinnaker retrospective study. INTERNATIONAL IMMUNOPHARMACOLOGY, 110. doi:10.1016/j.intimp.2022.108985
Abstract CT182: Phase I trials of personalized cancer vaccine TG4050 in surgically treated high-risk head and neck squamous cell carcinoma (HNSCC) and relapsing ovarian cancer (OvC) patients
Block, M. S., Delord, J. -P., Ottensmeier, C. H., Le Tourneau, C., Lalanne, A., Lantz, O., . . . Bendjama, K. (2022). Abstract CT182: Phase I trials of personalized cancer vaccine TG4050 in surgically treated high-risk head and neck squamous cell carcinoma (HNSCC) and relapsing ovarian cancer (OvC) patients. Cancer Research, 82(12_Supplement), CT182. doi:10.1158/1538-7445.am2022-ct182
Abstract CT213: A multicenter phase 1a/b study of NG-350A, a tumor-selective anti-CD40-antibody expressing adenoviral vector, and pembrolizumab in patients with metastatic or advanced epithelial tumors (FORTIFY)
Lillie, T., O'Hara, M., Ottensmeier, C., Parkes, E., Rosen, L., Krige, D., . . . Naing, A. (2022). Abstract CT213: A multicenter phase 1a/b study of NG-350A, a tumor-selective anti-CD40-antibody expressing adenoviral vector, and pembrolizumab in patients with metastatic or advanced epithelial tumors (FORTIFY). Cancer Research, 82(12_Supplement), CT213. doi:10.1158/1538-7445.am2022-ct213
Abstract CT214: A multicenter phase 1a/b study of NG-641, a tumor-selective transgene-expressing adenoviral vector, and nivolumab in patients with metastatic or advanced epithelial tumors (NEBULA)
Lillie, T., Parkes, E., Ottensmeier, C., Krige, D., Ravanfar, B., Evilevitch, V., . . . Rosen, L. (2022). Abstract CT214: A multicenter phase 1a/b study of NG-641, a tumor-selective transgene-expressing adenoviral vector, and nivolumab in patients with metastatic or advanced epithelial tumors (NEBULA). Cancer Research, 82(12_Supplement), CT214. doi:10.1158/1538-7445.am2022-ct214
061 T cell-mediated cerebellitis after ipilimumab for small cell lung cancer
Guillochon, R., Nolan, L., Nicoll, J., Jogai, S., Joseph-Pietras, D., Arriola, E., . . . Galea, I. (2022). 061 T cell-mediated cerebellitis after ipilimumab for small cell lung cancer. Journal of Neurology, Neurosurgery & Psychiatry, 93(6), A31.3-A31. doi:10.1136/jnnp-2022-abn.98
A local human Vδ1 T cell population is associated with survival in nonsmall-cell lung cancer.
Wu, Y., Biswas, D., Usaite, I., Angelova, M., Boeing, S., Karasaki, T., . . . Swanton, C. (2022). A local human Vδ1 T cell population is associated with survival in nonsmall-cell lung cancer.. Nature cancer, 3(6), 696-709. doi:10.1038/s43018-022-00376-z
FOCUS phase 3 trial results: Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases (PHP-OCM-301/301A).
Zager, J. S., Orloff, M. M., Ferrucci, P. F., Glazer, E. S., Ejaz, A., Richtig, E., . . . Ottensmeier, C. (2022). FOCUS phase 3 trial results: Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases (PHP-OCM-301/301A).. Journal of Clinical Oncology, 40(16_suppl), 9510. doi:10.1200/jco.2022.40.16_suppl.9510
NEBULA: A multicenter phase 1a/b study of a tumor-selective transgene-expressing adenoviral vector, NG-641, and nivolumab in patients with metastatic or advanced epithelial tumors.
Lillie, T., Parkes, E. E., Ottensmeier, C., Krige, D., Ravanfar, B., Evilevitch, V., . . . Rosen, L. S. (2022). NEBULA: A multicenter phase 1a/b study of a tumor-selective transgene-expressing adenoviral vector, NG-641, and nivolumab in patients with metastatic or advanced epithelial tumors.. Journal of Clinical Oncology, 40(16_suppl), TPS2682. doi:10.1200/jco.2022.40.16_suppl.tps2682
Phase 1 studies of personalized neoantigen vaccine TG4050 in ovarian carcinoma (OC) and head and neck squamous cell carcinoma (HNSCC).
Delord, J. -P., Block, M. S., Ottensmeier, C., Colon-Otero, G., Le Tourneau, C., Lalanne, A., . . . Bendjama, K. (2022). Phase 1 studies of personalized neoantigen vaccine TG4050 in ovarian carcinoma (OC) and head and neck squamous cell carcinoma (HNSCC).. Journal of Clinical Oncology, 40(16_suppl), 2637. doi:10.1200/jco.2022.40.16_suppl.2637
Intermittent PI3Kδ inhibition sustains anti-tumour immunity and curbs irAEs
Eschweiler, S., Ramirez-Suastegui, C., Li, Y., King, E., Chudley, L., Thomas, J., . . . Ottensmeier, C. H. (2022). Intermittent PI3Kδ inhibition sustains anti-tumour immunity and curbs irAEs. NATURE, 605(7911), 741-+. doi:10.1038/s41586-022-04685-2
Gewebsansässige Gedächtnis-T-Zellen (TRM) in primärem, metastasiertem und rezidivierendem Plattenepithelkarzinom des Kopfes und Halses (HNSCC)
von Witzleben, A., Ellis, M., Thomas, G. J., Hoffmann, T. K., Laban, S., & Ottensmeier, C. H. (2022). Gewebsansässige Gedächtnis-T-Zellen (TRM) in primärem, metastasiertem und rezidivierendem Plattenepithelkarzinom des Kopfes und Halses (HNSCC). In Laryngo-Rhino-Otologie. Georg Thieme Verlag. doi:10.1055/s-0042-1747243
Systemic therapy for pre-treated malignant mesothelioma: A systematic review, meta-analysis and network meta-analysis of randomised controlled trials
Banna, G. L., Signori, A., Curioni-Fontecedro, A., Cortellini, A., Ponzano, M., Giunta, E. F., . . . Ottensmeier, C. (2022). Systemic therapy for pre-treated malignant mesothelioma: A systematic review, meta-analysis and network meta-analysis of randomised controlled trials. EUROPEAN JOURNAL OF CANCER, 166, 287-299. doi:10.1016/j.ejca.2022.02.030
Tissue resident memory T cells (TRM) in primary, metastatic and recurrent head and neck squamous cell carcinoma (HNSCC) tissue
von Witzleben, A., Ellis, M., Thomas, G. J., Hoffmann, T. K., Laban, S., & Ottensmeier, C. H. (2022). Tissue resident memory T cells (TRM) in primary, metastatic and recurrent head and neck squamous cell carcinoma (HNSCC) tissue. In Laryngo-Rhino-Otologie. Georg Thieme Verlag. doi:10.1055/s-0042-1746611
CD33 Expression on Peripheral Blood Monocytes Predicts Efficacy of Anti-PD-1 Immunotherapy Against Non-Small Cell Lung Cancer
Olingy, C., Alimadadi, A., Araujo, D. J., Barry, D., Gutierrez, N. A., Werbin, M. H., . . . Hedrick, C. C. (2022). CD33 Expression on Peripheral Blood Monocytes Predicts Efficacy of Anti-PD-1 Immunotherapy Against Non-Small Cell Lung Cancer. FRONTIERS IN IMMUNOLOGY, 13. doi:10.3389/fimmu.2022.842653
HIF activation enhances FcγRIIb expression on mononuclear phagocytes impeding tumor targeting antibody immunotherapy
Hussain, K., Liu, R., Smith, R. C. G., Muller, K. T. J., Ghorbani, M., Macari, S., . . . Cragg, M. S. (2022). HIF activation enhances FcγRIIb expression on mononuclear phagocytes impeding tumor targeting antibody immunotherapy. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 41(1). doi:10.1186/s13046-022-02294-5
Changes in Gene Expression Patterns in the Tumor Microenvironment of Head and Neck Squamous Cell Carcinoma Under Chemoradiotherapy Depend on Response
Doescher, J., von Witzleben, A., Boukas, K., Weissinger, S. E., Thomas, G. J., Laban, S., . . . Ottensmeier, C. H. (2022). Changes in Gene Expression Patterns in the Tumor Microenvironment of Head and Neck Squamous Cell Carcinoma Under Chemoradiotherapy Depend on Response. FRONTIERS IN ONCOLOGY, 12. doi:10.3389/fonc.2022.862694
Chemosaturation with percutaneous hepatic perfusion of melphalan for metastatic uveal melanoma
Modi, S., Gibson, T., Vigneswaran, G., Patel, S., Wheater, M., Karydis, I., . . . Stedman, B. (2022). Chemosaturation with percutaneous hepatic perfusion of melphalan for metastatic uveal melanoma. MELANOMA RESEARCH, 32(2), 103-111. doi:10.1097/CMR.0000000000000806
Targeting the tumor mutanome for personalized vaccination in a TMB low non-small cell lung cancer.
McCann, K., von Witzleben, A., Thomas, J., Wang, C., Wood, O., Singh, D., . . . Ottensmeier, C. (2022). Targeting the tumor mutanome for personalized vaccination in a TMB low non-small cell lung cancer.. Journal for immunotherapy of cancer, 10(3). doi:10.1136/jitc-2021-003821
Utility of KI-67 as a prognostic biomarker in pulmonary neuroendocrine neoplasms: a systematic review and meta-analysis
Naheed, S., Holden, C., Tanno, L., Pattini, L., Pearce, N. W., Green, B., . . . Pelosi, G. (2022). Utility of KI-67 as a prognostic biomarker in pulmonary neuroendocrine neoplasms: a systematic review and meta-analysis. BMJ OPEN, 12(3). doi:10.1136/bmjopen-2020-041961
Analysis of Immune Landscape in Pancreatic and Ileal Neuroendocrine Tumours Demonstrates an Immune Cold Tumour Microenvironment
Tanno, L., Naheed, S., Dunbar, J., Tod, J., Lopez, M. A., Taylor, J., . . . Ottensmeier, C. H. (2022). Analysis of Immune Landscape in Pancreatic and Ileal Neuroendocrine Tumours Demonstrates an Immune Cold Tumour Microenvironment. NEUROENDOCRINOLOGY, 112(4), 370-383. doi:10.1159/000517688
Tumor-infiltrating NK cell subsets associated with the magnitude of T cell response in human lung cancer
CD8 T-cell-mediated cerebellitis directed against Purkinje cell antigen after ipilimumab for small cell lung cancer
Hardwick, M., Nolan, L., Nicoll, J., Jogai, S., Arriola, E., Joseph-Pietras, D., . . . Galea, I. (2021). CD8 T cell-mediated cerebellitis directed against Purkinje cell antigen after ipilimumab for small cell lung cancer. JOURNAL OF THE NEUROLOGICAL SCIENCES, 429, 30-31. doi:10.1016/j.jns.2021.118843
A multicenter phase 1a/b study of NG-350A, a tumor-selective anti-CD40-antibody expressing adenoviral vector, and pembrolizumab in patients with metastatic or advanced epithelial tumors (FORTIFY).
Lillie, T., O'Hara, M., Ottensmeier, C., Parkes, E., Rosen, L., Krige, D., . . . Naing, A. (2022). A multicenter phase 1a/b study of NG-350A, a tumor-selective anti-CD40-antibody expressing adenoviral vector, and pembrolizumab in patients with metastatic or advanced epithelial tumors (FORTIFY).. In CANCER RESEARCH Vol. 82. Retrieved from https://www.webofscience.com/
A multicenter phase 1a/b study of NG-641, a tumor-selective transgene-expressing adenoviral vector, and nivolumab in patients with metastatic or advanced epithelial tumors (NEBULA).
Lillie, T., Parkes, E., Ottensmeier, C., Krige, D., Ravanfar, B., Evilevitch, V., . . . Rosen, L. (2022). A multicenter phase 1a/b study of NG-641, a tumor-selective transgene-expressing adenoviral vector, and nivolumab in patients with metastatic or advanced epithelial tumors (NEBULA).. In CANCER RESEARCH Vol. 82. Retrieved from https://www.webofscience.com/
CONFIRM trial: what is the real efficacy of second-line immunotherapy in mesothelioma? reply
Fennell, D. A., Griffiths, G., Ottensmeier, C., Hanna, G. G., Danson, S., Szlosarek, P., & Nye, M. (2022). CONFIRM trial: what is the real efficacy of second-line immunotherapy in mesothelioma? reply. LANCET ONCOLOGY, 23(1), E14-E15. Retrieved from https://www.webofscience.com/
FOCUS phase 3 trial results: Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases (PHP-OCM-301/301A).
Zager, J. S., Orloff, M. M., Ferrucci, P. F., Glazer, E. S., Ejaz, A., Richtig, E., . . . Ottensmeier, C. (2022). FOCUS phase 3 trial results: Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases (PHP-OCM-301/301A).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 40. Retrieved from https://www.webofscience.com/
Methylation and expression signatures of surgical margins in comparison to tumor and healthy tissue
Abou Kors, T., Ezic, J., Ammerpohl, O., Benckendorff, J., Barth, T. F. E., Bens, M., . . . Laban, S. (2022). Methylation and expression signatures of surgical margins in comparison to tumor and healthy tissue. In ONCOLOGY RESEARCH AND TREATMENT Vol. 45 (pp. 126-127). Retrieved from https://www.webofscience.com/
NEBULA: A multicenter phase 1a/b study of a tumor-selective transgene-expressing adenoviral vector, NG-641, and nivolumab in patients with metastatic or advanced epithelial tumors
Lillie, T., Parkes, E. E., Ottensmeier, C., Krige, D., Ravanfar, B., Evilevitch, V., . . . Rosen, L. S. (2022). NEBULA: A multicenter phase 1a/b study of a tumor-selective transgene-expressing adenoviral vector, NG-641, and nivolumab in patients with metastatic or advanced epithelial tumors. In JOURNAL OF CLINICAL ONCOLOGY Vol. 40. Retrieved from https://www.webofscience.com/
Phase 1 studies of personalized neoantigen vaccine TG4050 in ovarian carcinoma (OC) and head and neck squamous cell carcinoma (HNSCC)
Delord, J. -P., Block, M. S., Ottensmeier, C., Colon-Otero, G., Le Tourneau, C., Lalanne, A., . . . Bendjama, K. (2022). Phase 1 studies of personalized neoantigen vaccine TG4050 in ovarian carcinoma (OC) and head and neck squamous cell carcinoma (HNSCC). In JOURNAL OF CLINICAL ONCOLOGY Vol. 40. Retrieved from https://www.webofscience.com/
Phase I trials of personalized cancer vaccine TG4050 in surgically treated high-risk head and neck squamous cell carcinoma (HNSCC) and relapsing ovarian cancer (OvC) patients.
Block, M. S., Delord, J. -P., Ottensmeier, C. H., Le Tourneau, C., Lalanne, A., Lantz, O., . . . Bendjama, K. (2022). Phase I trials of personalized cancer vaccine TG4050 in surgically treated high-risk head and neck squamous cell carcinoma (HNSCC) and relapsing ovarian cancer (OvC) patients.. In CANCER RESEARCH Vol. 82. Retrieved from https://www.webofscience.com/
2021
Transcriptomes and metabolism define mouse and human MAIT cell heterogeneity
Appraising the Costs of Genomic Testing for Histology-Independent Technologies: An Illustrative Example for NTRK Fusions
Beresford, L., Murphy, P., Dias, S., Claxton, L., Walton, M., Metcalf, R., . . . Hodgson, R. (2021). Appraising the Costs of Genomic Testing for Histology-Independent Technologies: An Illustrative Example for NTRK Fusions. Value in Health. doi:10.1016/j.jval.2021.11.1359
COVID-19 genetic risk variants are associated with expression of multiple genes in diverse immune cell types
Schmiedel, B. J., Chandra, V., Rocha, J., Gonzalez-Colin, C., Bhattacharyya, S., Madrigal, A., . . . Vijayanand, P. (2021). COVID-19 genetic risk variants are associated with expression of multiple genes in diverse immune cell types. NATURE COMMUNICATIONS, 12(1). doi:10.1038/s41467-021-26888-3
Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma
Au, L., Hatipoglu, E., Robert de Massy, M., Litchfield, K., Beattie, G., Rowan, A., . . . Verma, H. (2021). Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma. Cancer Cell, 39(11), 1497-1518.e11. doi:10.1016/j.ccell.2021.10.001
A MULTICENTRE PHASE 1B STUDY OF NG-641, A NOVEL TRANSGENE-ARMED AND TUMOUR-SELECTIVE ADENOVIRAL VECTOR, AND PEMBROLIZUMAB AS NEOADJUVANT TREATMENT FOR SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Ottensmeier, C., Evans, M., King, E., Karydis, I., Lillie, T., Krige, D., . . . Harrington, K. (2021). A MULTICENTRE PHASE 1B STUDY OF NG-641, A NOVEL TRANSGENE-ARMED AND TUMOUR-SELECTIVE ADENOVIRAL VECTOR, AND PEMBROLIZUMAB AS NEOADJUVANT TREATMENT FOR SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK. In JOURNAL FOR IMMUNOTHERAPY OF CANCER Vol. 9 (pp. A467). doi:10.1136/jitc-2021-SITC2021.437
IMMUNE PROFILING REVEALS ENRICHMENT OF DISTINCT IMMUNE SIGNATURES IN HIGH-RISK ORAL POTENTIALLY MALIGNANT DISORDERS
Gan, C., Lee, B. K. B., Lau, S. H., Kallarakkal, T. G., Zaini, Z. M., Zain, R. B., . . . Lim, K. P. (2021). IMMUNE PROFILING REVEALS ENRICHMENT OF DISTINCT IMMUNE SIGNATURES IN HIGH-RISK ORAL POTENTIALLY MALIGNANT DISORDERS. In JOURNAL FOR IMMUNOTHERAPY OF CANCER Vol. 9 (pp. A957). doi:10.1136/jitc-2021-SITC2021.911
Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial
Fennell, D. A., Ewings, S., Ottensmeier, C., Califano, R., Hanna, G. G., Hill, K., . . . Griffiths, G. (2021). Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial. LANCET ONCOLOGY, 22(11), 1530-1540. doi:10.1016/S1470-2045(21)00471-X
DNA Vaccines Targeting Novel Cancer-Associated Antigens Frequently Expressed in Head and Neck Cancer Enhance the Efficacy of Checkpoint Inhibitor
Wang, C., Zainal, N. S., Chai, S. J., Dickie, J., Gan, C. P., Zulaziz, N., . . . Lim, K. P. (2021). DNA Vaccines Targeting Novel Cancer-Associated Antigens Frequently Expressed in Head and Neck Cancer Enhance the Efficacy of Checkpoint Inhibitor. FRONTIERS IN IMMUNOLOGY, 12. doi:10.3389/fimmu.2021.763086
Automated Analysis of Proliferating Cells Spatial Organisation Predicts Prognosis in Lung Neuroendocrine Neoplasms
Bulloni, M., Sandrini, G., Stacchiotti, I., Barberis, M., Calabrese, F., Carvalho, L., . . . Pattini, L. (2021). Automated Analysis of Proliferating Cells Spatial Organisation Predicts Prognosis in Lung Neuroendocrine Neoplasms. CANCERS, 13(19). doi:10.3390/cancers13194875
Using DNA sequencing data to quantify T cell fraction and therapy response
Bentham, R., Litchfield, K., Watkins, T. B. K., Lim, E. L., Rosenthal, R., Martinez-Ruiz, C., . . . McGranahan, N. (2021). Using DNA sequencing data to quantify T cell fraction and therapy response. NATURE, 597(7877), 555-+. doi:10.1038/s41586-021-03894-5
Intratumoral follicular regulatory T cells curtail anti-PD-1 treatment efficacy
Eschweiler, S., Clarke, J., Ramirez-Suastegui, C., Panwar, B., Madrigal, A., Chee, S. J., . . . Vijayanand, P. (2021). Intratumoral follicular regulatory T cells curtail anti-PD-1 treatment efficacy. NATURE IMMUNOLOGY, 22(8), 1052-+. doi:10.1038/s41590-021-00958-6
Early-Phase Interventional Trials in Oral Cancer Prevention
McCarthy, C., Fedele, S., Ottensmeier, C., & Shaw, R. J. (2021). Early-Phase Interventional Trials in Oral Cancer Prevention. CANCERS, 13(15). doi:10.3390/cancers13153845
The DANTE trial protocol: a randomised phase III trial to evaluate the Duration of ANti-PD-1 monoclonal antibody Treatment in patients with metastatic mElanoma
Coen, O., Corrie, P., Marshall, H., Plummer, R., Ottensmeier, C., Hook, J., . . . Danson, S. (2021). The DANTE trial protocol: a randomised phase III trial to evaluate the Duration of ANti-PD-1 monoclonal antibody Treatment in patients with metastatic mElanoma. BMC CANCER, 21(1). doi:10.1186/s12885-021-08509-w
An open-label, multicenter phase I/IIa study evaluating the safety and clinical activity of clonal neoantigen reactive T cells in patients with advanced non-small cell lung cancer (CHIRON).
Jamal-Hanjani, M., Greystoke, A., Thistlethwaite, F., Summers, Y. J., Allison, J., Cave, J., . . . Forster, M. (2021). An open-label, multicenter phase I/IIa study evaluating the safety and clinical activity of clonal neoantigen reactive T cells in patients with advanced non-small cell lung cancer (CHIRON).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 39. doi:10.1200/JCO.2021.39.15_suppl.TPS9138
Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases: Preliminary results of FOCUS (PHP-OCM-301/301A) phase III trial.
Zager, J. S., Orloff, M., Ferrucci, P. F., Glazer, E. S., Ejaz, A., Richtig, E., . . . Ottensmeier, C. (2021). Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases: Preliminary results of FOCUS (PHP-OCM-301/301A) phase III trial.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 39. doi:10.1200/JCO.2021.39.15_suppl.9510
Correlation of HPV16 gene status and gene expression in OPSCC
von Witzleben, A., Currall, E., Wood, O., Chudley, L., Akinyegun, O., Thomas, J., . . . Ottensmeier, C. H. (2021). Correlation of HPV16 gene status and gene expression in OPSCC. In Laryngo-Rhino-Otologie. Georg Thieme Verlag KG. doi:10.1055/s-0041-1727978
Korrelation von HPV16 Genstatus und Genexpression in OPSCC
von Witzleben, A., Currall, E., Wood, O., Chudley, L., Akinyegun, O., Thomas, J., . . . Ottensmeier, C. H. (2021). Korrelation von HPV16 Genstatus und Genexpression in OPSCC. In Laryngo-Rhino-Otologie. Georg Thieme Verlag KG. doi:10.1055/s-0041-1727869
RNA-sequencing reveals an immune “hot” gene expression signature in oropharyngeal squamous cell carcinoma which is upregulated upon decitabine treatment in cell lines
Ezic, J., von Witzleben, A., Fehn, A., Bens, M., Thomas, J., Ammerpohl, O., . . . Laban, S. (2021). RNA-sequencing reveals an immune “hot” gene expression signature in oropharyngeal squamous cell carcinoma which is upregulated upon decitabine treatment in cell lines. In Laryngo-Rhino-Otologie. Georg Thieme Verlag KG. doi:10.1055/s-0041-1727963
Prospective longitudinal study of immune checkpoint molecule (ICM) expression in immune cell subsets during curative conventional therapy of head and neck squamous cell carcinoma (HNSCC)
von Witzleben, A., Fehn, A., Grages, A., Ezic, J., Jeske, S. S., Puntigam, L. K., . . . Laban, S. (2021). Prospective longitudinal study of immune checkpoint molecule (ICM) expression in immune cell subsets during curative conventional therapy of head and neck squamous cell carcinoma (HNSCC). INTERNATIONAL JOURNAL OF CANCER, 148(8), 2023-2035. doi:10.1002/ijc.33446
Melanoma-reactive T cells take up residence
Ganesan, A. -P., & Ottensmeier, C. H. H. (2021). Melanoma-reactive T cells take up residence. NATURE CANCER, 2(3), 253-255. doi:10.1038/s43018-021-00189-6
PS01.11 Nivolumab Versus Placebo in Relapsed Malignant Mesothelioma: The CONFIRM Phase 3 Trial
Fennell, D., Ottensmeier, C., Califano, R., Hanna, G., Ewings, S., Hill, K., . . . Lester, J. (2021). PS01.11 Nivolumab Versus Placebo in Relapsed Malignant Mesothelioma: The CONFIRM Phase 3 Trial. Journal of Thoracic Oncology, 16(3), S62. doi:10.1016/j.jtho.2021.01.323
Correlation of HPV16 Gene Status and Gene Expression With Antibody Seropositivity and TIL Status in OPSCC.
von Witzleben, A., Currall, E., Wood, O., Chudley, L., Akinyegun, O., Thomas, J., . . . Ottensmeier, C. H. (2021). Correlation of HPV16 Gene Status and Gene Expression With Antibody Seropositivity and TIL Status in OPSCC.. Frontiers in Oncology, 10, 591063. doi:10.3389/fonc.2020.591063
Severely ill COVID-19 patients display impaired exhaustion features in SARS-CoV-2-reactive CD8<SUP>+</SUP> T cells
Kusnadi, A., Ramirez-Suastegui, C., Fajardo, V., Chee, S. J., Meckiff, B. J., Simon, H., . . . Ottensmeier, C. H. (2021). Severely ill COVID-19 patients display impaired exhaustion features in SARS-CoV-2-reactive CD8<SUP>+</SUP> T cells. SCIENCE IMMUNOLOGY, 6(55). doi:10.1126/sciimmunol.abe4782
Analysis of immune landscape in pancreatic and ileal neuroendocrine tumors demonstrates an immune cold tumor microenvironment
Tanno, L., Naheed, S., Dunbar, J., Tod, J., Lopez, M. A., Taylor, J., . . . Ottensmeier, C. H. (2021). Analysis of immune landscape in pancreatic and ileal neuroendocrine tumors demonstrates an immune cold tumor microenvironment. In JOURNAL OF NEUROENDOCRINOLOGY Vol. 33 (pp. 22). Retrieved from https://www.webofscience.com/
Anti-immune defences involving down-regulation of MHC-I or beta-catenin activation do not explain immune coldness of pancreatic or ileal neuroendocrine tumors
Tanno, L., Naheed, S., Lopez, M. A., Taylor, J., Machado, M., Chee, S., . . . Ottensmeier, C. H. (2021). Anti-immune defences involving down-regulation of MHC-I or beta-catenin activation do not explain immune coldness of pancreatic or ileal neuroendocrine tumors. In JOURNAL OF NEUROENDOCRINOLOGY Vol. 33 (pp. 23). Retrieved from https://www.webofscience.com/
2020
Novel players: tissue-resident memory B cells
Savelyeva, N., & Ottensmeier, C. H. (2020). Novel players: tissue-resident memory B cells. BLOOD, 136(24), 2722-2723. doi:10.1182/blood.2020007890
Paracrine SPARC signaling dysregulates alveolar epithelial barrier integrity and function in lung fibrosis
Conforti, F., Ridley, R., Brereton, C., Alzetani, A., Johnson, B., Marshall, B. G., . . . Davies, D. E. (2020). Paracrine SPARC signaling dysregulates alveolar epithelial barrier integrity and function in lung fibrosis. CELL DEATH DISCOVERY, 6(1). doi:10.1038/s41420-020-0289-9
Imbalance of Regulatory and Cytotoxic SARS-CoV-2-Reactive CD4+ T Cells in COVID-19
Meckiff, B. J., Ramirez-Suastegui, C., Fajardo, V., Chee, S. J., Kusnadi, A., Simon, H., . . . Vijayanand, P. (2020). Imbalance of Regulatory and Cytotoxic SARS-CoV-2-Reactive CD4+ T Cells in COVID-19. Cell, 183(5), 1340-1353. doi:10.1016/j.cell.2020.10.001
Abstract PO-039: Spatially discrete signalling niches regulate fibroblast heterogeneity in human lung cancer
Hanley, C. J., Waise, S., Rachel, P., Lopez, M. -A., Taylor, J., Kimbley, L., . . . Thomas, G. (2020). Abstract PO-039: Spatially discrete signalling niches regulate fibroblast heterogeneity in human lung cancer. Cancer Research, 80(21_Supplement). doi:10.1158/1538-7445.tumhet2020-po-039
CTEN Induces Tumour Cell Invasion and Survival and Is Prognostic in Radiotherapy-Treated Head and Neck Cancer
Fleming, J. C., Woo, J., Moutasim, K., Hanley, C. J., Frampton, S. J., Wood, O., . . . Thomas, G. J. (2020). CTEN Induces Tumour Cell Invasion and Survival and Is Prognostic in Radiotherapy-Treated Head and Neck Cancer. CANCERS, 12(10). doi:10.3390/cancers12102963
HNSCC: Tumour Antigens and Their Targeting by Immunotherapy
von Witzleben, A., Wang, C., Laban, S., Savelyeva, N., & Ottensmeier, C. H. (2020). HNSCC: Tumour Antigens and Their Targeting by Immunotherapy. CELLS, 9(9). doi:10.3390/cells9092103
CyTOF mass cytometry reveals phenotypically distinct human blood neutrophil populations differentially correlated with melanoma stage
Zhu, Y. P., Eggert, T., Araujo, D. J., Vijayanand, P., Ottensmeier, C. H., & Hedrick, C. C. (2020). CyTOF mass cytometry reveals phenotypically distinct human blood neutrophil populations differentially correlated with melanoma stage. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 8(2). doi:10.1136/jitc-2019-000473
Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial
Middleton, G., Brock, K., Savage, J., Mant, R., Summers, Y., Connibear, J., . . . Billingham, L. (2020). Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial. The Lancet Respiratory Medicine, 8(9), 895-904. doi:10.1016/S2213-2600(20)30033-3
A phase Ib study to evaluate RO7198457, an individualized Neoantigen Specific immunoTherapy (iNeST), in combination with atezolizumab in patients with locally advanced or metastatic solid tumors
Lopez, J. S., Camidge, R., Iafolla, M., Rottey, S., Schuler, M., Hellmann, M., . . . Powles, T. (2020). A phase Ib study to evaluate RO7198457, an individualized Neoantigen Specific immunoTherapy (iNeST), in combination with atezolizumab in patients with locally advanced or metastatic solid tumors. In CANCER RESEARCH Vol. 80. doi:10.1158/1538-7445.AM2020-CT301
M1<SUP>hot</SUP>tumor-associated macrophages boost tissue-resident memory T cells infiltration and survival in human lung cancer
Garrido-Martin, E. M., Mellows, T. W. P., Clarke, J., Ganesan, A. -P., Wood, O., Cazaly, A., . . . Sanchez-Elsner, T. (2020). M1<SUP>hot</SUP>tumor-associated macrophages boost tissue-resident memory T cells infiltration and survival in human lung cancer. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 8(2). doi:10.1136/jitc-2020-000778
Severely ill COVID-19 patients display augmented functional properties in SARS-CoV-2-reactive CD8 + T cells.
Kusnadi, A., Ramírez-Suástegui, C., Fajardo, V., Chee, S. J., Meckiff, B. J., Simon, H., . . . Ottensmeier, C. H. (2020). Severely ill COVID-19 patients display augmented functional properties in SARS-CoV-2-reactive CD8 + T cells.. bioRxiv. doi:10.1101/2020.07.09.194027
Single-Cell Transcriptomic Analysis of SARS-CoV-2 Reactive CD4 + T Cells.
Meckiff, B. J., Ramírez-Suástegui, C., Fajardo, V., Chee, S. J., Kusnadi, A., Simon, H., . . . Vijayanand, P. (2020). Single-Cell Transcriptomic Analysis of SARS-CoV-2 Reactive CD4 + T Cells.. SSRN, 3641939. doi:10.2139/ssrn.3641939
A clonal expression biomarker associates with lung cancer mortality (vol 25, pg 1540, 2019)
Biswas, D., Birkbak, N. J., Rosenthal, R., Hiley, C. T., Lim, E. L., Papp, K., . . . Swanton, C. (2020). A clonal expression biomarker associates with lung cancer mortality (vol 25, pg 1540, 2019). NATURE MEDICINE, 26(7), 1148. doi:10.1038/s41591-020-0899-z
Geospatial immune variability illuminates differential evolution of lung adenocarcinoma
AbdulJabbar, K., Raza, S. E. A., Rosenthal, R., Jamal-Hanjani, M., Veeriah, S., Akarca, A., . . . Yuan, Y. (2020). Geospatial immune variability illuminates differential evolution of lung adenocarcinoma. NATURE MEDICINE, 26(7), 1054-+. doi:10.1038/s41591-020-0900-x
Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse (vol 25, pg 1534, 2019)
Chemi, F., Rothwell, D. G., McGranahan, N., Gulati, S., Abbosh, C., Pearce, S. P., . . . Dive, C. (2020). Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse (vol 25, pg 1534, 2019). NATURE MEDICINE, 26(7), 1147. doi:10.1038/s41591-020-0865-9
Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer (vol 25, pg1549, 2019)
Joshi, K., de Massy, M. R., Ismail, M., Reading, J. L., Uddin, I., Woolston, A., . . . Chain, B. (2020). Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer (vol 25, pg1549, 2019). NATURE MEDICINE, 26(7), 1148. doi:10.1038/s41591-020-0866-8
Single-cell transcriptomic analysis of SARS-CoV-2 reactive CD4+T cells
Meckiff, B. J., Ramírez-Suástegui, C., Fajardo, V., Chee, S. J., Kusnadi, A., Simon, H., . . . Vijayanand, P. (2020). Single-cell transcriptomic analysis of SARS-CoV-2 reactive CD4 + T cells.. bioRxiv. doi:10.1101/2020.06.12.148916
Spatially discrete signalling niches regulate fibroblast heterogeneity in human lung cancer
Hanley, C. J., Waise, S., Rachel, P., Lopez, M. -A., Taylor, J., Kimbley, L., . . . Thomas, G. (2020). Spatially discrete signalling niches regulate fibroblast heterogeneity in human lung cancer.. CANCER RESEARCH, 80(21). Retrieved from https://www.webofscience.com/
Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue
Litchfield, K., Stanislaw, S., Spain, L., Gallegos, L. L., Rowan, A., Schnidrig, D., . . . Turajlic, S. (2020). Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue. CELL REPORTS, 31(5). doi:10.1016/j.celrep.2020.107550
NOX4 Inhibition Potentiates Immunotherapy by Overcoming Cancer-Associated Fibroblast-Mediated CD8 T-cell Exclusion from Tumors
Ford, K., Hanley, C. J., Mellone, M., Szyndralewiez, C., Heitz, F., Wiesel, P., . . . Thomas, G. J. (2020). NOX4 Inhibition Potentiates Immunotherapy by Overcoming Cancer-Associated Fibroblast-Mediated CD8 T-cell Exclusion from Tumors. CANCER RESEARCH, 80(9), 1846-1860. doi:10.1158/0008-5472.CAN-19-3158
Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma
Cebon, J. S., Gore, M., Thompson, J. F., Davis, I. D., McArthur, G. A., Walpole, E., . . . Chen, W. (2020). Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 8(1). doi:10.1136/jitc-2019-000410
Immune checkpoint inhibitors in advanced nasopharyngeal carcinoma: Beyond an era of chemoradiation?
Masterson, L., Howard, J., Gonzalez-Cruz, J., Jackson, C., Barnett, C., Overton, L., . . . Lechner, M. (2020). Immune checkpoint inhibitors in advanced nasopharyngeal carcinoma: Beyond an era of chemoradiation?. INTERNATIONAL JOURNAL OF CANCER, 146(8), 2305-2314. doi:10.1002/ijc.32869
Interplay between whole-genome doubling and the accumulation of deleterious alterations in cancer evolution
Lopez, S., Lim, E. L., Horswell, S., Haase, K., Huebner, A., Dietzen, M., . . . McGranahan, N. (2020). Interplay between whole-genome doubling and the accumulation of deleterious alterations in cancer evolution. NATURE GENETICS, 52(3), 283-+. doi:10.1038/s41588-020-0584-7
Single-Cell Analysis of Cancer-Associated Fibroblast Heterogeneity in Non-Small Cell Lung Cancer: Relating Molecular Phenotype to Function
Waise, S., Hanley, C. J., Parker, R., Ottensmeier, C. H., Rose-Zerilli, M. J. J., & Thomas, G. J. (2020). Single-Cell Analysis of Cancer-Associated Fibroblast Heterogeneity in Non-Small Cell Lung Cancer: Relating Molecular Phenotype to Function. In JOURNAL OF PATHOLOGY Vol. 250 (pp. 9). Retrieved from https://www.webofscience.com/
Anti-PD-1 immunotherapy leads to tuberculosis reactivation via dysregulation of TNF-α
Tezera, L. B., Bielecka, M. K., Ogongo, P., Walker, N. F., Ellis, M., Garay-Baquero, D. J., . . . Elkington, P. T. (2020). Anti-PD-1 immunotherapy leads to tuberculosis reactivation via dysregulation of TNF-α. ELIFE, 9. doi:10.7554/eLife.52668
CD4+ follicular helper-like T cells are key players in anti-tumor immunity
Singh, D., Ganesan, A. P., Panwar, B., Eschweiler, S., Hanley, C. J., Madrigal, A., . . . Vijayanand, P. (2020). CD4<sup>+</sup>follicular helper-like T cells are key players in anti-tumor immunity. doi:10.1101/2020.01.08.898346
COULD THE COST OF GENOMIC TESTING CHALLENGE THE ECONOMIC VIABILITY OF NEW HISTOLOGY-INDEPENDENT CANCER THERAPIES?
Beresford, L., Murphy, P., Dias, S., Claxton, L., Llewellyn, A., Walton, M., . . . Hodgson, R. (2020). COULD THE COST OF GENOMIC TESTING CHALLENGE THE ECONOMIC VIABILITY OF NEW HISTOLOGY-INDEPENDENT CANCER THERAPIES?. In MEDICAL DECISION MAKING Vol. 40 (pp. E433-E434). Retrieved from https://www.webofscience.com/
Flow Cytometry in Cancer Immunotherapy: Applications, Quality Assurance, and Future
Gouttefangeas, C., Walter, S., Welters, M. J. P., Ottensmeier, C., van der Burg, S. H., & Chan, C. (2020). Flow Cytometry in Cancer Immunotherapy: Applications, Quality Assurance, and Future. In CANCER IMMUNOLOGY (pp. 761-783). doi:10.1007/978-3-030-30845-2_33
2019
An Optimized Method to Isolate Human Fibroblasts from Tissue for <i>ex vivo</i> Analysis
Waise, S., Parker, R., Rose-Zerilli, M. J. J., Layfield, D. M., Wood, O., West, J., . . . Hanley, C. J. (2019). An Optimized Method to Isolate Human Fibroblasts from Tissue for <i>ex vivo</i> Analysis. BIO-PROTOCOL, 9(23). doi:10.21769/BioProtoc.3440
Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial (vol 29, pg 1843, 2018)
Corrie, P. G., Marshall, A., Nathan, P. D., Lorigan, P., Gore, M., Tahir, S., . . . Middleton, M. R. (2019). Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial (vol 29, pg 1843, 2018). ANNALS OF ONCOLOGY, 30(12), 2013-2014. doi:10.1093/annonc/mdz237
CyTOF reveals phenotypically-distinct human blood neutrophil populations differentially correlated with melanoma stage
Zhu, Y. P., Eggert, T., Araujo, D., Vijayanand, P., Ottensmeier, C., & Hedrick, C. (2019). CyTOF reveals phenotypically-distinct human blood neutrophil populations differentially correlated with melanoma stage. doi:10.1101/826644
A clonal expression biomarker associates with lung cancer mortality
Biswas, D., Birkbak, N. J., Rosenthal, R., Hiley, C. T., Lim, E. L., Papp, K., . . . Swanton, C. (2019). A clonal expression biomarker associates with lung cancer mortality. NATURE MEDICINE, 25(10), 1540-+. doi:10.1038/s41591-019-0595-z
Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse
Chemi, F., Rothwell, D. G., McGranahan, N., Gulati, S., Abbosh, C., Pearce, S. P., . . . Dive, C. (2019). Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse. NATURE MEDICINE, 25(10), 1534-+. doi:10.1038/s41591-019-0593-1
Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer
Joshi, K., de Massy, M. R., Ismail, M., Reading, J. L., Uddin, I., Woolston, A., . . . Chain, B. (2019). Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer. NATURE MEDICINE, 25(10), 1549-+. doi:10.1038/s41591-019-0592-2
Single-cell transcriptomic analysis of tissue-resident memory T cells in human lung cancer
Clarke, J., Panwar, B., Madrigal, A., Singh, D., Gujar, R., Wood, O., . . . Vijayanand, P. (2019). Single-cell transcriptomic analysis of tissue-resident memory T cells in human lung cancer. JOURNAL OF EXPERIMENTAL MEDICINE, 216(9), 2128-2149. doi:10.1084/jem.20190249
The utility of Ki-67 as a prognostic biomarker in pulmonary neuroendocrine tumours: protocol for a systematic review and meta-analysis
Naheed, S., Holden, C., Tanno, L., Jaynes, E., Cave, J., Ottensmeier, C. H., & Pelosi, G. (2019). The utility of Ki-67 as a prognostic biomarker in pulmonary neuroendocrine tumours: protocol for a systematic review and meta-analysis. BMJ OPEN, 9(8). doi:10.1136/bmjopen-2019-031531
Autophagy inhibition-mediated epithelial-mesenchymal transition augments local myofibroblast differentiation in pulmonary fibrosis
Hill, C., Li, J., Liu, D., Conforti, F., Brereton, C. J., Yao, L., . . . Wang, Y. (2019). Autophagy inhibition-mediated epithelial-mesenchymal transition augments local myofibroblast differentiation in pulmonary fibrosis. CELL DEATH & DISEASE, 10. doi:10.1038/s41419-019-1820-x
Importance of the immune system in head and neck cancer
Mirza, A. H., Thomas, G., Ottensmeier, C. H., & King, E. V. (2019). Importance of the immune system in head and neck cancer. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 41(8), 2789-2800. doi:10.1002/hed.25716
An optimised tissue disaggregation and data processing pipeline for characterising fibroblast phenotypes using single-cell RNA sequencing
Waise, S., Parker, R., Rose-Zerilli, M. J. J., Layfield, D. M., Wood, O., West, J., . . . Hanley, C. J. (2019). An optimised tissue disaggregation and data processing pipeline for characterising fibroblast phenotypes using single-cell RNA sequencing. SCIENTIFIC REPORTS, 9. doi:10.1038/s41598-019-45842-4
Abstract 1466: Combination immunotherapy successfully control tumor growth in a transgenic mouse model
Lim, K. P., Zainal, S., Zulaziz, N., Gan, C. P., Chai, S. J., Lye, B. K. W., . . . Cheong, S. C. (2019). Abstract 1466: Combination immunotherapy successfully control tumor growth in a transgenic mouse model. In Clinical Research (Excluding Clinical Trials) (pp. 1466). American Association for Cancer Research. doi:10.1158/1538-7445.sabcs18-1466
Abstract 3762: Single-cell analysis of cancer-associated fibroblast heterogeneity in non-small cell lung cancer: Mapping molecular phenotypes in tumors
Waise, S., Hanley, C. J., Parker, R., Ottensmeier, C. H., Rose-Zerilli, M., & Thomas, G. J. (2019). Abstract 3762: Single-cell analysis of cancer-associated fibroblast heterogeneity in non-small cell lung cancer: Mapping molecular phenotypes in tumors. In Tumor Biology (pp. 3762). American Association for Cancer Research. doi:10.1158/1538-7445.sabcs18-3762
Combination immunotherapy successfully control tumor growth in a transgenic mouse model
Lim, K. P., Zainal, S., Zulaziz, N., Gan, C. P., Chai, S. J., Lye, B. K. W., . . . Cheong, S. C. (2019). Combination immunotherapy successfully control tumor growth in a transgenic mouse model. In CANCER RESEARCH Vol. 79. doi:10.1158/1538-7445.AM2019-1466
HPV Epitope Processing Differences Correlate with ERAP1 Allotype and Extent of CD8<SUP>+</SUP> T-cell Tumor Infiltration in OPSCC
Reeves, E., Wood, O., Ottensmeier, C. H., King, E. V., Thomas, G. J., Elliott, T., & James, E. (2019). HPV Epitope Processing Differences Correlate with ERAP1 Allotype and Extent of CD8<SUP>+</SUP> T-cell Tumor Infiltration in OPSCC. CANCER IMMUNOLOGY RESEARCH, 7(7), 1202-1213. doi:10.1158/2326-6066.CIR-18-0498
Single-cell analysis of cancer-associated fibroblast heterogeneity in non-small cell lung cancer: Mapping molecular phenotypes in tumors
Waise, S., Hanley, C. J., Parker, R., Ottensmeier, C. H., Rose-Zerilli, M., & Thomas, G. J. (2019). Single-cell analysis of cancer-associated fibroblast heterogeneity in non-small cell lung cancer: Mapping molecular phenotypes in tumors. In CANCER RESEARCH Vol. 79. doi:10.1158/1538-7445.AM2019-3762
Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer
Hardy-Werbin, M., Rocha, P., Arpi, O., Taus, A., Nonell, L., Duran, X., . . . Arriola, E. (2019). Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer. ONCOIMMUNOLOGY, 8(6). doi:10.1080/2162402X.2019.1593810
Identification of tumor antigens among the HLA peptidomes of glioblastoma tumors and plasma. (Retraction of Vol 17, Pg 2132, 2018)
Shraibman, B., Barnea, E., Kadosh, D. M., Haimovich, Y., Slobodin, G., Rosner, I., . . . Admon, A. (2019). Identification of tumor antigens among the HLA peptidomes of glioblastoma tumors and plasma. (Retraction of Vol 17, Pg 2132, 2018). MOLECULAR & CELLULAR PROTEOMICS, 18(6), 1270. doi:10.1074/mcp.W119.001571
Paracrine signalling during ZEB1-mediated epithelial-mesenchymal transition augments local myofibroblast differentiation in lung fibrosis
Yao, L., Conforti, F., Hill, C., Bell, J., Drawater, L., Li, J., . . . Wang, Y. (2019). Paracrine signalling during ZEB1-mediated epithelial-mesenchymal transition augments local myofibroblast differentiation in lung fibrosis. CELL DEATH AND DIFFERENTIATION, 26(5), 943-957. doi:10.1038/s41418-018-0175-7
Recent advances in the molecular landscape of lung neuroendocrine tumors
Pelosi, G., Bianchi, F., Hofman, P., Pattini, L., Stroebel, P., Calabrese, F., . . . Ottensmeier, C. H. (2019). Recent advances in the molecular landscape of lung neuroendocrine tumors. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 19(4), 281-297. doi:10.1080/14737159.2019.1595593
Neoantigen-directed immune escape in lung cancer evolution
Rosenthal, R., Cadieux, E. L., Salgado, R., Al Bakir, M., Moore, D. A., Hiley, C. T., . . . Kidd, A. (2019). Neoantigen-directed immune escape in lung cancer evolution. NATURE, 567(7749), 479-+. doi:10.1038/s41586-019-1032-7
Actively personalized vaccination trial for newly diagnosed glioblastoma (vol 565, pg 240, 2018)
Hilf, N., Kuttruff-Coqui, S., Frenzel, K., Bukur, V., Stevanovic, S., Gouttefangeas, C., . . . Wick, W. (2019). Actively personalized vaccination trial for newly diagnosed glioblastoma (vol 565, pg 240, 2018). NATURE, 566(7745), E13. doi:10.1038/s41586-019-0959-z
Recurrent group A Streptococcus tonsillitis is an immunosusceptibility disease involving antibody deficiency and aberrant T-FH cells
Dan, J. M., Havenar-Daughton, C., Kendric, K., Al-kolla, R., Kaushik, K., Rosales, S. L., . . . Crotty, S. (2019). Recurrent group A Streptococcus tonsillitis is an immunosusceptibility disease involving antibody deficiency and aberrant T-FH cells. Science Translational Medicine, 11(478). doi:10.1126/scitranslmed.aau3776
HPV, tumour metabolism and novel target identification in head and neck squamous cell carcinoma
Fleming, J. C., Woo, J., Moutasim, K., Mellone, M., Frampton, S. J., Mead, A., . . . Thomas, G. J. (2019). HPV, tumour metabolism and novel target identification in head and neck squamous cell carcinoma. British Journal of Cancer, 120(3), 356-367. doi:10.1038/s41416-018-0364-7
Immunomonitoring for actively personalized peptide vaccines (APVACs) during immunotherapeutic treatment of glioblastoma
Ulges, A., Hilf, N., Wick, W., Platten, M., Dietrich, P. -Y., Frenzel, K., . . . Mendrzyk, R. (2019). Immunomonitoring for actively personalized peptide vaccines (APVACs) during immunotherapeutic treatment of glioblastoma. In CANCER IMMUNOLOGY RESEARCH Vol. 7. doi:10.1158/2326-6074.CRICIMTEATIAACR18-A020
Plant viral particle vaccine induces a potent antitumor response through induction of antigen-specific T-cells and overcoming an immunosuppressive tumor microenvironment
Wang, C., Wang, Y., Allen, A. J., Jobsri, J., Thomas, G. J., Ottensmeier, C. H., & Savelyeva, N. (2019). Plant viral particle vaccine induces a potent antitumor response through induction of antigen-specific T-cells and overcoming an immunosuppressive tumor microenvironment. In CANCER IMMUNOLOGY RESEARCH Vol. 7. doi:10.1158/2326-6074.CRICIMTEATIAACR18-B139
Actively personalized vaccination trial for newly diagnosed glioblastoma
Hilf, N., Kuttruff-Coqui, S., Frenzel, K., Bukur, V., Stevanovic, S., Gouttefangeas, C., . . . Wick, W. (2019). Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature, 565(7738), 240-245. doi:10.1038/s41586-018-0810-y
A randomised phase III multicentre trial to evaluate the duration of anti-PD1 monoclonal antibody monotherapy in patients with metastatic melanoma (DANTE) - Stage 1 Results
Danson, S., Plummer, R., Ottensmeier, C., Hook, J., Marshall, H., Sagoo, G., . . . Corrie, P. (2019). A randomised phase III multicentre trial to evaluate the duration of anti-PD1 monoclonal antibody monotherapy in patients with metastatic melanoma (DANTE) - Stage 1 Results. In BRITISH JOURNAL OF CANCER Vol. 121 (pp. 23). Retrieved from https://www.webofscience.com/
Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma
Shraibman, B., Barnea, E., Kadosh, D. M., Haimovich, Y., Slobodin, G., Rosner, I., . . . Admon, A. (2019). Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. MOLECULAR & CELLULAR PROTEOMICS, 18(6), 1255-1268. doi:10.1074/mcp.RA119.001524
Investigating the Mechanisms Underlying Tumour Immune Evasion in Head and Neck Squamous Cell Carcinoma
Robinson, H., Fleming, J. C., Thirdborough, S., Ottensmeier, C., Thomas, G. J., & Moutasim, K. A. (2019). Investigating the Mechanisms Underlying Tumour Immune Evasion in Head and Neck Squamous Cell Carcinoma. In JOURNAL OF PATHOLOGY Vol. 248 (pp. S18). Retrieved from https://www.webofscience.com/
2018
Implications of Tuberculosis Reactivation after Immune Checkpoint Inhibition
Elkington, P. T., Bateman, A. C., Thomas, G. J., & Ottensmeier, C. H. (2018). Implications of Tuberculosis Reactivation after Immune Checkpoint Inhibition. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 198(11), 1451-1453. doi:10.1164/rccm.201807-1250LE
ATIM-20. GAPVAC-101 TRIAL OF A HIGHLY PERSONALIZED PEPTIDE VACCINATION FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
Wick, W., Dietrich, P. -Y., HIlf, N., Platten, M., Frenzel, K., Admon, A., . . . Singh-Jasuja, H. (2018). ATIM-20. GAPVAC-101 TRIAL OF A HIGHLY PERSONALIZED PEPTIDE VACCINATION FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA. Neuro-Oncology, 20(suppl_6), vi5. doi:10.1093/neuonc/noy148.015
ATIM-20. GAPVAC-101 TRIAL OF A HIGHLY PERSONALIZED PEPTIDE VACCINATION FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
Wick, W., Dietrich, P. -Y., HIlf, N., Platten, M., Frenzel, K., Admon, A., . . . Singh-Jasuja, H. (2018). ATIM-20. GAPVAC-101 TRIAL OF A HIGHLY PERSONALIZED PEPTIDE VACCINATION FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA. Neuro-oncology, 20(Suppl 6), vi5.
Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma (Retracted article. See vol. 18, pg. 1270, 2019)
Shraibman, B., Barnea, E., Kadosh, D. M., Haimovich, Y., Slobodin, G., Rosner, I., . . . Admon, A. (2018). Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma (Retracted article. See vol. 18, pg. 1270, 2019). MOLECULAR & CELLULAR PROTEOMICS, 17(11), 2132-2145. doi:10.1074/mcp.RA118.000792
Patient selection for anti-PD-1/PD-L1 therapy in advanced non-small-cell lung cancer: implications for clinical practice
Califano, R., Lal, R., Lewanski, C., Nicolson, M. C., Ottensmeier, C. H., Popat, S., . . . Postmus, P. E. (2018). Patient selection for anti-PD-1/PD-L1 therapy in advanced non-small-cell lung cancer: implications for clinical practice. FUTURE ONCOLOGY, 14(23), 2415-2431. doi:10.2217/fon-2018-0330
CD103+CD8+Lymphocytes Characterize the Immune Infiltration in a Case With Pseudoprogression in Squamous NSCLC
Rocha, P., Hardy-Werbin, M., Naranjo, D., Taus, A., Rodrigo, M., Zuccarino, F., . . . Arriola, E. (2018). CD103+CD8+Lymphocytes Characterize the Immune Infiltration in a Case With Pseudoprogression in Squamous NSCLC. JOURNAL OF THORACIC ONCOLOGY, 13(10), E193-E196. doi:10.1016/j.jtho.2018.05.008
Immunotherapy in the immunodeficient: A treatment paradox?
Campbell, N. J., Longley, J., Pascalis, A., Bennett, J., Remer, M., Stone, R., . . . Ottensmeier, C. (2018). Immunotherapy in the immunodeficient: A treatment paradox?. ANNALS OF ONCOLOGY, 29. Retrieved from https://www.webofscience.com/
Pembrolizumab in performance status 2 patients with non-small cell lung cancer (NSCLC): Results of the PePS2 trial
Middleton, G., Brock, K., Summers, Y., Connibear, J., Shah, R., Ottensmeier, C., . . . Billingham, L. (2018). Pembrolizumab in performance status 2 patients with non-small cell lung cancer (NSCLC): Results of the PePS2 trial. ANNALS OF ONCOLOGY, 29, 497. Retrieved from https://www.webofscience.com/
OS2.2 Highly personalized peptide vaccination for patients with newly diagnosed glioblastoma: the GAPVAC trial
Dietrich, P., Wick, W., Hilf, N., Frenzel, K., Gouttefangeas, C., Platten, M., . . . Singh-Jasuja, H. (2018). OS2.2 Highly personalized peptide vaccination for patients with newly diagnosed glioblastoma: the GAPVAC trial. Neuro-Oncology, 20(suppl_3), iii219. doi:10.1093/neuonc/noy139.015
Exosomal microRNAs in the lung: eliciting long-term intercellular communication?
Lekkas, A., Mellows, T., Garrido-Martin, M., Howarth, P. H., Friedmann, P. S., Vijayanand, P., . . . Sanchez-Elsner, T. (2018). Exosomal microRNAs in the lung: eliciting long-term intercellular communication?. In EUROPEAN RESPIRATORY JOURNAL Vol. 52. doi:10.1183/13993003.congress-2018.OA2118
OS2.2 Highly personalized peptide vaccination for patients with newly diagnosed glioblastoma: the GAPVAC trial
Dietrich, P., Wick, W., Hilf, N., Frenzel, K., Gouttefangeas, C., Platten, M., . . . GAPVAC Consortium. (2018). OS2.2 Highly personalized peptide vaccination for patients with newly diagnosed glioblastoma: the GAPVAC trial. Neuro-oncology, 20(Suppl 3), iii219.
Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial
Corrie, P. G., Marshall, A., Nathan, P. D., Lorigan, P., Gore, M., Tahir, S., . . . Middleton, M. R. (2018). Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial. ANNALS OF ONCOLOGY, 29(8), 1843-1852. doi:10.1093/annonc/mdy229
Nanoscale dysregulation of collagen structure-function disrupts mechano-homeostasis and mediates pulmonary fibrosis
Jones, M. G., Andriotis, O. G., Roberts, J. J. W., Lunn, K., Tear, V. J., Cao, L., . . . Davies, D. E. (2018). Nanoscale dysregulation of collagen structure-function disrupts mechano-homeostasis and mediates pulmonary fibrosis. ELIFE, 7. doi:10.7554/eLife.36354
Characterizing heterogeneity in the cancer-associated fibroblast population in non-small cell lung cancer: Relating phenotype to function
Waise, S., Hanley, C., Parker, R., Rose-Zerilli, M., Ottensmeier, C., & Thomas, G. (2018). Characterizing heterogeneity in the cancer-associated fibroblast population in non-small cell lung cancer: Relating phenotype to function. In CANCER RESEARCH Vol. 78. doi:10.1158/1538-7445.AM2018-5084
Th1/Th2 and inflammatory cytokines as biomarkers of response to ipilimumab in small cell lung cancer (SCLC) patients
Hardy-Werbin, M., Rocha, P., Arpi, O., Taus, A., Duran Jorda, X., Joseph-Pietras, D., . . . Arriola, E. (2018). Th1/Th2 and inflammatory cytokines as biomarkers of response to ipilimumab in small cell lung cancer (SCLC) patients. In CANCER RESEARCH Vol. 78. doi:10.1158/1538-7445.AM2018-LB-143
Evidence that recurrent Group A streptococcus tonsillitis is an immunosusceptibility disease involving antibody deficiency and aberrant Tfh cells
Dan, J., Havenar-Daughton, C., Kendric, K., Kaushik, K., Rosales, S., Anderson, E., . . . Crotty, S. (2018). Evidence that recurrent Group A streptococcus tonsillitis is an immunosusceptibility disease involving antibody deficiency and aberrant Tfh cells. doi:10.1101/356741
Targeting gp100 and TRP-2 with a DNA vaccine: Incorporating T cell epitopes with a human IgG1 antibody induces potent T cell responses that are associated with favourable clinical outcome in a phase I/II trial
Patel, P. M., Ottensmeier, C. H., Mulatero, C., Lorigan, P., Plummer, R., Pandha, H., . . . Durrant, L. G. (2018). Targeting gp100 and TRP-2 with a DNA vaccine: Incorporating T cell epitopes with a human IgG1 antibody induces potent T cell responses that are associated with favourable clinical outcome in a phase I/II trial. ONCOIMMUNOLOGY, 7(6). doi:10.1080/2162402X.2018.1433516
PO-516 E6/E7 RNA(LIP): a novel liposomal RNA vaccine for treatment of patients with HPV16-positive malignancies
Grunwitz, C., Jahndel, V., Braun, J., Schwarck-Kokarakis, D., Vascotto, F., Setzer, J., . . . Sahin, U. (2018). PO-516 E6/E7 RNA(LIP): a novel liposomal RNA vaccine for treatment of patients with HPV16-positive malignancies. ESMO Open, 3, A224-A225. doi:10.1136/esmoopen-2018-eacr25.531
A randomised, double-blind, placebo-controlled phase IIa trial of AMG319 given orally as neoadjuvant therapy in patients with human papillomavirus (HPV) positive and negative head and neck squamous cell carcinoma (HNSCC).
Ottensmeier, C. H. H., Jones, T., Sacco, J. J., McCaul, J. A., Brennan, P., Paterson, C., . . . King, E. (2018). A randomised, double-blind, placebo-controlled phase IIa trial of AMG319 given orally as neoadjuvant therapy in patients with human papillomavirus (HPV) positive and negative head and neck squamous cell carcinoma (HNSCC).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 36. doi:10.1200/JCO.2018.36.15_suppl.6068
CONFIRM: A phase III randomized trial to evaluate the efficacy of nivolumab versus placebo in relapsed mesothelioma
Fennell, D. A., Kirkpatrick, E. V., Cozens, K., Danson, S., Hanna, G. G., Lester, J. F., . . . Griffiths, G. (2018). CONFIRM: A phase III randomized trial to evaluate the efficacy of nivolumab versus placebo in relapsed mesothelioma. In JOURNAL OF CLINICAL ONCOLOGY Vol. 36. doi:10.1200/JCO.2018.36.15_suppl.TPS8586
GAPVAC-101: First-in-human trial of a highly personalized peptide vaccination approach for patients with newly diagnosed glioblastoma
Wick, W., Dietrich, P. -Y., Kuttruff, S., Hilf, N., Frenzel, K., Admon, A., . . . Singh, H. (2018). GAPVAC-101: First-in-human trial of a highly personalized peptide vaccination approach for patients with newly diagnosed glioblastoma. In JOURNAL OF CLINICAL ONCOLOGY Vol. 36. doi:10.1200/JCO.2018.36.15_suppl.2000
Immunotherapy in metastatic melanoma: When is it safe to stop?
Longley, J., Paschalis, A., Remer, M., Bennett, J., Muller, D. R., Stone, R., . . . Wheater, M. J. (2018). Immunotherapy in metastatic melanoma: When is it safe to stop?. In JOURNAL OF CLINICAL ONCOLOGY Vol. 36. doi:10.1200/JCO.2018.36.15_suppl.e21518
Percutaneous hepatic perfusion with melphalan in uveal melanoma: A safe and effective treatment modality in an orphan disease
Karydis, I., Gangi, A., Wheater, M. J., Choi, J., Wilson, I., Thomas, K., . . . Ottensmeier, C. (2018). Percutaneous hepatic perfusion with melphalan in uveal melanoma: A safe and effective treatment modality in an orphan disease. JOURNAL OF SURGICAL ONCOLOGY, 117(6), 1170-1178. doi:10.1002/jso.24956
CONFIRM: a double-blind, placebo controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial
Fennell, D. A., Kirkpatrick, E., Cozens, K., Nye, M., Lester, J., Hanna, G., . . . Griffiths, G. (2018). CONFIRM: a double-blind, placebo controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial. TRIALS, 19. doi:10.1186/s13063-018-2602-y
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
Vargas, F. A., Furness, A. J. S., Litchfield, K., Joshi, K., Rosenthal, R., Ghorani, E., . . . Quezada, S. A. (2018). Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies. CANCER CELL, 33(4), 649-+. doi:10.1016/j.ccell.2018.02.010
Linear doggybone DNA vaccine induces similar immunological responses to conventional plasmid DNA independently of immune recognition by TLR9 in a pre-clinical model
Allen, A., Wang, C., Caproni, L. J., Sugiyarto, G., Harden, E., Douglas, L. R., . . . Savelyeva, N. (2018). Linear doggybone DNA vaccine induces similar immunological responses to conventional plasmid DNA independently of immune recognition by TLR9 in a pre-clinical model. CANCER IMMUNOLOGY IMMUNOTHERAPY, 67(4), 627-638. doi:10.1007/s00262-017-2111-y
Validation of Immunomonitoring Methods for Application in Clinical Studies: The HLA-Peptide Multimer Staining Assay
Chandran, P. A., Laske, K., Cazaly, A., Rusch, E., Schmid-Horch, B., Rammensee, H. -G., . . . Gouttefangeas, C. (2018). Validation of Immunomonitoring Methods for Application in Clinical Studies: The HLA-Peptide Multimer Staining Assay. CYTOMETRY PART B-CLINICAL CYTOMETRY, 94(2), 342-353. doi:10.1002/cyto.b.21397
Assessment of neuronal autoantibodies in patients with small cell lung cancer treated with chemotherapy with or without ipilimumab
Hardy-Werbin, M., Arpi, O., Taus, A., Rocha, P., Joseph-Pietras, D., Nolan, L., . . . Arriola, E. (2018). Assessment of neuronal autoantibodies in patients with small cell lung cancer treated with chemotherapy with or without ipilimumab. ONCOIMMUNOLOGY, 7(2). doi:10.1080/2162402X.2017.1395125
BILATERAL METASTATIC CUTANEOUS MELANOMA TO RETINA AND VITREOUS AFTER IPILIMUMAB TREATED WITH PARS PLANA VITRECTOMY AND RADIOTHERAPY.
Kanavati, S., Ottensmeier, C., Foria, V., & Krishnan, R. (2018). BILATERAL METASTATIC CUTANEOUS MELANOMA TO RETINA AND VITREOUS AFTER IPILIMUMAB TREATED WITH PARS PLANA VITRECTOMY AND RADIOTHERAPY.. Retinal cases & brief reports, 12(3), 184-187. doi:10.1097/icb.0000000000000477
CONFIRM: a phase III randomised trial to evaluate the efficacy of nivolumab versus placebo in relapsed mesothelioma
Hanna, G., Griffiths, G., Kirkpatrick, E. V., Cozens, K., Kalevras, M., Maishman, T., . . . Fennell, D. (2018). CONFIRM: a phase III randomised trial to evaluate the efficacy of nivolumab versus placebo in relapsed mesothelioma. In LUNG CANCER Vol. 115 (pp. S84). doi:10.1016/S0169-5002(18)30216-2
Emerging role of clinical trials assistants (CTAs) - integrating clinical research into standard care
Fixmer, C., Lane, M., Johnson, B., Chee, S., Walters, J., & Ottensmeier, C. (2018). Emerging role of clinical trials assistants (CTAs) - integrating clinical research into standard care. In LUNG CANCER Vol. 115 (pp. S14-S15). doi:10.1016/S0169-5002(18)30061-8
GAPVAC-101 TRIAL OF A HIGHLY PERSONALIZED PEPTIDE VACCINATION FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
Wick, W., Dietrich, P. -Y., Hilf, N., Platten, M., Frenzel, K., Admon, A., . . . Singh-Jasuja, H. (2018). GAPVAC-101 TRIAL OF A HIGHLY PERSONALIZED PEPTIDE VACCINATION FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA. In NEURO-ONCOLOGY Vol. 20 (pp. 5). Retrieved from https://www.webofscience.com/
HIGHLY PERSONALIZED PEPTIDE VACCINATION FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA: THE GAPVAC TRIAL
Dietrich, P., Wick, W., Hilf, N., Frenzel, K., Gouttefangeas, C., Platten, M., . . . Singh-Jasuja, H. (2018). HIGHLY PERSONALIZED PEPTIDE VACCINATION FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA: THE GAPVAC TRIAL. In NEURO-ONCOLOGY Vol. 20 (pp. 219). Retrieved from https://www.webofscience.com/
Liver pseudoprogression in advanced lung squamous cell carcinoma treated with nivolumab: histology and immunohistochemical profile
Hans, D. N., Rocha, P., Arriola, E., Rodrigo, M. T., Ottensmeier, C. H., Iglesias, M., . . . Lloveras, B. (2018). Liver pseudoprogression in advanced lung squamous cell carcinoma treated with nivolumab: histology and immunohistochemical profile. In VIRCHOWS ARCHIV Vol. 473 (pp. S128). Retrieved from https://www.webofscience.com/
Real-world use of anti-PD-1 checkpoint inhibitors in the management of non-small cell lung cancer: experience from a large UK teaching hospital
Remer, M., Muller, D., Cave, J., Nolan, L., Fenton, P., Bates, A. T., . . . Ottensmeier, C. (2018). Real-world use of anti-PD-1 checkpoint inhibitors in the management of non-small cell lung cancer: experience from a large UK teaching hospital. In LUNG CANCER Vol. 115 (pp. S35). doi:10.1016/S0169-5002(18)30111-9
Single-Cell Analysis of Cancer-Associated Fibroblast Heterogeneity in Non-Small Cell Lung Cancer: Mapping Molecular Phenotypes in Tumours
Waise, S., Hanley, C. J., Parker, R., Ottensmeier, C. H., Rose-Zerilli, M. J., & Thomas, G. J. (2018). Single-Cell Analysis of Cancer-Associated Fibroblast Heterogeneity in Non-Small Cell Lung Cancer: Mapping Molecular Phenotypes in Tumours. In JOURNAL OF PATHOLOGY Vol. 246 (pp. S13). Retrieved from https://www.webofscience.com/
Targeting the Myofibroblastic Cancer-Associated Fibroblast Phenotype Through Inhibition of NOX4
Hanley, C. J., Mellone, M., Ford, K., Thirdborough, S. M., Mellows, T., Frampton, S. J., . . . Thomas, G. J. (2018). Targeting the Myofibroblastic Cancer-Associated Fibroblast Phenotype Through Inhibition of NOX4. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 110(1). doi:10.1093/jnci/djx121
2017
Head and Neck Squamous Cell Carcinomas Are Characterized by a Stable Immune Signature Within the Primary Tumor Over Time and Space
Wood, O., Clarke, J., Woo, J., Mirza, A. H., Woelk, C. H., Thomas, G. J., . . . Ottensmeier, C. H. (2017). Head and Neck Squamous Cell Carcinomas Are Characterized by a Stable Immune Signature Within the Primary Tumor Over Time and Space. CLINICAL CANCER RESEARCH, 23(24), 7641-7649. doi:10.1158/1078-0432.CCR-17-0373
COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-deloss
Crabb, S. J., Martin, K., Abab, J., Ratcliffe, I., Thornton, R., Lineton, B., . . . King, E. (2017). COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-deloss. EUROPEAN JOURNAL OF CANCER, 87, 75-83. doi:10.1016/j.ejca.2017.09.033
Towards personalised medicine in lung and thymus neuroendocrine tumours
Pelosi, G., Cave, J., & Ottensmeier, C. H. (2017). Towards personalised medicine in lung and thymus neuroendocrine tumours. LANCET ONCOLOGY, 18(12), 1563-1565. doi:10.1016/S1470-2045(17)30784-2
Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution
McGranahan, N., Rosenthal, R., Hiley, C. T., Rowan, A. J., Watkins, T. B. K., Wilson, G. A., . . . Swanton, C. (2017). Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. CELL, 171(6), 1259-+. doi:10.1016/j.cell.2017.10.001
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
Weber, J., Mandala, M., Del Vecchio, M., Gogas, H. J., Arance, A. M., Cowey, C. L., . . . Ascierto, P. A. (2017). Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. NEW ENGLAND JOURNAL OF MEDICINE, 377(19), 1824-1835. doi:10.1056/NEJMoa1709030
CONFIRM: A Phase III Randomized Trial to Evaluate the Efficacy of Nivolumab versus Placebo in Relapsed Mesothelioma
Fennell, D., Kirkpatrick, E., Cozens, K., Danson, S., Hanna, G., Lester, J., . . . Griffiths, G. (2017). CONFIRM: A Phase III Randomized Trial to Evaluate the Efficacy of Nivolumab versus Placebo in Relapsed Mesothelioma. In JOURNAL OF THORACIC ONCOLOGY Vol. 12 (pp. S2376). doi:10.1016/j.jtho.2017.09.1898
P1.15-001 Ipilimumab Increases Th1/Th2 and Inflammatory Cytokines Counteracting Chemotherapy Effects in Small Cell Lung Cancer
Hardy-Werbin, M., Rocha, P., Arpí, O., Taus, Á., Joseph-Pietras, D., Rovira, A., . . . Arriola, E. (2017). P1.15-001 Ipilimumab Increases Th1/Th2 and Inflammatory Cytokines Counteracting Chemotherapy Effects in Small Cell Lung Cancer. Journal of Thoracic Oncology, 12(11), S2043. doi:10.1016/j.jtho.2017.09.1037
Evaluating the effect of immune cells on the outcome of patients with mesothelioma
Chee, S. J., Lopez, M., Mellows, T., Gankande, S., Moutasim, K. A., Harris, S., . . . Ottensmeier, C. H. (2017). Evaluating the effect of immune cells on the outcome of patients with mesothelioma. BRITISH JOURNAL OF CANCER, 117(9), 1341-1348. doi:10.1038/bjc.2017.269
FAK-PD1: a phase I/IIa trial of FAK (defactinib) & PD-1 (pembrolizumab) inhibition
Symeonides, S., Evans, T. R. J., Coyle, V., Serrels, A., Thomson, F., Currie, D., . . . Ottensmeier, C. (2017). FAK-PD1: a phase I/IIa trial of FAK (defactinib) & PD-1 (pembrolizumab) inhibition. Annals of Oncology, 28, v426-v427. doi:10.1093/annonc/mdx376.071
FAK-PD1: a phase I/IIa trial of FAK (defactinib) & PD-1 (pembrolizumab) inhibition
Symeonides, S., Evans, T. R. J., Coyle, V., Serrels, A., Thomson, F., Currie, D., . . . Ottensmeier, C. (2017). FAK-PD1: a phase I/IIa trial of FAK (defactinib) & PD-1 (pembrolizumab) inhibition. Annals of Oncology, 28, v427. doi:10.1093/annonc/mdx376.072
Transcriptomic profiling reveals M1-high tumour associated macrophages that orchestrate the adaptive Anti-tumour response in human lung cancer
Garrido-Martin, E. M., Ottensmeier, C., Vijayanand, P., & Sanchez-Elsner, T. (2017). Transcriptomic profiling reveals M1-high tumour associated macrophages that orchestrate the adaptive Anti-tumour response in human lung cancer. In EUROPEAN RESPIRATORY JOURNAL Vol. 50. doi:10.1183/1393003.congress-2017.PA4951
Tissue-resident memory features are linked to the magnitude of cytotoxic T cell responses in human lung cancer
Ganesan, A. -P., Clarke, J., Wood, O., Garrido-Martin, E. M., Chee, S. J., Mellows, T., . . . Ottensmeier, C. H. (2017). Tissue-resident memory features are linked to the magnitude of cytotoxic T cell responses in human lung cancer. Nature Immunology, 18(8), 940-950. doi:10.1038/ni.3775
A distinct CD8<SUP>+</SUP> tumor infiltrating lymphocyte subset is associated with high TIL density, enhanced cytotoxicity and improved survival in patients with lung cancer
Ganesan, A. P., Wood, O., Garrido-Martin, E., Chee, S., Mellows, T., Clarke, J., . . . Ottensmeier, C. H. (2017). A distinct CD8<SUP>+</SUP> tumor infiltrating lymphocyte subset is associated with high TIL density, enhanced cytotoxicity and improved survival in patients with lung cancer. In CANCER RESEARCH Vol. 77. doi:10.1158/1538-7445.AM2017-2948
Tracking the Evolution of Non-Small-Cell Lung Cancer
Jamal-Hanjani, M., Wilson, G. A., McGranahan, N., Birkbak, N. J., Watkins, T. B. K., Veeriah, S., . . . Swanton, C. (2017). Tracking the Evolution of Non-Small-Cell Lung Cancer. NEW ENGLAND JOURNAL OF MEDICINE, 376(22), 2109-2121. doi:10.1056/NEJMoa1616288
Deciphering antitumour response and resistance with intratumour heterogeneity (DARWIN II).
Hiley, C. T., Ahmad, T., Jamal-Hanjani, M., Abbosh, C., Ngai, V., Hackshaw, A., . . . Swanton, C. (2017). Deciphering antitumour response and resistance with intratumour heterogeneity (DARWIN II).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 35. doi:10.1200/JCO.2017.35.15_suppl.TPS9099
Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Small-Cell Lung Cancer (LUNGSTAR)
Seckl, M. J., Ottensmeier, C. H., Cullen, M., Schmid, P., Ngai, Y., Muthukumar, D., . . . Hackshaw, A. (2017). Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Small-Cell Lung Cancer (LUNGSTAR). JOURNAL OF CLINICAL ONCOLOGY, 35(14), 1506-+. doi:10.1200/JCO.2016.69.7391
Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
Abbosh, C., Birkbak, N. J., Wilson, G. A., Jamal-Hanjani, M., Constantin, T., Salari, R., . . . Dessimoz, C. (2017). Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. NATURE, 545(7655), 446-+. doi:10.1038/nature22364
Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors
Vargas, F. A., Furness, A. J. S., Solomon, I., Joshi, K., Mekkaoui, L., Lesko, M. H., . . . Quezada, S. A. (2017). Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors. IMMUNITY, 46(4), 577-586. doi:10.1016/j.immuni.2017.03.013
AST-VAC2: An allogeneic dendritic cell cancer immunotherapy entering clinical trials in patients with lung cancer in the advanced and adjuvant setting
Ottensmeier, C., Farmer-Hall, H., Acton, G., Lentfer, H., Nishimoto, K., Shoukat-Mumtaz, U., . . . Lebkowski, J. (2017). AST-VAC2: An allogeneic dendritic cell cancer immunotherapy entering clinical trials in patients with lung cancer in the advanced and adjuvant setting. In JOURNAL FOR IMMUNOTHERAPY OF CANCER Vol. 5. Retrieved from https://www.webofscience.com/
B-Cell Tumors
Ottensmeier, C., & Stevenson, F. (2017). B-Cell Tumors. In Encyclopedia of Cancer (pp. 441-446). Springer Berlin Heidelberg. doi:10.1007/978-3-662-46875-3_559
Cancer Vaccines Preface
Savelyeva, N., & Ottensmeier, C. (2017). Cancer Vaccines Preface. In CANCER VACCINES (Vol. 405, pp. V-VI). Retrieved from https://www.webofscience.com/
FAK-PD1: a phase I/IIa trial of FAK (defactinib) & PD-1 (pembrolizumab) inhibition
Symeonides, S., Evans, T. R. J., Coyle, V., Serrels, A., Thomson, F., Currie, D., . . . Ottensmeier, C. (2017). FAK-PD1: a phase I/IIa trial of FAK (defactinib) & PD-1 (pembrolizumab) inhibition. In ANNALS OF ONCOLOGY Vol. 28. Retrieved from https://www.webofscience.com/
Ipilimumab Increases Th1/Th2 and Inflammatory Cytokines Counteracting Chemotherapy Effects in Small Cell Lung Cancer
Hardy-Werbin, M., Rocha, P., Arpi, O., Taus, A., Joseph-Pietras, D., Rovira, A., . . . Arriola, E. (2017). Ipilimumab Increases Th1/Th2 and Inflammatory Cytokines Counteracting Chemotherapy Effects in Small Cell Lung Cancer. In JOURNAL OF THORACIC ONCOLOGY Vol. 12 (pp. S2042). Retrieved from https://www.webofscience.com/
Linked CD4 T Cell Help: Broadening Immune Attack Against Cancer by Vaccination
Savelyeva, N., Allen, A., Chotprakaikiat, W., Harden, E., Jobsri, J., Godeseth, R., . . . Ottensmeier, C. (2017). Linked CD4 T Cell Help: Broadening Immune Attack Against Cancer by Vaccination. CANCER VACCINES, 405, 123-143. doi:10.1007/82_2016_500
Novel Approaches for Vaccination Against HPV-Induced Cancers
King, E., Ottensmeier, C., & Pollock, K. G. J. (2017). Novel Approaches for Vaccination Against HPV-Induced Cancers. CANCER VACCINES, 405, 33-53. doi:10.1007/82_2015_430
Percutaneous Hepatic Perfusion (PHP) for Unresectable Metastatic Ocular Melanoma to the Liver: A Multi-Institutional Report of Outcomes
Gangi, A., Karydis, I., Thomas, K., Sileno, S., Hardman, D., Choi, J., . . . Zager, J. S. (2017). Percutaneous Hepatic Perfusion (PHP) for Unresectable Metastatic Ocular Melanoma to the Liver: A Multi-Institutional Report of Outcomes. In ANNALS OF SURGICAL ONCOLOGY Vol. 24 (pp. S147). Retrieved from https://www.webofscience.com/
2016
Induction of fibroblast senescence generates a non-fibrogenic myofibroblast phenotype that differentially impacts on cancer prognosis
Mellone, M., Hanley, C. J., Thirdborough, S., Mellows, T., Garcia, E., Woo, J., . . . Thomas, G. J. (2017). Induction of fibroblast senescence generates a non-fibrogenic myofibroblast phenotype that differentially impacts on cancer prognosis. AGING-US, 9(1), 128-146. doi:10.18632/aging.101127
Human Papillomavirus Drives Tumor Development Throughout the Head and Neck: Improved Prognosis Is Associated With an Immune Response Largely Restricted to the Oropharynx
Chakravarthy, A., Henderson, S., Thirdborough, S. M., Ottensmeier, C. H., Su, X., Lechner, M., . . . Fenton, T. R. (2016). Human Papillomavirus Drives Tumor Development Throughout the Head and Neck: Improved Prognosis Is Associated With an Immune Response Largely Restricted to the Oropharynx. JOURNAL OF CLINICAL ONCOLOGY, 34(34), 4132-+. doi:10.1200/JCO.2016.68.2955
Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunologic and Clinical Outcomes
McCann, K. J., Mander, A., Cazaly, A., Chudley, L., Stasakova, J., Thirdborough, S. M., . . . Ottensmeier, C. H. (2016). Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunologic and Clinical Outcomes. CLINICAL CANCER RESEARCH, 22(19), 4827-4836. doi:10.1158/1078-0432.CCR-15-2507
Evaluation of immune infiltration in the colonic mucosa of patients with ipilimumab-related colitis
Arriola, E., Wheater, M., Lopez, M. A., Thomas, G., & Ottensmeier, C. (2016). Evaluation of immune infiltration in the colonic mucosa of patients with ipilimumab-related colitis. ONCOIMMUNOLOGY, 5(9). doi:10.1080/2162402X.2016.1209615
LSC Abstract - Transcriptomic profiling of macrophages isolated from human non-small cell lung carcinoma (NSCLC) reveals novel macrophage subsets with distinct tumour response features
Garrido-Martin, E. M., Martinez-Nunez, R., Mellows, T., Ottensmeier, C. H., Vijayanand, P., & Sanchez-Elsner, T. (2016). LSC Abstract - Transcriptomic profiling of macrophages isolated from human non-small cell lung carcinoma (NSCLC) reveals novel macrophage subsets with distinct tumour response features. In EUROPEAN RESPIRATORY JOURNAL Vol. 48. doi:10.1183/13993003.congress-2016.YI2
LSC Abstract - Transcriptomic profiling of macrophages isolated from human non-small cell lung carcinoma (NSCLC) reveals novel macrophage subsets with distinct tumour response features
Garrido-Martin, E. M., Martinez-Nunez, R., Mellows, T., Ottensmeier, C. H., Vijayanand, P., & Sanchez-Elsner, T. (2016). LSC Abstract - Transcriptomic profiling of macrophages isolated from human non-small cell lung carcinoma (NSCLC) reveals novel macrophage subsets with distinct tumour response features. In EUROPEAN RESPIRATORY JOURNAL Vol. 48. doi:10.1183/13993003.congress-2016.OA1771
Gene expression analysis of TIL rich HPV-driven head and neck tumors reveals a distinct B-cell signature when compared to HPV independent tumors
Wood, O., Woo, J., Seumois, G., Savelyeva, N., McCann, K. J., Singh, D., . . . Consortium, S. P. A. R. C. (2016). Gene expression analysis of TIL rich HPV-driven head and neck tumors reveals a distinct B-cell signature when compared to HPV independent tumors. Oncotarget, 7(35), 56781-56797. doi:10.18632/oncotarget.10788
GAPVAC-101 phase I trial: First data of an innovative actively personalized peptide vaccination trial in patients with newly diagnosed glioblastoma
Hilf, N., Frenzel, K., Kuttruff-Coqui, S., Heesch, S., Kreiter, S., Admon, A., . . . Singh-Jasuja, H. (2016). GAPVAC-101 phase I trial: First data of an innovative actively personalized peptide vaccination trial in patients with newly diagnosed glioblastoma. In CANCER RESEARCH Vol. 76. doi:10.1158/1538-7445.AM2016-2654
Upregulated Glucose Metabolism Correlates Inversely with CD8(+) T-cell Infiltration and Survival in Squamous Cell Carcinoma
Ottensmeier, C. H., Perry, K. L., Harden, E. L., Stasakova, J., Jenei, V., Fleming, J., . . . Thirdborough, S. M. (2016). Upregulated Glucose Metabolism Correlates Inversely with CD8(+) T-cell Infiltration and Survival in Squamous Cell Carcinoma. Cancer Research, 76(14), 4136-4148. doi:10.1158/0008-5472.CAN-15-3121
A plant-expressed conjugate vaccine breaks CD4<SUP>+</SUP> tolerance and induces potent immunity against metastatic Her2<SUP>+</SUP> breast cancer
Chotprakaikiat, W., Allen, A., Bui-Minh, D., Harden, E., Jobsri, J., Cavallo, F., . . . Savelyeva, N. (2016). A plant-expressed conjugate vaccine breaks CD4<SUP>+</SUP> tolerance and induces potent immunity against metastatic Her2<SUP>+</SUP> breast cancer. ONCOIMMUNOLOGY, 5(6). doi:10.1080/2162402X.2016.1166323
Tumour infiltrating lymphocytes correlate with improved survival in patients with oesophageal adenocarcinoma
Noble, F., Mellows, T., Matthews, L. H. M., Bateman, A. C., Harris, S., Underwood, T. J., . . . Ottensmeier, C. H. (2016). Tumour infiltrating lymphocytes correlate with improved survival in patients with oesophageal adenocarcinoma. CANCER IMMUNOLOGY IMMUNOTHERAPY, 65(6), 651-662. doi:10.1007/s00262-016-1826-5
UK experience of combined BRAF and MEK inhibition with dabrafenib and trametinib (D+1) in the metastatic melanoma (MM) named patient programme.
Ellis, S. G., Pallan, L., Hategan, M., Price, N., Arkenau, H. -T., Steven, N., . . . Wheater, M. J. (2016). UK experience of combined BRAF and MEK inhibition with dabrafenib and trametinib (D+1) in the metastatic melanoma (MM) named patient programme.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 34. doi:10.1200/JCO.2016.34.15_suppl.e21027
UKMCC-01: A phase II study of pazopanib (PAZ) in metastatic Merkel cell carcinoma.
Nathan, P. D., Gaunt, P., Wheatley, K., Bowden, S. J., Savage, J., Faust, G., . . . Steven, N. M. (2016). UKMCC-01: A phase II study of pazopanib (PAZ) in metastatic Merkel cell carcinoma.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 34. doi:10.1200/JCO.2016.34.15_suppl.9542
Clinical activity and safety of Pembrolizumab in Ipilimumab pre-treated patients with uveal melanoma
Karydis, I., Chan, P. Y., Wheater, M., Arriola, E., Szlosarek, P. W., & Ottensmeier, C. H. (2016). Clinical activity and safety of Pembrolizumab in Ipilimumab pre-treated patients with uveal melanoma. ONCOIMMUNOLOGY, 5(5). doi:10.1080/2162402X.2016.1143997
Mucosal-Associated Invariant T (MAIT) Cells Are Impaired in Th17 Associated Primary and Secondary Immunodeficiencies
Gao, Y., Rae, W., Ramakrishnan, K. A., Barcenas-Morales, G., Doffinger, R., Eren, E., . . . Williams, A. P. (2016). Mucosal-Associated Invariant T (MAIT) Cells Are Impaired in Th17 Associated Primary and Secondary Immunodeficiencies. PLOS ONE, 11(5). doi:10.1371/journal.pone.0155059
Response to vaccination via tumour draining lymph nodes does not demonstrate a tumour suppressive effect in patients with breast cancer: A peri-surgical window study
Layfield, D., Clarke, J., Savelyeva, N., Cutress, R., & Ottensmeier, C. (2016). Response to vaccination via tumour draining lymph nodes does not demonstrate a tumour suppressive effect in patients with breast cancer: A peri-surgical window study. European Journal of Surgical Oncology (EJSO), 42(5), S43. doi:10.1016/j.ejso.2016.02.169
TG4010: a vaccine with a therapeutic role in cancer
Arriola, E., & Ottensmeier, C. (2016). TG4010: a vaccine with a therapeutic role in cancer. IMMUNOTHERAPY, 8(5), 511-519. doi:10.2217/imt-2016-0015
TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial
Quoix, E., Lena, H., Losonczy, G., Forget, F., Chouaid, C., Papai, Z., . . . Limacher, J. -M. (2016). TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial. The Lancet Oncology, 17(2), 212-223. doi:10.1016/S1470-2045(15)00483-0
Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry: results from an interim study
Mandruzzato, S., Brandau, S., Britten, C. M., Bronte, V., Damuzzo, V., Gouttefangeas, C., . . . Walter, S. (2016). Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry: results from an interim study. CANCER IMMUNOLOGY IMMUNOTHERAPY, 65(2), 161-169. doi:10.1007/s00262-015-1782-5
Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC
Arriola, E., Wheater, M., Galea, I., Cross, N., Maishman, T., Hamid, D., . . . Ottensmeier, C. (2016). Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC. JOURNAL OF THORACIC ONCOLOGY, 11(9), 1511-1521. doi:10.1016/j.jtho.2016.05.028
Patterns of clinical response in talimogene laherparepvec (T-VEC) treated patients with stage IIIB-IVM1a melanoma in the OPTiM phase III trial
Harrington, K., Kaufman, H., Middleton, M., Melcher, A., Ottensmeier, C., Safaei, R., . . . Andtbacka, R. H. I. (2016). Patterns of clinical response in talimogene laherparepvec (T-VEC) treated patients with stage IIIB-IVM1a melanoma in the OPTiM phase III trial. In MELANOMA RESEARCH Vol. 26 (pp. E4-E5). Retrieved from https://www.webofscience.com/
Pharmacodynamic biomarkers for first in class early phase immuno-oncology trials; opportunities and challenges
Katugampola, S., Spicer, J., Karagianis, S., Joseph, D., Bax, H., Pellizzari, G., . . . Jones, P. (2016). Pharmacodynamic biomarkers for first in class early phase immuno-oncology trials; opportunities and challenges. In EUROPEAN JOURNAL OF CANCER Vol. 55 (pp. S27). Retrieved from https://www.webofscience.com/
The prognostic value of tumour infiltrating lymphocytes in cancer
Mirza, A. H., Ottensmeier, C. H., Thomas, G. J., & King, E. V. (2016). The prognostic value of tumour infiltrating lymphocytes in cancer. Current Trends in Immunology, 17, 27-36.
Timing of onset and resolution of adverse events in patients with unresectable stage IIIB-IVM1a melanoma treated with talimogene laherparepvec (T-VEC) in OPTiM
Andtbacka, R., Kaufman, H., Harrington, K., Middleton, M., Melcher, A., Ottensmeier, C., . . . Collichio, F. (2016). Timing of onset and resolution of adverse events in patients with unresectable stage IIIB-IVM1a melanoma treated with talimogene laherparepvec (T-VEC) in OPTiM. In MELANOMA RESEARCH Vol. 26 (pp. E36-E37). Retrieved from https://www.webofscience.com/
Wilms’ tumour antigen 1 Immunity via DNA fusion gene vaccination in haematological malignancies by intramuscular injection followed by intramuscular electroporation: a Phase II non-randomised clinical trial (WIN)
Ottensmeier, C., Bowers, M., Hamid, D., Maishman, T., Regan, S., Wood, W., . . . Stanton, L. (2016). Wilms’ tumour antigen 1 Immunity via DNA fusion gene vaccination in haematological malignancies by intramuscular injection followed by intramuscular electroporation: a Phase II non-randomised clinical trial (WIN).
2015
Systematic review and meta-analysis of immunohistochemical prognostic biomarkers in resected oesophageal adenocarcinoma (vol 113, pg 107, 2015)
Matthews, L. H. M., Noble, F., Tod, J., Jaynes, E., Harris, S., Primrose, J. N., . . . Underwood, T. J. (2015). Systematic review and meta-analysis of immunohistochemical prognostic biomarkers in resected oesophageal adenocarcinoma (vol 113, pg 107, 2015). BRITISH JOURNAL OF CANCER, 113(12), 1746. doi:10.1038/bjc.2015.460
Infliximab for IPILIMUMAB-Related Colitis-Letter
Arriola, E., Wheater, M., Karydis, I., Thomas, G., & Ottensmeier, C. (2015). Infliximab for IPILIMUMAB-Related Colitis-Letter. CLINICAL CANCER RESEARCH, 21(24), 5642-5643. doi:10.1158/1078-0432.CCR-15-2471
Uveal Melanoma UK National Guidelines
Nathan, P., Cohen, V., Coupland, S., Curtis, K., Damato, B., Evans, J., . . . Turnbull, N. (2015). Uveal Melanoma UK National Guidelines. EUROPEAN JOURNAL OF CANCER, 51(16), 2404-2412. doi:10.1016/j.ejca.2015.07.013
Immunosuppression for ipilimumab-related toxicity can cause <i>pneumocystis</i> pneumonia but spare antitumor immune control
Arriola, E., Wheater, M., Krishnan, R., Smart, J., Foria, V., & Ottensmeier, C. (2015). Immunosuppression for ipilimumab-related toxicity can cause <i>pneumocystis</i> pneumonia but spare antitumor immune control. ONCOIMMUNOLOGY, 4(10). doi:10.1080/2162402X.2015.1040218
Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients
Ahmad, S. S., Qian, W., Ellis, S., Mason, E., Khattak, M. A., Gupta, A., . . . Corrie, P. G. (2015). Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients. MELANOMA RESEARCH, 25(5), 432-442. doi:10.1097/CMR.0000000000000185
Vaccination Expands Antigen-Specific CD4<SUP>+</SUP> Memory T Cells and Mobilizes Bystander Central Memory T Cells
Li Causi, E., Parikh, S. C., Chudley, L., Layfield, D. M., Ottensmeier, C. H., Stevenson, F. K., & Di Genova, G. (2015). Vaccination Expands Antigen-Specific CD4<SUP>+</SUP> Memory T Cells and Mobilizes Bystander Central Memory T Cells. PLOS ONE, 10(9). doi:10.1371/journal.pone.0136717
Seropositivity to tumour antigens as a potential new biomarker for melanoma relapse
Clark, L., Hepburne-Scott, H., Ottensmeier, C., Middleton, M., Myers, K. A., Tarlton, A., . . . Nathan, P. (2015). Seropositivity to tumour antigens as a potential new biomarker for melanoma relapse. In EUROPEAN JOURNAL OF CANCER Vol. 51 (pp. S686). doi:10.1016/S0959-8049(16)31871-8
Idiotypic DNA vaccination for the treatment of multiple myeloma: safety and immunogenicity in a phase I clinical study
McCann, K. J., Godeseth, R., Chudley, L., Mander, A., Di Genova, G., Lloyd-Evans, P., . . . Ottensmeier, C. H. (2015). Idiotypic DNA vaccination for the treatment of multiple myeloma: safety and immunogenicity in a phase I clinical study. CANCER IMMUNOLOGY IMMUNOTHERAPY, 64(8), 1021-1032. doi:10.1007/s00262-015-1703-7
Staging and treatment of oropharyngeal cancer in the human papillomavirus era
Ward, M. J., Mellows, T., Harris, S., Webb, A., Patel, N. N., Cox, H. J., . . . King, E. V. (2015). Staging and treatment of oropharyngeal cancer in the human papillomavirus era. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 37(7), 1002-1013. doi:10.1002/hed.23697
Systematic review and meta-analysis of immunohistochemical prognostic biomarkers in resected oesophageal adenocarcinoma
Matthews, L. H. M., Noble, F., Tod, J., Jaynes, E., Harris, S., Primrose, J. N., . . . Underwood, T. J. (2015). Systematic review and meta-analysis of immunohistochemical prognostic biomarkers in resected oesophageal adenocarcinoma. BRITISH JOURNAL OF CANCER, 113(1), 107-118. doi:10.1038/bjc.2015.179
An adjuvant clinical trial of SCIB1, a DNA vaccine that targets dendritic cells <i>in vivo</i>, in fully resected melanoma patients.
Patel, P. M., Ottensmeier, C., Mulatero, C., Lorigan, P., Plummer, R., Hannaman, D., . . . Durrant, L. G. (2015). An adjuvant clinical trial of SCIB1, a DNA vaccine that targets dendritic cells <i>in vivo</i>, in fully resected melanoma patients.. Journal of Clinical Oncology, 33(15_suppl), 9035. doi:10.1200/jco.2015.33.15_suppl.9035
Evaluation of the impact of infliximab use for the treatment of ipilimumab related diarrhoea on the outcome of patients with advanced melanoma.
Arriola, E., Wheater, M. J., Warrier, A., Karydis, I., & Ottensmeier, C. H. H. (2015). Evaluation of the impact of infliximab use for the treatment of ipilimumab related diarrhoea on the outcome of patients with advanced melanoma.. Journal of Clinical Oncology, 33(15_suppl), 9045. doi:10.1200/jco.2015.33.15_suppl.9045
Results of the phase IIb part of TIME study evaluating TG4010 immunotherapy in stage IV non-small cell lung cancer (NSCLC) patients receiving first line chemotherapy.
Quoix, E. A., Forget, F., Papai-Szekely, Z., Ottensmeier, C. H. H., Nemunaitis, J. J., Felip, E., . . . Limacher, J. -M. (2015). Results of the phase IIb part of TIME study evaluating TG4010 immunotherapy in stage IV non-small cell lung cancer (NSCLC) patients receiving first line chemotherapy.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 33. doi:10.1200/jco.2015.33.15_suppl.3034
Seropositivity to tumour antigens as a potential new biomarker for melanoma relapse.
Clark, L. L., Hepburne-Scott, H., Middleton, M. R., Ottensmeier, C. H. H., Myers, K. A., Tarlton, A. B., . . . Nathan, P. D. (2015). Seropositivity to tumour antigens as a potential new biomarker for melanoma relapse.. Journal of Clinical Oncology, 33(15_suppl), e20049. doi:10.1200/jco.2015.33.15_suppl.e20049
Single centre experience of chemosaturation percutaneous hepatic perfusion in the treatment of metastatic uveal melanoma.
Hickson, G., Karydis, I., Wheater, M. J., Takar, A., Wilson, I., Pearce, N., . . . Stedman, B. (2015). Single centre experience of chemosaturation percutaneous hepatic perfusion in the treatment of metastatic uveal melanoma.. Journal of Clinical Oncology, 33(15_suppl), e20000. doi:10.1200/jco.2015.33.15_suppl.e20000
The association of T cells with survival in mesothelioma.
Chee, S. J., Lopez, M., Mellows, T., Alzetani, A., Thomas, G., & Ottensmeier, C. H. H. (2015). The association of T cells with survival in mesothelioma.. Journal of Clinical Oncology, 33(15_suppl), 7560. doi:10.1200/jco.2015.33.15_suppl.7560
T-cell immune monitoring assays to guide the development of new cancer vaccines
Britten, C. M., Janetzki, S., Gouttefangeas, C., Welters, M. J. P., Kalos, M., Ottensmeier, C., . . . van der Burg, S. H. (2011). T-cell immune monitoring assays to guide the development of new cancer vaccines. In Cancer Vaccines: From Research to Clinical Practice (pp. 156-166). Informa Healthcare. doi:10.3109/9781841848303.012
Data analysis as a source of variability of the HLA-peptide multimer assay: from manual gating to automated recognition of cell clusters
Gouttefangeas, C., Chan, C., Attig, S., Kollgaard, T. T., Rammensee, H. -G., Stevanovic, S., . . . Britten, C. M. (2015). Data analysis as a source of variability of the HLA-peptide multimer assay: from manual gating to automated recognition of cell clusters. CANCER IMMUNOLOGY IMMUNOTHERAPY, 64(5), 585-598. doi:10.1007/s00262-014-1649-1
Clinical and Biological Effects of an Agonist Anti-CD40 Antibody: A Cancer Research UK Phase I Study
Johnson, P., Challis, R., Chowdhury, F., Gao, Y., Harvey, M., Geldart, T., . . . Williams, A. (2015). Clinical and Biological Effects of an Agonist Anti-CD40 Antibody: A Cancer Research UK Phase I Study. CLINICAL CANCER RESEARCH, 21(6), 1321-1328. doi:10.1158/1078-0432.CCR-14-2355
NY-ESO-1 specific antibody and cellular responses in melanoma patients primed with NY-ESO-1 protein in ISCOMATRIX and boosted with recombinant NY-ESO-1 fowlpox virus
Chen, J. -L., Dawoodji, A., Tarlton, A., Gnjatic, S., Tajar, A., Karydis, I., . . . Cerundolo, V. (2015). NY-ESO-1 specific antibody and cellular responses in melanoma patients primed with NY-ESO-1 protein in ISCOMATRIX and boosted with recombinant NY-ESO-1 fowlpox virus. INTERNATIONAL JOURNAL OF CANCER, 136(6), E590-E601. doi:10.1002/ijc.29118
Plant Virus Particles Carrying Tumour Antigen Activate TLR7 and Induce High Levels of Protective Antibody
Jobsri, J., Allen, A., Rajagopal, D., Shipton, M., Kanyuka, K., Lomonossoff, G. P., . . . Savelyeva, N. (2015). Plant Virus Particles Carrying Tumour Antigen Activate TLR7 and Induce High Levels of Protective Antibody. PLOS ONE, 10(2). doi:10.1371/journal.pone.0118096
An adjuvant clinical trial of SCIB1, a DNA vaccine that targets dendritic cells <i>in vivo</i>, in fully resected melanoma patients
Patel, P. M., Ottensmeier, C., Mulatero, C., Lorigan, P., Plummer, R., Hannaman, D., . . . Durrant, L. G. (2015). An adjuvant clinical trial of SCIB1, a DNA vaccine that targets dendritic cells <i>in vivo</i>, in fully resected melanoma patients. In JOURNAL OF CLINICAL ONCOLOGY Vol. 33. Retrieved from https://www.webofscience.com/
Evaluation of the impact of infliximab use for the treatment of ipilimumab related diarrhoea on the outcome of patients with advanced melanoma.
Arriola, E., Wheater, M. J., Warrier, A., Karydis, I., & Ottensmeier, C. H. H. (2015). Evaluation of the impact of infliximab use for the treatment of ipilimumab related diarrhoea on the outcome of patients with advanced melanoma.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 33. Retrieved from https://www.webofscience.com/
Flow Cytometry in Cancer Immunotherapy: Applications, Quality Assurance, and Future
Gouttefangeas, C., Walter, S., Welters, M. J. P., Ottensmeier, C., van der Burg, S. H., Britten, C. M., & Chan, C. (2015). Flow Cytometry in Cancer Immunotherapy: Applications, Quality Assurance, and Future. In Cancer Immunology (pp. 471-490). Springer Berlin Heidelberg. doi:10.1007/978-3-662-44006-3_25
Seropositivity to tumour antigens as a potential new biomarker for melanoma relapse.
Clark, L. L., Hepburne-Scott, H., Middleton, M. R., Ottensmeier, C. H. H., Myers, K. A., Tarlton, A. B., . . . Nathan, P. D. (2015). Seropositivity to tumour antigens as a potential new biomarker for melanoma relapse.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 33. Retrieved from https://www.webofscience.com/
Single centre experience of chemosaturation percutaneous hepatic perfusion in the treatment of metastatic uveal melanoma.
Hickson, G., Karydis, I., Wheater, M. J., Takar, A., Wilson, I., Pearce, N., . . . Stedman, B. (2015). Single centre experience of chemosaturation percutaneous hepatic perfusion in the treatment of metastatic uveal melanoma.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 33. Retrieved from https://www.webofscience.com/
TG4010 Immunotherapy plus Chemotherapy as First Line Treatment of Advanced NSCLC: Phase 2b Results
Quoix, E., Forget, F., Chouaid, C., Papai, Z., Losonczy, G., Felip, E., . . . Lena, H. (2015). TG4010 Immunotherapy plus Chemotherapy as First Line Treatment of Advanced NSCLC: Phase 2b Results. In JOURNAL OF THORACIC ONCOLOGY Vol. 10 (pp. S208). Retrieved from https://www.webofscience.com/
TG4010 immunotherapy plus chemotherapy as first-line treatment of advanced non small cell lung cancer (NSCLC): Phase IIb results of the TIME trial
Nemunaitis, J., Papai, Z., Léna, H., Losonczy, G., Forget, F., Chouaid, C., . . . Quoix, E. (2015). TG4010 immunotherapy plus chemotherapy as first-line treatment of advanced non small cell lung cancer (NSCLC): Phase IIb results of the TIME trial. Journal for immunotherapy of cancer, 3(Suppl 2), P441. doi:10.1186/2051-1426-3-s2-p441
The association of T cells with survival in mesothelioma.
Chee, S. J., Lopez, M., Mellows, T., Alzetani, A., Thomas, G., & Ottensmeier, C. H. H. (2015). The association of T cells with survival in mesothelioma.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 33. Retrieved from https://www.webofscience.com/
2014
106. Initial UK experience of melphalan percutaneous hepatic perfusion (PHP) for treatment of inoperable ocular melanoma metastases
Stedman, B., Wilson, I., El Berm, H., Fennell, J., Gupta, S., Ottensmeier, C., . . . Pearce, N. W. (2014). 106. Initial UK experience of melphalan percutaneous hepatic perfusion (PHP) for treatment of inoperable ocular melanoma metastases. European Journal of Surgical Oncology (EJSO), 40(11), S50. doi:10.1016/j.ejso.2014.08.102
Harmonisation of short-term in vitro culture for the expansion of antigen-specific CD8<SUP>+</SUP> T cells with detection by ELISPOT and HLA-multimer staining
Chudley, L., McCann, K. J., Coleman, A., Cazaly, A. M., Bidmon, N., Britten, C. M., . . . Ottensmeier, C. H. (2014). Harmonisation of short-term in vitro culture for the expansion of antigen-specific CD8<SUP>+</SUP> T cells with detection by ELISPOT and HLA-multimer staining. CANCER IMMUNOLOGY IMMUNOTHERAPY, 63(11), 1199-1211. doi:10.1007/s00262-014-1593-0
TIME, a Phase 2b/3 Study Evaluating TG4010 in Combination With First-Line Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC): Phase 2b Results
Quoix, E., Losonczy, G., Forget, F., Chouaid, C., Papai, Z., Gervais, R., . . . Lena, H. (2014). TIME, a Phase 2b/3 Study Evaluating TG4010 in Combination With First-Line Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC): Phase 2b Results. In INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS Vol. 90 (pp. S35). doi:10.1016/j.ijrobp.2014.08.211
Phase I/II trial of a novel antibody DNA immunotherapy, targeting CD64, in the treatment of Melanoma
Durrant, L. G., Ottensmeier, C. H., Lorigan, P., Mulatero, C., Plummer, R., Cunell, M., . . . Patel, P. (2014). Phase I/II trial of a novel antibody DNA immunotherapy, targeting CD64, in the treatment of Melanoma. In CANCER RESEARCH Vol. 74. doi:10.1158/1538-7445.AM2014-CT331
The effect of neoadjuvant chemotherapy on physical fitness and survival in patients undergoing oesophagogastric cancer surgery
Jack, S., West, M. A., Raw, D., Marwood, S., Ambler, G., Cope, T. M., . . . Grocott, M. P. W. (2014). The effect of neoadjuvant chemotherapy on physical fitness and survival in patients undergoing oesophagogastric cancer surgery. EJSO, 40(10), 1313-1320. doi:10.1016/j.ejso.2014.03.010
Anti-CTLA-4 therapy broadens the melanoma-reactive CD8(+) T cell response
Kvistborg, P., Philips, D., Kelderman, S., Hageman, L., Ottensmeier, C., Joseph-Pietras, D., . . . Schumacher, T. N. (2014). Anti-CTLA-4 therapy broadens the melanoma-reactive CD8(+) T cell response. SCIENCE TRANSLATIONAL MEDICINE, 6(254). doi:10.1126/scitranslmed.3008918
A NOVEL PHASE II TRIAL OF IPILIMUMAB, CARBOPLATIN AND ETOPOSIDE (ICE) FOR THE FIRST LINE TREATMENT OF EXTENSIVE STAGE SMALL CELL LUNG CANCER (SCLC)
Ottensmeier, C., Galea, I., Cross, N., Maishman, T., Hamid, D., Cave, J., . . . Nolan, L. (2014). A NOVEL PHASE II TRIAL OF IPILIMUMAB, CARBOPLATIN AND ETOPOSIDE (ICE) FOR THE FIRST LINE TREATMENT OF EXTENSIVE STAGE SMALL CELL LUNG CANCER (SCLC). In ANNALS OF ONCOLOGY Vol. 25. doi:10.1093/annonc/mdu355.15
A Retrospective Analysis of Safety and Outcome of Radiotherapy Given Following Treatment with Ipilimumab for Metastatic Melanoma
Killick, E., Shepherd, B., King, A., Gorf, L., Ellis, S., Joseph-Pietras, D., . . . Ottensmeier, C. (2014). A Retrospective Analysis of Safety and Outcome of Radiotherapy Given Following Treatment with Ipilimumab for Metastatic Melanoma. Annals of Oncology, 25, iv380. doi:10.1093/annonc/mdu344.15
Time, a Phase 2B/3 Study Evaluating Tg4010 in Combination with First Line Therapy in Advanced Non Small Cell Lung Cancer (Nsclc). Phase 2B Results
Quoix, E., Losonczy, G., Forget, F., Chouaid, C., Papai, Z., Gervais, R., . . . Lena, H. (2014). Time, a Phase 2B/3 Study Evaluating Tg4010 in Combination with First Line Therapy in Advanced Non Small Cell Lung Cancer (Nsclc). Phase 2B Results. Annals of Oncology, 25, iv364. doi:10.1093/annonc/mdu342.8
Randomized Trial of Erlotinib Plus Whole-Brain Radiotherapy for NSCLC Patients With Multiple Brain Metastases
Lee, S. M., Lewanski, C. R., Counsell, N., Ottensmeier, C., Bates, A., Patel, N., . . . Faivre-Finn, C. (2014). Randomized Trial of Erlotinib Plus Whole-Brain Radiotherapy for NSCLC Patients With Multiple Brain Metastases. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 106(7). doi:10.1093/jnci/dju151
Phase I trial of ImmunoBody in melanoma patients.
Patel, P. M., Durrant, L. G., Ottensmeier, C., Mulatero, C., Lorigan, P., Plummer, R., . . . Hannaman, D. (2014). Phase I trial of ImmunoBody in melanoma patients.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 32. doi:10.1200/jco.2014.32.15_suppl.3061
Randomized, double-blind phase II trial of NY-ESO-1 ISCOMATRIX vaccine and ISCOMATRIX adjuvant alone in patients with resected stage IIc, III, or IV malignant melanoma.
Cebon, J. S., McArthur, G. A., Chen, W., Davis, I. D., Gore, M. E., Thompson, J. F., . . . Evans, T. R. J. (2014). Randomized, double-blind phase II trial of NY-ESO-1 ISCOMATRIX vaccine and ISCOMATRIX adjuvant alone in patients with resected stage IIc, III, or IV malignant melanoma.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 32. doi:10.1200/jco.2014.32.15_suppl.9050
DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type <i>BRAF</i> advanced melanoma
Gupta, A., Love, S., Schuh, A., Shanyinde, M., Larkin, J. M., Plummer, R., . . . Middleton, M. R. (2014). DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type <i>BRAF</i> advanced melanoma. ANNALS OF ONCOLOGY, 25(5), 968-974. doi:10.1093/annonc/mdu054
A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors
Angevin, E., Tabernero, J., Elez, E., Cohen, S. J., Bahleda, R., van Laethem, J. -L., . . . Kurzrock, R. (2014). A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors. CLINICAL CANCER RESEARCH, 20(8), 2192-2204. doi:10.1158/1078-0432.CCR-13-2200
Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer
Ward, M. J., Thirdborough, S. M., Mellows, T., Riley, C., Harris, S., Suchak, K., . . . Thomas, G. J. (2014). Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer. BRITISH JOURNAL OF CANCER, 110(2), 489-500. doi:10.1038/bjc.2013.639
Afatinib use in non-small cell lung cancer previously sensitive to epidermal growth factor receptor inhibitors: The United Kingdom Named Patient Programme
Khan, F., Ottensmeier, C., Popat, S., Dua, D., Dorey, N., Ellis, S., . . . Danson, S. J. (2014). Afatinib use in non-small cell lung cancer previously sensitive to epidermal growth factor receptor inhibitors: The United Kingdom Named Patient Programme. EUROPEAN JOURNAL OF CANCER, 50(10), 1717-1721. doi:10.1016/j.ejca.2014.03.001
B-cell Tumors
Ottensmeier, C., & Stevenson, F. (2014). B-cell Tumors. In Encyclopedia of Cancer (pp. 1-6). Springer Berlin Heidelberg. doi:10.1007/978-3-642-27841-9_559-2
Mucosal-Associated Invariant T Cells in Primary and Secondary Immunodeficiency Patients
Gao, Y., Ramakrishnan, K. A., Barcenas-Morales, G., Doeffinger, R., Pengelly, R., Ennis, S., . . . Williams, A. (2014). Mucosal-Associated Invariant T Cells in Primary and Secondary Immunodeficiency Patients. In JOURNAL OF CLINICAL IMMUNOLOGY Vol. 34 (pp. S497-S498). Retrieved from https://www.webofscience.com/
Suppression of Hedgehog signalling promotes pro-tumourigenic integrin expression and function
Moutasim, K. A., Mellows, T., Mellone, M., Lopez, M. -A., Tod, J., Kiely, P. C., . . . Thomas, G. J. (2014). Suppression of Hedgehog signalling promotes pro-tumourigenic integrin expression and function. JOURNAL OF PATHOLOGY, 233(2), 196-208. doi:10.1002/path.4342
Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial
Butts, C., Socinski, M. A., Mitchell, P. L., Thatcher, N., Havel, L., Krzakowski, M., . . . Shepherd, F. A. (2014). Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. LANCET ONCOLOGY, 15(1), 59-68. doi:10.1016/S1470-2045(13)70510-2
The immune response in HPV<SUP>+</SUP> oropharyngeal cancer
King, E. V., Ottensmeier, C. H., & Thomas, G. J. (2014). The immune response in HPV<SUP>+</SUP> oropharyngeal cancer. ONCOIMMUNOLOGY, 3(1). doi:10.4161/onci.27254
The role of the reporting framework MIATA within current efforts to advance immune monitoring
Janetzki, S., Britten, C. M., Davis, M. M., Hoos, A., Huber, C., Kalos, M., . . . Walter, S. (2014). The role of the reporting framework MIATA within current efforts to advance immune monitoring. JOURNAL OF IMMUNOLOGICAL METHODS, 409, 6-8. doi:10.1016/j.jim.2014.05.003
Treatment and outcome in epidermal growth factor receptor mutant non-small cell lung cancer: A retrospective audit across four NHS trusts
Killick, E., Bennett, J., Bates, A., Bhatnagar, A., Fenton, P., Ottensmeier, C., . . . Nolan, L. (2014). Treatment and outcome in epidermal growth factor receptor mutant non-small cell lung cancer: A retrospective audit across four NHS trusts. In LUNG CANCER Vol. 83 (pp. S10-S11). doi:10.1016/S0169-5002(14)70027-3
Tumour Infiltrating Lymphocytes Associate with Improved Survival in Oesophageal Adenocarcinoma
Noble, F., Mellows, T., Matthews, L. M., Bateman, A., Byrne, J., Bailey, I., . . . Ottensmeier, C. (2014). Tumour Infiltrating Lymphocytes Associate with Improved Survival in Oesophageal Adenocarcinoma. In BRITISH JOURNAL OF SURGERY Vol. 101 (pp. 36). Retrieved from https://www.webofscience.com/
2013
Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial)
Ramalingam, S., Crawford, J., Chang, A., Manegold, C., Perez-Soler, R., Douillard, J. -Y., . . . Giaccone, G. (2013). Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial). ANNALS OF ONCOLOGY, 24(11), 2875-2880. doi:10.1093/annonc/mdt371
FOXO3 expression during colorectal cancer progression: biomarker potential reflects a tumour suppressor role
Bullock, M. D., Bruce, A., Sreekumar, R., Curtis, N., Cheung, T., Reading, I., . . . Mirnezami, A. H. (2013). FOXO3 expression during colorectal cancer progression: biomarker potential reflects a tumour suppressor role. BRITISH JOURNAL OF CANCER, 109(2), 387-394. doi:10.1038/bjc.2013.355
New horizons for prostate cancer: part 2
Dearnaley, D., Ottensmeier, C., Attard, G., & Crabb, S. (2013). New horizons for prostate cancer: part 2. Trends in Urology & Men's Health, 4(4), 13-16. doi:10.1002/tre.339
A multicenter phase III randomized double-blind placebo controlled trial of pravastatin added to first-line standard chemotherapy in patients with small cell lung cancer (SCLC).
Seckl, M., Ottensmeier, C., Cullen, M. H., Schmid, P., James, L. E., Wadsworth, C., . . . Khan, I. (2013). A multicenter phase III randomized double-blind placebo controlled trial of pravastatin added to first-line standard chemotherapy in patients with small cell lung cancer (SCLC).. Journal of Clinical Oncology, 31(15_suppl), 7595. doi:10.1200/jco.2013.31.15_suppl.7595
DOC-MEK: A double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt <i>BRAF</i> advanced melanoma.
Gupta, A., Love, S., Schuh, A., Collins, L., Thomason, A., Asher, R., . . . Middleton, M. R. (2013). DOC-MEK: A double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt <i>BRAF</i> advanced melanoma.. Journal of Clinical Oncology, 31(15_suppl), 9068. doi:10.1200/jco.2013.31.15_suppl.9068
Dissection of anti-CTLA4-induced cytotoxic T-cell responses in melanoma.
Haanen, J. B. A. G., Kvistborg, P., Philips, D., Kelderman, S., Heemskerk, B., Ottensmeier, C., . . . Schumacher, T. (2013). Dissection of anti-CTLA4-induced cytotoxic T-cell responses in melanoma.. Journal of Clinical Oncology, 31(15_suppl), 9078. doi:10.1200/jco.2013.31.15_suppl.9078
Ipilimumab in the real world: The U.K. expanded access programme (EAP) experience in advanced melanoma.
Ahmad, S., Qian, W., Ellis, S. G., Khattak, M. A., Gupta, A., Thillai, K., . . . Corrie, P. (2013). Ipilimumab in the real world: The U.K. expanded access programme (EAP) experience in advanced melanoma.. Journal of Clinical Oncology, 31(15_suppl), 3018. doi:10.1200/jco.2013.31.15_suppl.3018
Sunitinib versus dacarbazine as first-line treatment in patients with metastatic uveal melanoma.
Sacco, J. J., Nathan, P. D., Danson, S., Lorigan, P., Nicholson, S., Ottensmeier, C., . . . Marshall, E. (2013). Sunitinib versus dacarbazine as first-line treatment in patients with metastatic uveal melanoma.. Journal of Clinical Oncology, 31(15_suppl), 9031. doi:10.1200/jco.2013.31.15_suppl.9031
New horizons for prostate cancer: part 1
Dearnaley, D., Ottensmeier, C., Attard, G., & Crabb, S. (2013). New horizons for prostate cancer: part 1. Trends in Urology & Men's Health, 4(3), 38-40. doi:10.1002/tre.334
A trial of agonistic anti-CD40 antibody: Biological effects in a Cancer Research UK phase I study.
Johnson, P. W., Challis, R., Chowdhury, F., Chan, C., Smith, A., Steven, N., . . . Glennie, M. (2013). A trial of agonistic anti-CD40 antibody: Biological effects in a Cancer Research UK phase I study.. In CANCER RESEARCH Vol. 73. doi:10.1158/1538-7445.AM2013-LB-142
Serum-free freezing media support high cell quality and excellent ELISPOT assay performance across a wide variety of different assay protocols
Filbert, H., Attig, S., Bidmon, N., Renard, B. Y., Janetzki, S., Sahin, U., . . . Britten, C. M. (2013). Serum-free freezing media support high cell quality and excellent ELISPOT assay performance across a wide variety of different assay protocols. CANCER IMMUNOLOGY IMMUNOTHERAPY, 62(4), 615-627. doi:10.1007/s00262-012-1359-5
The development of standard samples with a defined number of antigen-specific T cells to harmonize T cell assays: a proof-of-principle study
Singh, S. K., Tummers, B., Schumacher, T. N., Gomez, R., Franken, K. L. M. C., Verdegaal, E. M., . . . van der Burg, S. H. (2013). The development of standard samples with a defined number of antigen-specific T cells to harmonize T cell assays: a proof-of-principle study. CANCER IMMUNOLOGY IMMUNOTHERAPY, 62(3), 489-501. doi:10.1007/s00262-012-1351-0
A MULTICENTER PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO CONTROLLED TRIAL OF PRAVASTATIN ADDED TO FIRST-LINE STANDARD CHEMOTHERAPY IN PATIENTS WITH SMALL CELL LUNG CANCER (SCLC)
Seckl, M. J., Ottensmeier, C., Cullen, M., Schmid, P., James, L., Wadsworth, C., . . . Khan, I. (2013). A MULTICENTER PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO CONTROLLED TRIAL OF PRAVASTATIN ADDED TO FIRST-LINE STANDARD CHEMOTHERAPY IN PATIENTS WITH SMALL CELL LUNG CANCER (SCLC). In JOURNAL OF THORACIC ONCOLOGY Vol. 8 (pp. S219). Retrieved from https://www.webofscience.com/
A RANDOMISED PLACEBO-CONTROLLED MULTICENTRE PHASE II TRIAL OF ERLOTINIB PLUS WHOLE BRAIN RADIOTHERAPY FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER WITH MULTIPLE BRAIN METASTASES (TACTIC)
Lee, S. M., Lewanski, C., Counsell, N., Ottensmeier, C., Bates, A. T., Patel, N., . . . Faivre-Finn, C. (2013). A RANDOMISED PLACEBO-CONTROLLED MULTICENTRE PHASE II TRIAL OF ERLOTINIB PLUS WHOLE BRAIN RADIOTHERAPY FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER WITH MULTIPLE BRAIN METASTASES (TACTIC). In JOURNAL OF THORACIC ONCOLOGY Vol. 8 (pp. S298-S299). Retrieved from https://www.webofscience.com/
Afatanib use in non-small cell cancer patients whose tumours have been previously sensitive to EGFR inhibitors: the UK Named Patient Use experience
Khan, F., Ottensmeier, C., Popat, S., & Danson, S. J. (2013). Afatanib use in non-small cell cancer patients whose tumours have been previously sensitive to EGFR inhibitors: the UK Named Patient Use experience. In LUNG CANCER Vol. 79 (pp. S10-S11). doi:10.1016/S0169-5002(13)70030-8
Chapter 15 Genetic Vaccines against Cancer Design, Testing and Clinical Performance
Stevenson, F. K., di Genova, G., Ottensmeier, C. H., & Savelyeva, N. (2013). Chapter 15 Genetic Vaccines against Cancer Design, Testing and Clinical Performance. In Cancer Immunotherapy (pp. 223-239). Elsevier. doi:10.1016/b978-0-12-394296-8.00015-4
DOC-MEK: A double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt <i>BRAF</i> advanced melanoma
Gupta, A., Love, S., Schuh, A., Collins, L., Thomason, A., Asher, R., . . . Middleton, M. R. (2013). DOC-MEK: A double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt <i>BRAF</i> advanced melanoma. In JOURNAL OF CLINICAL ONCOLOGY Vol. 31. Retrieved from https://www.webofscience.com/
Dissection of anti-CTLA4-induced cytotoxic T-cell responses in melanoma
Haanen, J. B. A. G., Kvistborg, P., Philips, D., Kelderman, S., Heemskerk, B., Ottensmeier, C., . . . Schumacher, T. (2013). Dissection of anti-CTLA4-induced cytotoxic T-cell responses in melanoma. In JOURNAL OF CLINICAL ONCOLOGY Vol. 31. Retrieved from https://www.webofscience.com/
Genetic Vaccines against Cancer
Stevenson, F. K., di Genova, G., Ottensmeier, C. H., & Savelyeva, N. (2013). Genetic Vaccines against Cancer. In Cancer Immunotherapy (pp. 223-239). Elsevier. doi:10.1016/b978-0-12-394296-8.00015-4
Ipilimumab in the real world: The UK expanded access programme (EAP) experience in advanced melanoma.
Ahmad, S., Qian, W., Ellis, S. G., Khattak, M. A., Gupta, A., Thillai, K., . . . Corrie, P. (2013). Ipilimumab in the real world: The UK expanded access programme (EAP) experience in advanced melanoma.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 31. Retrieved from https://www.webofscience.com/
Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052)
O'Brien, M. E. R., Gaafar, R. M., Popat, S., Grossi, F., Price, A., Talbot, D. C., . . . Baas, P. (2013). Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052). EUROPEAN JOURNAL OF CANCER, 49(13), 2815-2822. doi:10.1016/j.ejca.2013.05.008
Sunitinib versus dacarbazine as first-line treatment in patients with metastatic uveal melanoma
Sacco, J. J., Nathan, P. D., Danson, S., Lorigan, P., Nicholson, S., Ottensmeier, C., . . . Marshall, E. (2013). Sunitinib versus dacarbazine as first-line treatment in patients with metastatic uveal melanoma. In JOURNAL OF CLINICAL ONCOLOGY Vol. 31. Retrieved from https://www.webofscience.com/
Tumour infiltrating lymphocytes levels within colorectal liver metastases correlate with oncological outcomes
Curtis, N., Primrose, J. N., Mirnezami, A. H., Thomas, G. J., Bruce, A., Pugh, S., & Ottensmeier, C. H. (2013). Tumour infiltrating lymphocytes levels within colorectal liver metastases correlate with oncological outcomes. In EUROPEAN JOURNAL OF CANCER Vol. 49 (pp. S564). Retrieved from https://www.webofscience.com/
2012
A Phase I Clinical Trial of Irinotecan and Carboplatin in Patients with Extensive Stage Small Cell Lung Cancer
Crabb, S. J., Bradbury, J., Nolan, L., Selman, D., Muthuramalingam, S. R., Cave, J., . . . Ottensmeier, C. (2012). A Phase I Clinical Trial of Irinotecan and Carboplatin in Patients with Extensive Stage Small Cell Lung Cancer. CHEMOTHERAPY, 58(4), 257-263. doi:10.1159/000341274
DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8<SUP>+</SUP> T-cell responses and increases PSA doubling time
Chudley, L., McCann, K., Mander, A., Tjelle, T., Campos-Perez, J., Godeseth, R., . . . Ottensmeier, C. (2012). DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8<SUP>+</SUP> T-cell responses and increases PSA doubling time. CANCER IMMUNOLOGY IMMUNOTHERAPY, 61(11), 2161-2170. doi:10.1007/s00262-012-1270-0
Cancer classification using the Immunoscore: a worldwide task force
Galon, J., Pages, F., Marincola, F. M., Angell, H. K., Thurin, M., Lugli, A., . . . Fox, B. A. (2012). Cancer classification using the Immunoscore: a worldwide task force. JOURNAL OF TRANSLATIONAL MEDICINE, 10. doi:10.1186/1479-5876-10-205
The adaptive immune response to colorectal cancer: From the laboratory to clinical practice
Curtis, N. J., Primrose, J. N., Thomas, G. J., Mirnezami, A. H., & Ottensmeier, C. H. (2012). The adaptive immune response to colorectal cancer: From the laboratory to clinical practice. EJSO, 38(10), 889-896. doi:10.1016/j.ejso.2012.05.011
T Cell Assays and MIATA: The Essential Minimum for Maximum Impact
Britten, C. M., Janetzki, S., Butterfield, L. H., Ferrari, G., Gouttefangeas, C., Huber, C., . . . Davis, M. M. (2012). T Cell Assays and MIATA: The Essential Minimum for Maximum Impact. IMMUNITY, 37(1), 1-2. doi:10.1016/j.immuni.2012.07.010
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M., . . . Schadendorf, D. (2012). Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma. NEW ENGLAND JOURNAL OF MEDICINE, 367(2), 107-114. doi:10.1056/NEJMoa1203421
Harmonization of the intracellular cytokine staining assay
Welters, M. J. P., Gouttefangeas, C., Ramwadhdoebe, T. H., Letsch, A., Ottensmeier, C. H., Britten, C. M., & van der Burg, S. H. (2012). Harmonization of the intracellular cytokine staining assay. CANCER IMMUNOLOGY IMMUNOTHERAPY, 61(7), 967-978. doi:10.1007/s00262-012-1282-9
Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment
Revicki, D. A., van den Eertwegh, A. J. M., Lorigan, P., Lebbe, C., Linette, G., Ottensmeier, C. H., . . . Kotapati, S. (2012). Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment. HEALTH AND QUALITY OF LIFE OUTCOMES, 10. doi:10.1186/1477-7525-10-66
A randomized phase II study of sunitinib versus dacarbazine in the treatment of patients with metastatic uveal melanoma.
Marshall, E., Coupland, S., Corrie, P., Damato, B., Danson, S., Dobson, L., . . . Nathan, P. D. (2012). A randomized phase II study of sunitinib versus dacarbazine in the treatment of patients with metastatic uveal melanoma.. Journal of Clinical Oncology, 30(15_suppl), TPS8605. doi:10.1200/jco.2012.30.15_suppl.tps8605
Biomarker for benefit from ipilimumab: Correlation of breadth of humoral tumor-antigen-specific immunity with outcome.
Ellis, S. G., Wheater, M., Tier, K., Cazaly, A., Smart, J., Theaker, J., . . . Ottensmeier, C. H. H. (2012). Biomarker for benefit from ipilimumab: Correlation of breadth of humoral tumor-antigen-specific immunity with outcome.. Journal of Clinical Oncology, 30(15_suppl), 8566. doi:10.1200/jco.2012.30.15_suppl.8566
Phase I/II, two-part, open-label, multiple-dose, dose-escalation study of siltuximab in patients with solid tumors.
Angevin, E., Elez, E., Cohen, S. J., Van Laethem, J. -L., Ottensmeier, C., Joly, F., . . . Kurzrock, R. (2012). Phase I/II, two-part, open-label, multiple-dose, dose-escalation study of siltuximab in patients with solid tumors.. Journal of Clinical Oncology, 30(15_suppl), 2583. doi:10.1200/jco.2012.30.15_suppl.2583
Phase II study of bortezomib with cisplatin as first-line treatment of malignant pleural mesothelioma (MPM): EORTC 08052.
O'Brien, M., Gaafar, R. M., Popat, S., Grossi, F., Price, A., Talbot, D. C., . . . Baas, P. (2012). Phase II study of bortezomib with cisplatin as first-line treatment of malignant pleural mesothelioma (MPM): EORTC 08052.. Journal of Clinical Oncology, 30(15_suppl), 7081. doi:10.1200/jco.2012.30.15_suppl.7081
A randomized phase II study of sunitinib versus dacarbazine in the treatment of patients with metastatic uveal melanoma.
Marshall, E., Coupland, S., Corrie, P., Damato, B., Danson, S., Dobson, L., . . . Nathan, P. D. (2012). A randomized phase II study of sunitinib versus dacarbazine in the treatment of patients with metastatic uveal melanoma.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 30. Retrieved from https://www.webofscience.com/
Biomarker for benefit from ipilimumab: Correlation of breadth of humoral tumor-antigen-specific immunity with outcome.
Ellis, S. G., Wheater, M., Tier, K., Cazaly, A., Smart, J., Theaker, J., . . . Ottensmeier, C. H. H. (2012). Biomarker for benefit from ipilimumab: Correlation of breadth of humoral tumor-antigen-specific immunity with outcome.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 30. Retrieved from https://www.webofscience.com/
CD8+T-cell cross-competition is governed by peptide-MHC class I stability
Galea, I., Stasakova, J., Dunscombe, M. S., Ottensmeier, C. H., Elliott, T., & Thirdborough, S. M. (2012). CD8+T-cell cross-competition is governed by peptide-MHC class I stability. EUROPEAN JOURNAL OF IMMUNOLOGY, 42(1), 256-263. doi:10.1002/eji.201142010
Dissection of Anti-CTLA4-induced Cytotoxic T Cell Responses in Melanoma
Kvistborg, P., Philips, D., Kelderman, S., Hemskerk, B., Ottensmeier, C., Ribas, A., . . . Schumacher, T. (2012). Dissection of Anti-CTLA4-induced Cytotoxic T Cell Responses in Melanoma. In JOURNAL OF IMMUNOTHERAPY Vol. 35 (pp. 760-761). Retrieved from https://www.webofscience.com/
Harmonization of Cellular Immunological Biomarkers by an International Network: The Cancer Immunotherapy Immunoguiding Program (CIP)
Welters, M. J., Gouttefangeas, C., Ottensmeier, C. H., Walter, S., Britten, C. M., & van der Burg, S. H. (2012). Harmonization of Cellular Immunological Biomarkers by an International Network: The Cancer Immunotherapy Immunoguiding Program (CIP). In JOURNAL OF IMMUNOTHERAPY Vol. 35 (pp. 762). Retrieved from https://www.webofscience.com/
Phase I/II, two-part, open-label, multiple-dose, dose-escalation study of siltuximab in patients with solid tumors
Angevin, E., Elez, E., Cohen, S. J., Van Laethem, J. -L., Ottensmeier, C., Joly, F., . . . Kurzrock, R. (2012). Phase I/II, two-part, open-label, multiple-dose, dose-escalation study of siltuximab in patients with solid tumors. In JOURNAL OF CLINICAL ONCOLOGY Vol. 30. Retrieved from https://www.webofscience.com/
Phase II study of bortezomib with cisplatin as first-line treatment of malignant pleural mesothelioma (MPM): EORTC 08052
O'Brien, M., Gaafar, R. M., Popat, S., Grossi, F., Price, A., Talbot, D. C., . . . Baas, P. (2012). Phase II study of bortezomib with cisplatin as first-line treatment of malignant pleural mesothelioma (MPM): EORTC 08052. In JOURNAL OF CLINICAL ONCOLOGY Vol. 30. Retrieved from https://www.webofscience.com/
The Cancer Immunotherapy Immunoguiding Program (CIP): An international network for the harmonization of cellular immunological biomarkers
Walter, S., Gouttefangeas, C., Britten, C. M., Ottensmeier, C. H., Welters, M. J. P., & van der Burg, S. H. (2012). The Cancer Immunotherapy Immunoguiding Program (CIP): An international network for the harmonization of cellular immunological biomarkers. In TUMOR BIOLOGY Vol. 33 (pp. 65). Retrieved from https://www.webofscience.com/
2011
Defining the critical hurdles in cancer immunotherapy
Fox, B. A., Schendel, D. J., Butterfield, L. H., Aamdal, S., Allison, J. P., Ascierto, P. A., . . . Disis, M. L. (2011). Defining the critical hurdles in cancer immunotherapy. JOURNAL OF TRANSLATIONAL MEDICINE, 9. doi:10.1186/1479-5876-9-214
Harmonization of Immune Biomarker Assays for Clinical Studies
van der Burg, S. H., Kalos, M., Gouttefangeas, C., Janetzki, S., Ottensmeier, C., Welters, M. J. P., . . . Hoos, A. (2011). Harmonization of Immune Biomarker Assays for Clinical Studies. SCIENCE TRANSLATIONAL MEDICINE, 3(108). doi:10.1126/scitranslmed.3002785
DNA fusion gene vaccines induce cytotoxic T-cell attack on naturally processed peptides of human prostate-specific membrane antigen
Vittes, G. E., Harden, E. L., Ottensmeier, C. H., Rice, J., & Stevenson, F. K. (2011). DNA fusion gene vaccines induce cytotoxic T-cell attack on naturally processed peptides of human prostate-specific membrane antigen. EUROPEAN JOURNAL OF IMMUNOLOGY, 41(8), 2447-2456. doi:10.1002/eji.201141518
DNA fusion vaccines enter the clinic
Stevenson, F. K., Mander, A., Chudley, L., & Ottensmeier, C. H. (2011). DNA fusion vaccines enter the clinic. CANCER IMMUNOLOGY IMMUNOTHERAPY, 60(8), 1147-1151. doi:10.1007/s00262-011-1042-2
A randomised, phase II study of intetumumab, an anti-α<sub>v</sub>-integrin mAb, alone and with dacarbazine in stage IV melanoma
O'Day, S., Pavlick, A., Loquai, C., Lawson, D., Gutzmer, R., Richards, J., . . . Ho, P. (2011). A randomised, phase II study of intetumumab, an anti-α<sub>v</sub>-integrin mAb, alone and with dacarbazine in stage IV melanoma. BRITISH JOURNAL OF CANCER, 105(3), 346-352. doi:10.1038/bjc.2011.183
Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies
Eisen, T., Marais, R., Affolter, A., Lorigan, P., Robert, C., Corrie, P., . . . Gore, M. E. (2011). Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies. BRITISH JOURNAL OF CANCER, 105(3), 353-359. doi:10.1038/bjc.2011.257
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., . . . McArthur, G. A. (2011). Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. NEW ENGLAND JOURNAL OF MEDICINE, 364(26), 2507-2516. doi:10.1056/NEJMoa1103782
B-Cell Tumors
Ottensmeier, C., & Stevenson, F. (2011). B-Cell Tumors. In Encyclopedia of Cancer (pp. 351-356). Springer Berlin Heidelberg. doi:10.1007/978-3-642-16483-5_559
Phase I dose finding study of irinotecan in combination with carboplatin in treatment naive extensive stage small cell lung cancer
Nolan, L., Bradbury, J. A., Muthuramalingam, S., Cave, J., Johnson, P. W. M., Ottensmeier, C. H., & Crabb, S. C. (2011). Phase I dose finding study of irinotecan in combination with carboplatin in treatment naive extensive stage small cell lung cancer. In LUNG CANCER Vol. 71 (pp. S41). doi:10.1016/S0169-5002(11)70119-2
2010
A panel of human cell-based artificial APC enables the expansion of long-lived antigen-specific CD4+ T cells restricted by prevalent HLA-DR alleles.
Butler, M. O., Ansén, S., Tanaka, M., Imataki, O., Berezovskaya, A., Mooney, M. M., . . . Hirano, N. (2010). A panel of human cell-based artificial APC enables the expansion of long-lived antigen-specific CD4+ T cells restricted by prevalent HLA-DR alleles.. International immunology, 22(11), 863-873. doi:10.1093/intimm/dxq440
Ig gene diversification and selection in follicular lymphoma, diffuse large B cell lymphoma and primary central nervous system lymphoma revealed by lineage tree and mutation analyses
Zuckerman, N. S., McCann, K. J., Ottensmeier, C. H., Barak, M., Shahaf, G., Edelman, H., . . . Mehr, R. (2010). Ig gene diversification and selection in follicular lymphoma, diffuse large B cell lymphoma and primary central nervous system lymphoma revealed by lineage tree and mutation analyses. INTERNATIONAL IMMUNOLOGY, 22(11), 875-887. doi:10.1093/intimm/dxq441
Melanoma sentinel node biopsy and prediction models for relapse and overall survival
Mitra, A., Conway, C., Walker, C., Cook, M., Powell, B., Lobo, S., . . . Newton-Bishop, J. A. (2010). Melanoma sentinel node biopsy and prediction models for relapse and overall survival. BRITISH JOURNAL OF CANCER, 103(8), 1229-1236. doi:10.1038/sj.bjc.6605849
Response definition criteria for ELISPOT assays revisited
Moodie, Z., Price, L., Gouttefangeas, C., Mander, A., Janetzki, S., Loewer, M., . . . Britten, C. M. (2010). Response definition criteria for ELISPOT assays revisited. CANCER IMMUNOLOGY IMMUNOTHERAPY, 59(10), 1489-1501. doi:10.1007/s00262-010-0875-4
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., . . . Urba, W. J. (2010). Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. NEW ENGLAND JOURNAL OF MEDICINE, 363(8), 711-723. doi:10.1056/NEJMoa1003466
Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine
Dangoor, A., Lorigan, P., Keilholz, U., Schadendorf, D., Harris, A., Ottensmeier, C., . . . Hawkins, R. (2010). Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine. CANCER IMMUNOLOGY IMMUNOTHERAPY, 59(6), 863-873. doi:10.1007/s00262-009-0811-7
A Cancer Research UK phase I study evaluating safety, tolerability, and biological effects of chimeric anti-CD40 monoclonal antibody (Mab), Chi Lob 7/4
Johnson, P. W., Steven, N. M., Chowdhury, F., Dobbyn, J., Hall, E., Ashton-Key, M., . . . Glennie, M. (2010). A Cancer Research UK phase I study evaluating safety, tolerability, and biological effects of chimeric anti-CD40 monoclonal antibody (Mab), Chi Lob 7/4. In JOURNAL OF CLINICAL ONCOLOGY Vol. 28. doi:10.1200/jco.2010.28.15_suppl.2507
Clinical and immunological responses to a DNA fusion vaccine in patients with carcinoembryonic antigen-expressing tumors: A Cancer Research UK phase I/II study.
Ottensmeier, C. H., Mander, A., McCann, K., Low, L., Hall, E., Bateman, A., . . . O'Callaghan, A. (2010). Clinical and immunological responses to a DNA fusion vaccine in patients with carcinoembryonic antigen-expressing tumors: A Cancer Research UK phase I/II study.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 28. doi:10.1200/jco.2010.28.15_suppl.2579
DNA vaccines against cancer come of age
Stevenson, F. K., Ottensmeier, C. H., & Rice, J. (2010). DNA vaccines against cancer come of age. CURRENT OPINION IN IMMUNOLOGY, 22(2), 264-270. doi:10.1016/j.coi.2010.01.019
Serum is not required for ex vivo IFN-γ ELISPOT: a collaborative study of different protocols from the European CIMT Immunoguiding Program
Mander, A., Gouttefangeas, C., Ottensmeier, C., Welters, M. J. P., Low, L., van der Burg, S. H., & Britten, C. M. (2010). Serum is not required for ex vivo IFN-γ ELISPOT: a collaborative study of different protocols from the European CIMT Immunoguiding Program. CANCER IMMUNOLOGY IMMUNOTHERAPY, 59(4), 619-627. doi:10.1007/s00262-009-0814-4
HEALTH RELATED QUALITY OF LIFE (HRQL) OUTCOMES OF IPILIMUMAB TREATMENT IN PATIENTS WITH PREVIOUSLY TREATED UNRESECTABLE STAGE III OR IV MELANOMA (USIII/IV MEL)
Revicki, D., Kotapati, S., van Den Eertwegh, A. J., Lorigan, P., Linette, G., Ottensmeier, C. H., . . . Wagner, S. (2010). HEALTH RELATED QUALITY OF LIFE (HRQL) OUTCOMES OF IPILIMUMAB TREATMENT IN PATIENTS WITH PREVIOUSLY TREATED UNRESECTABLE STAGE III OR IV MELANOMA (USIII/IV MEL). In ANNALS OF ONCOLOGY Vol. 21 (pp. 402-403). Retrieved from https://www.webofscience.com/
IPILIMUMAB IMPROVES SURVIVAL IN PREVIOUSLY TREATED, ADVANCED MELANOMA PATIENTS WITH POOR PROGNOSTIC FACTORS: SUBGROUP ANALYSES FROM A PHASE III TRIAL
Lebbe, C., McDermott, D. F., Robert, C., Lorigan, P., Ottensmeier, C. H., Wolchok, J., . . . Weber, J. S. (2010). IPILIMUMAB IMPROVES SURVIVAL IN PREVIOUSLY TREATED, ADVANCED MELANOMA PATIENTS WITH POOR PROGNOSTIC FACTORS: SUBGROUP ANALYSES FROM A PHASE III TRIAL. In ANNALS OF ONCOLOGY Vol. 21 (pp. 401). Retrieved from https://www.webofscience.com/
IPILIMUMAB PRODUCES DURABLE OBJECTIVE RESPONSES IN PATIENTS WITH PREVIOUSLY TREATED, ADVANCED MELANOMA: RESULTS FROM A PHASE III TRIAL
Ottensmeier, C., Weber, R., Haanen, J. B., Robert, C., Schadendorf, D., Lutzky, J., . . . O'day, S. (2010). IPILIMUMAB PRODUCES DURABLE OBJECTIVE RESPONSES IN PATIENTS WITH PREVIOUSLY TREATED, ADVANCED MELANOMA: RESULTS FROM A PHASE III TRIAL. In ANNALS OF ONCOLOGY Vol. 21 (pp. 401-402). Retrieved from https://www.webofscience.com/
RE-INDUCTION WITH IPILIMUMAB, GP100 PEPTIDE VACCINE, OR A COMBINATION OF BOTH IN A PHASE III STUDY OF PREVIOUSLY-TREATED PATIENTS WITH ADVANCED MELANOMA: UPDATE OF CLINICAL CHARACTERISTICS OF PATIENTS
Robert, C., Hodi, F. S., O'Day, S. J., Peschel, C., Ottensmeier, C. H., Trefzer, U., . . . Schadendorf, D. (2010). RE-INDUCTION WITH IPILIMUMAB, GP100 PEPTIDE VACCINE, OR A COMBINATION OF BOTH IN A PHASE III STUDY OF PREVIOUSLY-TREATED PATIENTS WITH ADVANCED MELANOMA: UPDATE OF CLINICAL CHARACTERISTICS OF PATIENTS. In ANNALS OF ONCOLOGY Vol. 21 (pp. 403-404). Retrieved from https://www.webofscience.com/
2009
First case report of Muir-Torre syndrome associated with non-small cell lung cancer
Nolan, L., Eccles, D., Cross, E., Crawford, G., Beck, N., Bateman, A., & Ottensmeier, C. (2009). First case report of Muir-Torre syndrome associated with non-small cell lung cancer. FAMILIAL CANCER, 8(4), 359-362. doi:10.1007/s10689-009-9247-7
DNA Vaccination with Electroporation Induces Increased Antibody Responses in Patients with Prostate Cancer
Low, L., Mander, A., McCann, K., Dearnaley, D., Tjelle, T., Mathiesen, I., . . . Ottensmeier, C. H. (2009). DNA Vaccination with Electroporation Induces Increased Antibody Responses in Patients with Prostate Cancer. HUMAN GENE THERAPY, 20(11), 1269-1278. doi:10.1089/hum.2009.067
Randomized Double-Blind Placebo-Controlled Trial of Thalidomide in Combination With Gemcitabine and Carboplatin in Advanced Non-Small-Cell Lung Cancer
Lee, S. M., Rudd, R., Woll, P. J., Ottensmeier, C., Gilligan, D., Price, A., . . . Hackshaw, A. (2009). Randomized Double-Blind Placebo-Controlled Trial of Thalidomide in Combination With Gemcitabine and Carboplatin in Advanced Non-Small-Cell Lung Cancer. JOURNAL OF CLINICAL ONCOLOGY, 27(31), 5248-5254. doi:10.1200/JCO.2009.21.9733
Primary central nervous system lymphoma: tumor-related clones exist in the blood and bone marrow with evidence for separate development
McCann, K. J., Ashton-Key, M., Smith, K., Stevenson, F. K., & Ottensmeier, C. H. (2009). Primary central nervous system lymphoma: tumor-related clones exist in the blood and bone marrow with evidence for separate development. BLOOD, 113(19), 4677-4680. doi:10.1182/blood-2008-09-179366
Fit for purpose? A case study: validation of immunological endpoint assays for the detection of cellular and humoral responses to anti-tumour DNA fusion vaccines
Mander, A., Chowdhury, F., Low, L., & Ottensmeier, C. H. (2009). Fit for purpose? A case study: validation of immunological endpoint assays for the detection of cellular and humoral responses to anti-tumour DNA fusion vaccines. CANCER IMMUNOLOGY IMMUNOTHERAPY, 58(5), 789-800. doi:10.1007/s00262-008-0633-z
The Synthesis and in vivo Evaluation of 2′,2′-Difluoro KRN7000
Leung, L., Tomassi, C., Van Beneden, K., Decruy, T., Trappeniers, M., Elewaut, D., . . . Linclau, B. (2009). The Synthesis and in vivo Evaluation of 2′,2′-Difluoro KRN7000. CHEMMEDCHEM, 4(3), 329-334. doi:10.1002/cmdc.200800348
Defining Multiple Myeloma as a Target for DNA Fusion Gene Vaccines
Sahota, S. S., Zojer, N., Babbage, G., Joseph-Pietras, D., Weston-Bell, N., Vanderkerken, K., . . . Ottensmeier, C. H. (2009). Defining Multiple Myeloma as a Target for DNA Fusion Gene Vaccines. In CLINICAL LYMPHOMA & MYELOMA Vol. 9 (pp. S23-S24). doi:10.1016/S1557-9190(11)70813-7
B-cell Tumors
Ottensmeier, C., & Stevenson, F. (n.d.). B-cell Tumors. In Encyclopedia of Cancer (pp. 305-309). Springer Berlin Heidelberg. doi:10.1007/978-3-540-47648-1_559
2008
Synthesis and In Vivo Evaluation of 4-Deoxy-4,4-difluoro-KRN7000
Leung, L., Tomassi, C., Van Beneden, K., Decruy, T., Elewaut, D., Elliott, T., . . . Linclau, B. (2008). Synthesis and In Vivo Evaluation of 4-Deoxy-4,4-difluoro-KRN7000. ORGANIC LETTERS, 10(20), 4433-4436. doi:10.1021/ol801663m
Survival from melanoma of the skin in England and Wales up to 2001 - Clinical commentary
Ottensmeier, C. H., & Gore, M. (2008). Survival from melanoma of the skin in England and Wales up to 2001 - Clinical commentary. BRITISH JOURNAL OF CANCER, 99, S50-S52. doi:10.1038/sj.bjc.6604586
Synthesis and in vitro evaluation of α-GalCer epimers
Trappeniers, M., Goormans, S., Van Beneden, K., Decruy, T., Linclau, B., Al-Shamkhani, A., . . . Van Calenbergh, S. (2008). Synthesis and in vitro evaluation of α-GalCer epimers. CHEMMEDCHEM, 3(7), 1061-1070. doi:10.1002/cmdc.200800021
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma:: final results of EORTC 18991, a randomised phase III trial
Eggermont, A. M. M., Suciu, S., Santinami, M., Testori, A., Kruit, W. H. J., Marsden, J., . . . Keilholz, U. (2008). Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma:: final results of EORTC 18991, a randomised phase III trial. LANCET, 372(9633), 117-126. doi:10.1016/S0140-6736(08)61033-8
Two randomised phase III, double blind, placebo controlled trials of thalidomide in patients with advanced non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC)
Lee, S., Rudd, R. M., Woll, P. J., Ottensmeier, C. H., James, L. E., Gower, N. H., . . . Hackshaw, A. (2008). Two randomised phase III, double blind, placebo controlled trials of thalidomide in patients with advanced non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Journal of Clinical Oncology, 26(15_suppl), 8045. doi:10.1200/jco.2008.26.15_suppl.8045
Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial
Muers, M. F., Stephens, R. J., Fisher, P., Darlison, L., Higgs, C. M. B., Lowry, E., . . . Parmar, M. K. B. (2008). Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. LANCET, 371(9625), 1685-1694. doi:10.1016/S0140-6736(08)60727-8
Sound implementation of human papillomavirus vaccination as a community-randomized trial
Lehtinen, M., French, K. M., Dillner, J., Paavonen, J., & Garnett, G. (2008). Sound implementation of human papillomavirus vaccination as a community-randomized trial. Therapy, 5(3), 289-294. doi:10.2217/14750708.5.3.289
Remarkable selective glycosylation of the immunoglobulin variable region in follicular lymphoma
McCann, K. J., Ottensmeier, C. H., Callard, A., Radcliffe, C. M., Harvey, D. J., Dwek, R. A., . . . Stevenson, F. K. (2008). Remarkable selective glycosylation of the immunoglobulin variable region in follicular lymphoma. MOLECULAR IMMUNOLOGY, 45(6), 1567-1572. doi:10.1016/j.molimm.2007.10.009
The CIMT-monitoring panel:: a two-step approach to harmonize the enumeration of antigen-specific CD8<SUP>+</SUP> T lymphocytes by structural and functional assays
Britten, C. M., Gouttefangeas, C., Welters, M. J. P., Pawelec, G., Koch, S., Ottensmeier, C., . . . van der Burg, S. H. (2008). The CIMT-monitoring panel:: a two-step approach to harmonize the enumeration of antigen-specific CD8<SUP>+</SUP> T lymphocytes by structural and functional assays. CANCER IMMUNOLOGY IMMUNOTHERAPY, 57(3), 289-302. doi:10.1007/s00262-007-0378-0
DNA vaccines: precision tools for activating effective immunity against cancer
Rice, J., Ottensmeier, C. H., & Stevenson, F. K. (2008). DNA vaccines: precision tools for activating effective immunity against cancer. NATURE REVIEWS CANCER, 8(2), 108-120. doi:10.1038/nrc2326
Taking electroporation-based delivery of DNA vaccination into humans: a generic clinical protocol.
Tjelle, T. E., Rabussay, D., Ottensmeier, C., Mathiesen, I., & Kjeken, R. (2008). Taking electroporation-based delivery of DNA vaccination into humans: a generic clinical protocol.. Methods in molecular biology (Clifton, N.J.), 423, 497-507. doi:10.1007/978-1-59745-194-9_39
Temporal activation of interferon regulatory factor-7 amplifies the performance of DNA vaccines in tolerant mice
Shah, V., Slebioda, T. R., James, S., Ottensmeier, C. H., & Thirdborough, S. M. (2008). Temporal activation of interferon regulatory factor-7 amplifies the performance of DNA vaccines in tolerant mice. In IMMUNOLOGY Vol. 125 (pp. 49). Retrieved from https://www.webofscience.com/
The relationship between invariant NKT cell frequency and cytokine diversity
Gao, Y., Ottensmeier, C. H., Elliott, T. J., & Williams, A. P. (2008). The relationship between invariant NKT cell frequency and cytokine diversity. In IMMUNOLOGY Vol. 125 (pp. 90). Retrieved from https://www.webofscience.com/
Two randomised phase III, double blind, placebo controlled trials of thalidomide in patients with advanced non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC)
Lee, S., Rudd, R. M., Woll, P. J., Ottensmeier, C. H., James, L. E., Gower, N. H., . . . Hackshaw, A. (2008). Two randomised phase III, double blind, placebo controlled trials of thalidomide in patients with advanced non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). In JOURNAL OF CLINICAL ONCOLOGY Vol. 26. Retrieved from https://www.webofscience.com/
2007
Cancer Vaccines
Stevenson, F. K., Genova, G. D., Ottensmeier, C., & Savelyeva, N. (2007). Cancer Vaccines. In Cancer Immunotherapy (pp. 183-204). Elsevier. doi:10.1016/b978-012372551-6/50075-4
A phase III randomised, double blind, placebo controlled trial of gemcitabine/carboplatin with or without thalidomide in advanced non-small cell lung cancer (NSCLC)
Lee, S. -M., Woll, P. J., Rudd, R. M., Gower, N. H., Ottensmeier, C. H., Ali, K., . . . Hackshaw, A. (2007). A phase III randomised, double blind, placebo controlled trial of gemcitabine/carboplatin with or without thalidomide in advanced non-small cell lung cancer (NSCLC). In JOURNAL OF THORACIC ONCOLOGY Vol. 2 (pp. S359). doi:10.1097/01.JTO.0000283190.70038.e9
An open-label phase II study of sorafenib and dacarbazine as first-line therapy in patients with advanced melanoma
Eisen, T., Marais, R., Affolter, A., Lorigan, P., Ottensmeier, C., Robert, C., . . . Gore, M. (2007). An open-label phase II study of sorafenib and dacarbazine as first-line therapy in patients with advanced melanoma. Journal of Clinical Oncology, 25(18_suppl), 8529. doi:10.1200/jco.2007.25.18_suppl.8529
An open-label phase II study of sorafenib and dacarbazine as first-line therapy in patients with advanced melanoma
Eisen, T., Marais, R., Affolter, A., Lorigan, P., Ottensmeier, C., Robert, C., . . . Gore, M. (2007). An open-label phase II study of sorafenib and dacarbazine as first-line therapy in patients with advanced melanoma. In JOURNAL OF CLINICAL ONCOLOGY Vol. 25. Retrieved from https://www.webofscience.com/
Cancer Vaccines
Stevenson, F. K., di Genova, G., Ottensmeier, C., & Savelyeva, N. (2007). Cancer Vaccines. In Cancer Immunotherapy: Immune Suppression and Tumor Growth (pp. 183-204). doi:10.1016/B978-012372551-6/50075-4
Chapter 11 Cancer Vaccines
Stevenson, F. K., di Genova, G., Ottensmeier, C., & Savelyeva, N. (2007). Chapter 11 Cancer Vaccines. In Cancer Immunotherapy (pp. 183-204). Elsevier. doi:10.1016/b978-012372551-6/50075-4
DNA vaccines to suppress myeloma
Stevenson, E. K., Campos-Perez, J., Sahota, S., & Ottensmeier, C. (2007). DNA vaccines to suppress myeloma. In HAEMATOLOGICA-THE HEMATOLOGY JOURNAL Vol. 92 (pp. 45-46). Retrieved from https://www.webofscience.com/
The CIMT monitoring panel:: enumeration of antigen-specific CD8<SUP>+</SUP> T lymphocytes by structural and functional assays
Britten, C. M., Gouttefangeas, C., Schoenmaekers-Welters, M. J. P., Pawelec, G., Koch, S., Ottensmeier, C., . . . van der Burg, S. H. (2007). The CIMT monitoring panel:: enumeration of antigen-specific CD8<SUP>+</SUP> T lymphocytes by structural and functional assays. In CANCER IMMUNOLOGY IMMUNOTHERAPY Vol. 56 (pp. 406-407). Retrieved from https://www.webofscience.com/
2006
Phase I/II trial of Hi-8 PrimeBoost therapeutic vaccine in stage III/IV metastatic melanoma
Hawkins, R., Dangoor, A., Lorigan, P., Keilholz, U., Schadendorf, D., Harris, A., . . . Cripps, M. (2006). Phase I/II trial of Hi-8 PrimeBoost therapeutic vaccine in stage III/IV metastatic melanoma. Melanoma Research, 16(Supplement 1), S34. doi:10.1097/00008390-200609001-00059
Phase I/II trial of a PrimeBoost therapeutic vaccine in stage III/IV metastatic melanoma
Hawkins, R. E., Dangoor, A., Keilholz, U., Schadendorf, D., Harris, A., Ottensmeier, C., . . . Pearce, G. (2006). Phase I/II trial of a PrimeBoost therapeutic vaccine in stage III/IV metastatic melanoma. Journal of Clinical Oncology, 24(18_suppl), 8030. doi:10.1200/jco.2006.24.18_suppl.8030
Vinflunine - an active chemotherapy for treatment of advanced non-small-cell lung cancer previously treated with a platinum-based regimen: results of a phase II study
Bennouna, J., Breton, J. -L., Tourani, J. -M., Ottensmeier, C., O'Brien, M., Kosmidis, P., . . . Douillard, J. -Y. (2006). Vinflunine - an active chemotherapy for treatment of advanced non-small-cell lung cancer previously treated with a platinum-based regimen: results of a phase II study. BRITISH JOURNAL OF CANCER, 94(10), 1383-1388. doi:10.1038/sj.bjc.6603106
Immunoglobulin heavy chain locus events and expression of activation-induced cytidine deaminase in epithelial breast cancer cell lines
Babbage, G., Ottensmeier, C. H., Blaydes, J., Stevenson, F. K., & Sahota, S. S. (2006). Immunoglobulin heavy chain locus events and expression of activation-induced cytidine deaminase in epithelial breast cancer cell lines. CANCER RESEARCH, 66(8), 3996-4000. doi:10.1158/0008-5472.CAN-05-3704
Universal N-glycosylation sites introduced into the B-cell receptor of follicular lymphoma by somatic mutation: a second tumorigenic event?
McCann, K. J., Johnson, P. W. M., Stevenson, F. K., & Ottensmeier, C. H. (2006). Universal N-glycosylation sites introduced into the B-cell receptor of follicular lymphoma by somatic mutation: a second tumorigenic event?. LEUKEMIA, 20(3), 530-534. doi:10.1038/sj.leu.2404095
Phase I/II trial of a PrimeBoost therapeutic vaccine in stage III/IV metastatic melanoma.
Hawkins, R. E., Dangoor, A., Keilholz, U., Schadendorf, D., Harris, A., Ottensmeier, C., . . . Pearce, G. (2006). Phase I/II trial of a PrimeBoost therapeutic vaccine in stage III/IV metastatic melanoma.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 24 (pp. 460S). Retrieved from https://www.webofscience.com/
The Immunophenotyping of primary diffuse large B-cell lymphomas of the central nervous system
Hickling, M., McCann, K., Ottensmeier, C., & Ashton-Key, M. (2006). The Immunophenotyping of primary diffuse large B-cell lymphomas of the central nervous system. In JOURNAL OF PATHOLOGY Vol. 208 (pp. 22A). Retrieved from https://www.webofscience.com/
2005
Immunogenetic Profiling of Follicular Lymphoma Reveals Universal N-Glycosylation Sites Introduced into the B Cell Receptor by Somatic Mutation and Suggests Relevance to Lymphoma Pathogenesis.
Ottensmeier, C. H., McCann, K. J., Johnson, P., & Stevenoson, F. K. (2005). Immunogenetic Profiling of Follicular Lymphoma Reveals Universal N-Glycosylation Sites Introduced into the B Cell Receptor by Somatic Mutation and Suggests Relevance to Lymphoma Pathogenesis.. Blood, 106(11), 606. doi:10.1182/blood.v106.11.606.606
Evaluation of a novel heterologous PrimeBoost immunotherapy in stage III/IV metastatic melanoma patients
Hawkins, R. E., Keilholz, U., Dangoor, A., Harris, A., Ottensmeier, C., Schadendorf, D., . . . Pearce, G. (2005). Evaluation of a novel heterologous PrimeBoost immunotherapy in stage III/IV metastatic melanoma patients. Journal of Clinical Oncology, 23(16_suppl), 2570. doi:10.1200/jco.2005.23.16_suppl.2570
A DNA fusion gene vaccine induces epitope-specific cytotoxic T cells able to kill human cells expressing pp65 of cytomegalovirus
King, A. T., Thirdborough, S. M., Rice, J., Khan, N., Stevenson, F. K., & Ottensmeier, C. H. (2005). A DNA fusion gene vaccine induces epitope-specific cytotoxic T cells able to kill human cells expressing pp65 of cytomegalovirus. In BRITISH JOURNAL OF SURGERY Vol. 92 (pp. 1304-1305). Retrieved from https://www.webofscience.com/
Determining mutational status of immunoglobulin v genes in chronic lymphocytic leukemia: a useful prognostic indicator.
Sahota, S. S., Babbage, G., Zojer, N., Ottensmeier, C. H., & Stevenson, F. K. (2005). Determining mutational status of immunoglobulin v genes in chronic lymphocytic leukemia: a useful prognostic indicator.. Methods in molecular medicine, 115, 129-144. doi:10.1385/1-59259-936-2:129
Evaluation of a novel heterologous PrimeBoost immunotherapy in stage III/IV metastatic melanoma patients.
Hawkins, R. E., Keilholz, U., Dangoor, A., Harris, A., Ottensmeier, C., Schadendorf, D., . . . Pearce, G. (2005). Evaluation of a novel heterologous PrimeBoost immunotherapy in stage III/IV metastatic melanoma patients.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 23 (pp. 183S). Retrieved from https://www.webofscience.com/
Idiotype gene rescue in follicular lymphoma.
McCann, K., Sahota, S. S., Stevenson, F. K., & Ottensmeier, C. H. (2005). Idiotype gene rescue in follicular lymphoma.. Methods in molecular medicine, 115, 145-171. doi:10.1385/1-59259-936-2:145
Immunogenetic profiling of follicular lymphoma reveals universal N-glycosylation sites introduced into the B cell receptor by somatic mutation and suggests relevance to lymphoma pathogenesis.
Ottensmeier, C. H., McCann, K. J., Johnson, P., & Stevenoson, F. K. (2005). Immunogenetic profiling of follicular lymphoma reveals universal N-glycosylation sites introduced into the B cell receptor by somatic mutation and suggests relevance to lymphoma pathogenesis.. In BLOOD Vol. 106 (pp. 180A). Retrieved from https://www.webofscience.com/
2004
Dose seeking evaluation of a novel heterologous primeboost immunotherapy in stage III and IV metastatic melanoma patients
Malinoski, F., Hawkins, R., Ottensmeier, C., Smyth, J., Harris, A., Schadendorf, D., . . . Schneider, J. (2004). Dose seeking evaluation of a novel heterologous primeboost immunotherapy in stage III and IV metastatic melanoma patients. In JOURNAL OF IMMUNOTHERAPY Vol. 27 (pp. S27). doi:10.1097/00002371-200411000-00099
DNA vaccines to attack cancer
Stevenson, F. K., Ottensmeier, C. H., Johnson, P., Zhu, D. L., Buchan, S. L., McCann, K. J., . . . Rice, J. (2004). DNA vaccines to attack cancer. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 101, 14646-14652. doi:10.1073/pnas.0404896101
Phase II study of IV Vinflunine (VFL) as second line treatment of patients (pts) with advanced non-small-cell lung cancer (NSCLC) previously treated with a platinum based regimen. Final results
Bennouna, J., Tan, E. H., Obrien, M., Kosmidis, P., Breton, J. -L., Ottensmeier, C., . . . Douillard, J. -Y. (2004). Phase II study of IV Vinflunine (VFL) as second line treatment of patients (pts) with advanced non-small-cell lung cancer (NSCLC) previously treated with a platinum based regimen. Final results. Journal of Clinical Oncology, 22(14_suppl), 7139. doi:10.1200/jco.2004.22.90140.7139
Phase II study of IV Vinflunine (VFL) as second line treatment of patients (pts) with advanced non-small-cell lung cancer (NSCLC) previously treated with a platinum based regimen. Final results
Bennouna, J., Tan, E. H., Obrien, M., Kosmidis, P., Breton, J. -L., Ottensmeier, C., . . . Douillard, J. -Y. (2004). Phase II study of IV Vinflunine (VFL) as second line treatment of patients (pts) with advanced non-small-cell lung cancer (NSCLC) previously treated with a platinum based regimen. Final results. Journal of Clinical Oncology, 22(14_suppl), 7139. doi:10.1200/jco.2004.22.14_suppl.7139
DNA fusion gene vaccines against cancer: from the laboratory to the clinic
Stevenson, F. K., Rice, J., Ottensmeier, C. H., Thirdborough, S. M., & Zhu, D. L. (2004). DNA fusion gene vaccines against cancer: from the laboratory to the clinic. IMMUNOLOGICAL REVIEWS, 199(1), 156-180. doi:10.1111/j.0105-2896.2004.00145.x
Phase II study of IV Vinflunine (VFL) as second line treatment of patients (pts) with advanced non-small-cell lung cancer (NSCLC) previously treated with a platinum based regimen. Final results.
Bennouna, J., Tan, E. H., Obrien, M., Kosmidis, P., Breton, J. L., Ottensmeier, C., . . . Douillard, J. Y. (2004). Phase II study of IV Vinflunine (VFL) as second line treatment of patients (pts) with advanced non-small-cell lung cancer (NSCLC) previously treated with a platinum based regimen. Final results.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 22 (pp. 651S). Retrieved from https://www.webofscience.com/
2003
Anti-idiotype vaccines
McCarthy, H., Ottensmeier, C. H., Hamblin, T. J., & Stevenson, F. K. (2003). Anti-idiotype vaccines. BRITISH JOURNAL OF HAEMATOLOGY, 123(5), 770-781. doi:10.1046/j.1365-2141.2003.04698.x
Vaccine therapy in NHL: Future promises and current limitations
Stevenson, F. K., King, A., & Ottensmeier, C. H. (2003). Vaccine therapy in NHL: Future promises and current limitations. In LEUKEMIA & LYMPHOMA Vol. 44 (pp. S85-S90). doi:10.1080/10428190310001623711
DNA vaccination in B cell malignancies and solid tumours
Ottensmeier, C. (2003). DNA vaccination in B cell malignancies and solid tumours. In BRITISH JOURNAL OF CANCER Vol. 88 (pp. S2). Retrieved from https://www.webofscience.com/
Incidence of potential glycosylation sites in immunoglobulin variable regions distinguishes between subsets of Burkitt's lymphoma and mucosa-associated lymphoid tissue lymphoma
Zhu, D., Ottensmeier, C. H., Du, M. Q., McCarthy, H., & Stevenson, F. K. (2003). Incidence of potential glycosylation sites in immunoglobulin variable regions distinguishes between subsets of Burkitt's lymphoma and mucosa-associated lymphoid tissue lymphoma. BRITISH JOURNAL OF HAEMATOLOGY, 120(2), 217-222. doi:10.1046/j.1365-2141.2003.04064.x
Origins of the malignant clone in typical Waldenstrom's macroglobulinernia
Sahota, S. S., Forconi, F., Ottensmeier, C. H., & Stevenson, F. K. (2003). Origins of the malignant clone in typical Waldenstrom's macroglobulinernia. SEMINARS IN ONCOLOGY, 30(2), 136-141. doi:10.1053/sonc.2003.50072
2002
Glycosylation of V region genes in follicular lymphoma as a result of the somatic hypermutation mechanism
Belessi, C., Stamatopoulos, K., & Kosmas, C. (2002). Glycosylation of V region genes in follicular lymphoma as a result of the somatic hypermutation mechanism. BLOOD, 100(6), 2269-2270. doi:10.1182/blood-2002-05-1403
Typical Waldenstrom macroglobulinemia is derived from a B-cell arrested after cessation of somatic mutation but prior to isotype switch events
Sahota, S. S., Forconi, F., Ottensmeier, C. H., Provan, D., Oscier, D. G., Hamblin, T. J., & Stevenson, F. K. (2002). Typical Waldenstrom macroglobulinemia is derived from a B-cell arrested after cessation of somatic mutation but prior to isotype switch events. BLOOD, 100(4), 1505-1507. doi:10.1182/blood.V100.4.1505.h81602001505_1505_1507
Acquisition of potential N-glycosylation sites in the immunoglobulin variable region by somatic mutation is a distinctive feature of follicular lymphoma
Zhu, D. L., McCarthy, H., Ottensmeier, C. H., Johnson, P., Hamblin, T. J., & Stevenson, F. K. (2002). Acquisition of potential N-glycosylation sites in the immunoglobulin variable region by somatic mutation is a distinctive feature of follicular lymphoma. BLOOD, 99(7), 2562-2568. doi:10.1182/blood.V99.7.2562
DNA vaccination against cancer
Stevenson, F. K., Ottensmeier, C. H., McCarthy, H., Di Genova, G., Snow, R., Zhu, D., . . . Rice, J. (2002). DNA vaccination against cancer. In INTERNATIONAL JOURNAL OF CANCER (pp. 16-17). Retrieved from https://www.webofscience.com/
Glycosylation sites in the surface Ig of B-cell malignancies: A substitute for antigen in maintaining tumor survival in the germinal center?
Stevenson, F. K., Zhu, D. L., Ottensmeier, C. H., Du, M. Q., & McCarthy, H. (2002). Glycosylation sites in the surface Ig of B-cell malignancies: A substitute for antigen in maintaining tumor survival in the germinal center?. In BLOOD Vol. 100 (pp. 157A). Retrieved from https://www.webofscience.com/
High incidence of novel N-glycosylation sites in the immunoglobulin variable region genes of follicular lymphoma
Zhu, D. L., McCarthy, H., Ottensmeier, C. H., Johnson, P., Hamblin, T. J., & Stevenson, F. K. (2002). High incidence of novel N-glycosylation sites in the immunoglobulin variable region genes of follicular lymphoma. BLOOD, 100(6), 2270-2271. Retrieved from https://www.webofscience.com/
2001
The classification of lymphomas and leukemias
Ottensmeier, C. (2001). The classification of lymphomas and leukemias. In CHEMICO-BIOLOGICAL INTERACTIONS Vol. 135 (pp. 653-664). doi:10.1016/S0009-2797(01)00201-0
A phase I and pharmacokinetic study of vinflunine given on days 1 and 8 every 3 weeks
Johnson, P., Judson, I., Ottensmeier, C., O'Donnell, A., Pinel, M. C., Puozzo, C., & Fumoleau, P. (2001). A phase I and pharmacokinetic study of vinflunine given on days 1 and 8 every 3 weeks. In BRITISH JOURNAL OF CANCER Vol. 85 (pp. 94). Retrieved from https://www.webofscience.com/
B-cell Tumours
Ottensmeier, C., & Stevenson, F. (n.d.). B-cell Tumours. In Encyclopedic Reference of Cancer (pp. 93-98). Springer-Verlag. doi:10.1007/3-540-30683-8_154
The assessment of immune capacity in patients with B cell malignancies
McCarthy, H., Ottensmeier, C., Chilton, S., Duncombe, A., Johnson, P., Hamblin, T., & Stevenson, F. (2001). The assessment of immune capacity in patients with B cell malignancies. In BRITISH JOURNAL OF CANCER Vol. 85 (pp. 59). Retrieved from https://www.webofscience.com/
The occurrence and significance of V gene mutations in B cell-derived human malignancy
Stevenson, F. K., Sahota, S. S., Ottensmeier, C. H., Zhu, D. L., Forconi, F., & Hamblin, T. J. (2001). The occurrence and significance of V gene mutations in B cell-derived human malignancy. ADVANCES IN CANCER RESEARCH, VOL 83, 83, 81-116. doi:10.1016/S0065-230X(01)83004-9
Typical Waldenstrom's macroglobulinemia and IgM-secreting MGUS are each derived from B-cells arrested following cessation of somatic mutation but prior to isotype switch events.
Sahota, S. S., Forconi, F., Ottensmeier, C. H., Provan, D., Oscier, D. G., Hamblin, T. J., & Stevenson, F. K. (2001). Typical Waldenstrom's macroglobulinemia and IgM-secreting MGUS are each derived from B-cells arrested following cessation of somatic mutation but prior to isotype switch events.. In BLOOD Vol. 98 (pp. 154A). Retrieved from https://www.webofscience.com/
2000
Isotype switch variants reveal clonally related subpopulations in diffuse large B-cell lymphoma
Ottensmeier, C. H., & Stevenson, F. K. (2000). Isotype switch variants reveal clonally related subpopulations in diffuse large B-cell lymphoma. BLOOD, 96(7), 2550-2556. Retrieved from https://www.webofscience.com/
Isotype switch variants reveal clonally-related subpopulations in diffuse large B cell lymphomas: Insights into the biology of germinal centre lymphomas
Ottensmeier, C. H., Wilkins, B. S., Sweetenham, J. W., & Stevenson, F. K. (2000). Isotype switch variants reveal clonally-related subpopulations in diffuse large B cell lymphomas: Insights into the biology of germinal centre lymphomas. In BRITISH JOURNAL OF CANCER Vol. 83 (pp. 83). Retrieved from https://www.webofscience.com/
1999
Immunocytochemical assessment of bone marrow aspirates for monitoring response to chemotherapy in small-cell lung cancer patients
Pelosi, G., Pasini, F., Ottensmeier, C., Pavanel, F., Bresaola, E., Bonetti, A., . . . Cetto, G. L. (1999). Immunocytochemical assessment of bone marrow aspirates for monitoring response to chemotherapy in small-cell lung cancer patients. BRITISH JOURNAL OF CANCER, 81(7), 1213-1221. doi:10.1038/sj.bjc.6690831
1998
Analysis of V<sub>H</sub> genes in follicular and diffuse lymphoma shows ongoing somatic mutation and multiple isotype transcripts in early disease with changes during disease progression
Ottensmeier, C. H., Thompsett, A. R., Zhu, D. L., Wilkins, B. S., Sweetenham, J. W., & Stevenson, F. K. (1998). Analysis of V<sub>H</sub> genes in follicular and diffuse lymphoma shows ongoing somatic mutation and multiple isotype transcripts in early disease with changes during disease progression. BLOOD, 91(11), 4292-4299. doi:10.1182/blood.V91.11.4292.411a02_4292_4299
Analysis of VH Genes in Follicular and Diffuse Lymphoma Shows Ongoing Somatic Mutation and Multiple Isotype Transcripts in Early Disease With Changes During Disease Progression
Ottensmeier, C. H., Thompsett, A. R., Zhu, D., Wilkins, B. S., Sweetenham, J. W., & Stevenson, F. K. (1998). Analysis of VH Genes in Follicular and Diffuse Lymphoma Shows Ongoing Somatic Mutation and Multiple Isotype Transcripts in Early Disease With Changes During Disease Progression. Blood, 91(11), 4292-4299. doi:10.1182/blood.v91.11.4292
Insight into the origin and clonal history of B-cell tumors as revealed by analysis of immunoglobulin variable region genes
Stevenson, F., Sahota, S., Zhu, D. L., Ottensmeier, C., Chapman, C., Oscier, D., & Hamblin, T. (1998). Insight into the origin and clonal history of B-cell tumors as revealed by analysis of immunoglobulin variable region genes. IMMUNOLOGICAL REVIEWS, 162, 247-259. doi:10.1111/j.1600-065X.1998.tb01446.x
1997
Immunogenetic features of diffuse and follicular lymphoma vary with disease status and reveal multiple isotype expression.
Ottensmeier, C. H., Wilkins, B. S., & Stevenson, F. K. (1997). Immunogenetic features of diffuse and follicular lymphoma vary with disease status and reveal multiple isotype expression.. In BLOOD Vol. 90 (pp. 3932). Retrieved from https://www.webofscience.com/
1996
Absence of constitutive EGF receptor activation in ovarian cancer cell lines
Ottensmeier, C., Swanson, L., Strobel, T., Druker, B., Niloff, J., & Cannistra, S. A. (1996). Absence of constitutive EGF receptor activation in ovarian cancer cell lines. BRITISH JOURNAL OF CANCER, 74(3), 446-452. doi:10.1038/bjc.1996.379
Histological transformation of indolent (follicular) lymphoma
Ottensmeier, C., & Mead, G. (1996). Histological transformation of indolent (follicular) lymphoma. ANNALS OF ONCOLOGY, 7(8), 849-853. Retrieved from https://www.webofscience.com/
1995
CD44 VARIANT EXPRESSION IS A COMMON FEATURE OF EPITHELIAL OVARIAN-CANCER - LACK OF ASSOCIATION WITH STANDARD PROGNOSTIC FACTORS
CANNISTRA, S. A., ABUJAWDEH, G., NILOFF, J., STROBEL, T., SWANSON, L., ANDERSEN, J., & OTTENSMEIER, C. (1995). CD44 VARIANT EXPRESSION IS A COMMON FEATURE OF EPITHELIAL OVARIAN-CANCER - LACK OF ASSOCIATION WITH STANDARD PROGNOSTIC FACTORS. JOURNAL OF CLINICAL ONCOLOGY, 13(8), 1912-1921. doi:10.1200/JCO.1995.13.8.1912
EXPRESSION AND FUNCTION OF BETA-1 AND ALPHA-V-BETA-3 INTEGRINS IN OVARIAN-CANCER
CANNISTRA, S. A., OTTENSMEIER, C., NILOFF, J., ORTA, B., & DICARLO, J. (1995). EXPRESSION AND FUNCTION OF BETA-1 AND ALPHA-V-BETA-3 INTEGRINS IN OVARIAN-CANCER. GYNECOLOGIC ONCOLOGY, 58(2), 216-225. doi:10.1006/gyno.1995.1214
FUNCTIONAL-HETEROGENEITY OF CD44 MOLECULES IN OVARIAN-CANCER CELL-LINES
CANNISTRA, S. A., DEFRANZO, B., NILOFF, J., & OTTENSMEIER, C. (1995). FUNCTIONAL-HETEROGENEITY OF CD44 MOLECULES IN OVARIAN-CANCER CELL-LINES. CLINICAL CANCER RESEARCH, 1(3), 333-342. Retrieved from https://www.webofscience.com/
1994
VASCULAR CELL-ADHESION MOLECULE-1 EXPRESSED BY PERITONEAL MESOTHELIUM PARTLY MEDIATES THE BINDING OF ACTIVATED HUMAN T-LYMPHOCYTES
CANNISTRA, S. A., OTTENSMEIER, C., TIDY, J., & DEFRANZO, B. (1994). VASCULAR CELL-ADHESION MOLECULE-1 EXPRESSED BY PERITONEAL MESOTHELIUM PARTLY MEDIATES THE BINDING OF ACTIVATED HUMAN T-LYMPHOCYTES. EXPERIMENTAL HEMATOLOGY, 22(10), 996-1002. Retrieved from https://www.webofscience.com/
1993
BINDING OF OVARIAN-CANCER CELLS TO PERITONEAL MESOTHELIUM IN-VITRO IS PARTLY MEDIATED BY CD44H
CANNISTRA, S. A., KANSAS, G. S., NILOFF, J., DEFRANZO, B., KIM, Y., & OTTENSMEIER, C. (1993). BINDING OF OVARIAN-CANCER CELLS TO PERITONEAL MESOTHELIUM IN-VITRO IS PARTLY MEDIATED BY CD44H. CANCER RESEARCH, 53(16), 3830-3838. Retrieved from https://www.webofscience.com/
1992
INTERLEUKIN-2 FOLLOWED BY FLUOROURACIL AND FOLINIC ACID IN REFRACTORY COLORECTAL-CANCER - RESULTS OF A CLINICAL PHASE-II STUDY
HIDDEMANN, W., RUELFS, C., OTTENSMEIER, C., RUCKLE, H., MUSCH, E., KOCH, O., & VANDELOO, J. (1992). INTERLEUKIN-2 FOLLOWED BY FLUOROURACIL AND FOLINIC ACID IN REFRACTORY COLORECTAL-CANCER - RESULTS OF A CLINICAL PHASE-II STUDY. SEMINARS IN ONCOLOGY, 19(2), 225-227. Retrieved from https://www.webofscience.com/
1991
TREATMENT OF ADVANCED CHRONIC LYMPHOCYTIC-LEUKEMIA BY FLUDARABINE - RESULTS OF A CLINICAL PHASE-II STUDY
HIDDEMANN, W., ROTTMANN, R., WORMANN, B., THIEL, A., ESSINK, M., OTTENSMEIER, C., . . . VANDELOO, J. (1991). TREATMENT OF ADVANCED CHRONIC LYMPHOCYTIC-LEUKEMIA BY FLUDARABINE - RESULTS OF A CLINICAL PHASE-II STUDY. ANNALS OF HEMATOLOGY, 63(1), 1-4. doi:10.1007/BF01714952
1985
[Incidence and significance of DNA aneuploidies in breast tumors].
Hiddemann, W., Müller, K. M., von Bassewitz, D. B., Ottensmeier, C., Meyer Kramer, J., & Büchner, T. (1985). [Incidence and significance of DNA aneuploidies in breast tumors].. Verhandlungen der Deutschen Gesellschaft fur Pathologie, 69, 545-548.